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Abstract 
The identification of a blood-based diagnostic biomarker for breast cancer (BC) 
would be particularly beneficial to those at increased risk of developing BC and 
could result in earlier detection which may increase survival rates due to earlier 
treatment. Alterations in α-1-acid glycoprotein (AGP) glycosylation levels occur 
during disease and this study sought to determine the diagnostic potential of 
AGP glycan variation in triple negative breast cancer (TNBC) compared to BC 
of unknown type and healthy controls as well as women at increased risk of 
developing BC compared to age-matched healthy controls. 
AGP was isolated from blood of two different sample populations using low 
pressure chromatography. AGP purity was confirmed using SDS-PAGE and 
concentration determined using spectrophotometry. Structural analysis of AGP 
glycan monosaccharide and oligosaccharide content was undertaken using high 
pH anion-exchange chromatography with pulsed amperometric detection 
(HPAEC-PAD).  
Increased AGP concentrations were observed, in comparison to their controls, 
in BC of unknown type, TNBC and “at-risk” samples. Quantitative alterations in 
monosaccharide composition were also present. N-acetylgalactosamine 
(GalNAc) was present in over 88% of TNBC samples and was inversely 
correlated with age. For the TNBC groups, GalNAc was also present at higher 
levels in samples of individuals with family history of BC. There was an overall 
increase in GlcNAc levels compared to age-matched healthy controls and 
GalNAc presence in 81% of “at risk” samples.  
Oligosaccharide analysis revealed increased branching in BC of unknown type 
and TNBC <35 years of age, whereas the “normal” healthy population and 
TNBC >35 possessed less branching. A similar trend was observed between 
the “at risk” samples and the age-matched controls. These branching patterns 
aligned well with the corresponding monosaccharide data. 
Overall, this study indicated that alterations in AGP levels and glycosylation 
exist between TNBC compared to BC of unknown type and “normal” healthy 
controls as well as an “at risk” population and age-matched healthy controls. 
The data could underpin the development of a new diagnostic BC biomarker. 
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Preface 
This thesis is a written account of independent postgraduate research 
undertaken by the author, investigating Alpha-1-acid glycoprotein (AGP) 
glycosylation as a potential biomarker of breast cancer (BC) in women at risk of 
BC development. 
Acute phase reaction (APR) as a result of pathological and physiological 
conditions causes AGP (a positive acute phase protein) plasma concentration 
to increase 2-5 fold, with increased expression of abnormal AGP glycoforms 
compared to normal AGP glycoforms. Raised AGP levels have been identified 
in BC patients and progression of the disease has been linked to increasing 
AGP plasma levels. Additionally, there is evidence that unique alterations of 
AGP glycosylation are present in other disease conditions thus there is a strong 
possibility that the same is true of BC. 
Chapter 1 provides an overview of current knowledge regarding glycan 
biosynthesis and their attachment to proteins as well as more detailed 
information about AGP’s structure and known functions. Furthermore, the 
recent links between triple negative breast cancer (TNBC) occurrence and 
BRCA1 and BRCA2 mutations are introduced with discussion of the patient 
pathway and current guidelines for increased surveillance of these individuals. 
Chapter 2 summarises the materials and methodology used to conduct the 
research including low pressure chromatography for isolation of AGP, SDS-
PAGE to prove successful AGP isolation, spectrophotometry for calculation of 
concentration of AGP present in samples, acid hydrolysis and enzyme digestion 
to cleave monosaccharides and oligosaccharide for analysis and finally high pH 
anion exchange chromatography with pulsed amperometric detection (HPAEC-
PAD) for analysis of AGP glycan composition (monosaccharides) and structure 
(oligosaccharides). 
Chapter 3 discusses the two datasets of samples recruited for the study. 
Dataset 1 was comprised of plasma samples from women suffering from TNBC 
at various ages compared to “normal” healthy samples and women with BC with 
an unknown molecular subtype. Dataset 2 was composed of women at 
increased risk developing BC due to family history risk. This cohort were 
recruited from a local NHS familial breast screening clinic (for women under age 
XVI 
 
50 with an increased risk due to genetic testing or family history risk 
assessment) who then were compared to age-matched healthy controls in a 
case-control style manner. 
Chapter 4 illustrates the results of AGP isolation and level determination from 
both datasets. Discussion is given regarding the variations or similarities in AGP 
levels in different sample populations of both dataset 1 and dataset 2 as well as 
the isolation method chosen. 
Chapter 5 provides a comprehensive overview of HPAEC-PAD and its use for 
analysis of monosaccharide content of glycans. Monosaccharide content results 
of AGP glycans using HPAEC-PAD are displayed and discussed, as variation in 
these levels can indicate alterations in structure.  
Chapter 6 presents the versatility of HPAEC-PAD and its subsequent use for 
structural analysis of intact AGP glycans (oligosaccharide). An explanation of 
the technical aspects of the technique is given as well as presentation and 
discussion of sample results from datasets 1 and 2. 
Lastly, chapter 7 details the conclusions drawn from this study in terms of 
AGP’s potential use a BC biomarker in “at risk” individuals. Additionally this 
chapter give suggestions for future work that could supplement the current 
research. 
The results of this study have been published in part in the following publication: 
Dewar, E., Matthews-Smith, G., Cetnarskyj, R., and Smith, K.D., (2014). Alpha-
1-Acid Glycoprotein as a Breast Cancer Biomarker in At Risk Individuals. 9th 
European Breast Cancer Conference (abstract number 240), Glasgow, March  
2014. 
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Aims 
To evaluate the diagnostic potential of alterations to AGP levels and 
glycosylation patterns in TNBC compared to BC of an unknown molecular type 
as well as “normal” healthy controls and women at increased risk of BC 
development compared to a ‘normal’ healthy age-matched control population. 
 
Hypothesis 
This study hypothesised that significant differences in AGP levels, 
monosaccharide content and oligosaccharide (glycan) structure may be present 
in TNBC samples compared to BC of an unknown molecular type and “normal” 
healthy controls. It was also hypothesised that modifications to AGP glycan 
content, structure and levels occur in women at increased risk of BC 
development, which may be seen at the early stages of BC development, 
compared to “normal” healthy age-matched controls. 
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Chapter 1 – Literature Review 
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1.1 Breast Cancer. 
1.1.1 Breast Cancer Overview. 
 
Breast cancer (BC) is the most common cancer in women in the UK with over 
49,000 new cases in 2011 and accounts for almost a third of cancers diagnosed 
in women (Information Services Division: ISD Scotland., 2014; Northern Ireland 
Cancer Registry., 2013; Office for National Statistics., 2011; Welsh Cancer 
Intelligence and Surveillance Unit., 2014). This type of cancer occurs when the 
DNA of ductal epithelial cells of the breast is altered from proto-oncogenes to 
oncogenes, leading to formation of malignant masses, or tumours, in the breast 
tissue. These DNA modifications can be sporadic or inherited with family history 
being a significant risk factor in BC development. Inherited BCs are often 
diagnosed at a young age and are more commonly bilateral (National Cancer 
Institute., 2014). However, the majority of BCs are sporadic and tend to occur 
when somatic cells i.e. non-germline cells that are not inherited become 
mutated. This may be due to the individual having several risk factors linked to 
BC development (see Table 1.1), with scientists estimating that 42% of BC 
incidences could be prevented by being physically active, drinking less alcohol 
and reducing obesity (World Cancer Research Fund., 2011). Other risk factors 
for the general population include being female (Siegel, et al., 2012), aging 
(Sasieni, et al., 2011) and hormone replacement therapy (Beral, 2003; Ritte, et 
al., 2012).  
 
1.1.2 High Risk Factors for Breast Cancer Development. 
 
Assessing increased risk using family history is formally defined using a specific 
criteria. In Scotland the criteria used are strong family history of BC as well as 
mutations of BRCA1 and BRCA2 genes which are considered high risk factors 
for BC development (The Scottish Government., 2009). Currently Clinical 
Genetics departments (CGD) in Scotland are the gatekeepers for early breast 
screening based on family history which has been assessed using the criteria. If 
a person has a family history of BC or ovarian cancer their GP can refer them to 
clinical genetics after consulting guidelines for risk assessment and CGD will 
formally take and confirm the cancers in a family history to then apply a risk of 
low, moderate, high or very high risk of the individual developing BC (see Table 
3 
 
1.1) devised by Scottish Intercollegiate Guidelines Network (SIGN) which is an 
adaptation of the guidelines used in England and Wales provided by the 
National Institute for Health and Care Excellence (NICE; National Institute for 
Health and Care Excellence. (2013)). Once risk level is determined, if 
individuals have at least a 20% chance of having a BRCA1 and BRCA2 
mutation, the two genes most associated with BC development, and there is a 
living affected family member that person will be offered the option to have 
genetic testing (The Scottish Government., 2009).   
 
 
Table 1.1 Scottish Government Breast Cancer Risk Stratification.  
Criteria for assessment of risk of breast cancer development in Scotland (The Scottish 
Government., 2009).  
 
A family history of BC has long been recognised as a predictor of BC 
development. A first degree relative i.e. mother or sister diagnosed with BC over 
age 50 effectively doubles an individual’s risk of developing BC, or trebles if the 
relative was premenopausal at diagnosis or if there were two first-degree 
relatives diagnosed. There is a lesser risk (1.5 fold) associated with a second 
degree relative i.e. a grandparent or aunt diagnosed with BC (Pharoah, et al., 
1997). The risk also increases if multiple first degree relatives are diagnosed 
with almost a 4 fold risk if three or more first degree relatives are diagnosed 
(Collaborative Group on Hormonal Factors in Breast Cancer., 2001). The 
aforementioned risk is also inversely proportional to the age of the relative and 
is far higher if a brother rather than a sister is diagnosed with BC (Bevier, et al., 
2012).  
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If a BRCA1 or BRCA2 mutation is detected the affected individual will be offered 
extra surveillance and possibly prophylactic surgery in the form of a 
mastectomy to remove breast tissue to aid the prevention of BC development. 
BRCA1 of BRCA2 mutation carriers are also at increased risk of ovarian cancer 
(Gayther and Pharoah, 2010) and as such may also be offered a salpingo-
oophorectomy (removal of fallopian tubes and ovaries)  to reduce the risk of 
developing ovarian cancer. Women who are considered low risk can enrol in the 
National Breast Cancer Screening Programme from age 50, for screening every 
three years. Unaffected individuals with a family history assessed as moderate 
will have screening offered from the age of 40 occurring every two years, 
increasing to annually between ages 40-50.  In contrast, the very high risk BC 
group can be offered screening from age 25, with mammography every two 
years increasing to annually then eighteen months when they reach age 50 as 
this is an interim screen alongside the national screening service (see Table 
1.2). 
 
 
Table 1.2 Scottish Breast Cancer Surveillance Guidelines.  (The Scottish 
Government., 2009). 
 
Mutations of BRCA1 and BRCA2 are dominantly inherited, accounting for 
approximately 20-25% of hereditary BCs (Easton, 1999) and 5-10% of BCs 
overall (Campeau, et al., 2008). BRCA1 and BRCA2 are genes (located on 
chromosomes 17q21 and 13q12-13 respectively) found in breast cells and other 
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tissue which produce tumour suppressor proteins that aid the repair of DNA 
when cells divide. Individuals have two copies of these genes, one inherited 
from their mother and one from their father. If a mutation occurs in either copy, 
the function may be lost and damaged DNA is not repaired. It is the 
accumulation of unrepaired DNA that causes BC when these genes are 
mutated, not the genes themselves (Hall, et al., 1990; Wooster, et al., 1994). 
These genes have been extensively studied to assess the risk of BC 
development in mutation carriers. Initially it was concluded there was an 84% 
chance of developing BC for individuals carrying a BRCA1 or BRCA2 mutation 
(Ford, et al., 1994). However, further studies examined the BC risk of each 
gene separately, and discovered that BRCA1 mutations conferred a 54-65% 
risk of developing BC by aged 70 or 45% if a BRCA2 mutation was present 
(Antoniou, et al., 2003; Easton, et al., 1995). Conversely, a recent, UK based 
study known as EMBRACE (Mavaddat, et al., 2013) found that by age 70, 
BRCA1 mutation carriers had a 65% risk of BC development while BRCA2 
mutation carriers had a 45% risk. Other genetic mutations are associated with 
BC development to a lesser extent – CHEK2, TP53, PTEN, STK11 and CDH1 
(Campeau, et al., 2008; Walsh, et al., 2006) – however not all BCs occurring 
among relatives can be attributed to a genetic mutation. 
 
Prophylactic mastectomy and salpingo-oophorectomy are offered to mutation 
carriers and high risk relatives. Studies have shown that preventative surgery 
significantly lowers risk of BC development by approximately 90%, but does not 
entirely eradicate it (Hartmann, et al., 1999; Heemskerk-Gerritsen, et al., 2013; 
Rebbeck, et al., 2004). However, even after risk-reducing mastectomies a small 
number of women still go on to develop BC (Rebbeck, et al., 2004; Skytte, et 
al., 2011). 
While mastectomy is considered the most effective risk-reducing strategy for 
BC, there is evidence that oophorectomy can also reduce risk of BC 
development. This procedure is primarily used for prevention of ovarian cancer 
but several studies have shown protective effects for breast cancer as well 
particularly if performed before age 50. For instance oophorectomy prior to age 
40 reduced the risk of BC development by 64% and 31% in BRCA1 and BRCA2 
mutation carriers respectively (Domchek, et al., 2010; Rebbeck, et al., 2009). 
This risk reduction does not appear to be affected by hormone replacement 
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therapy which may be given to prevent the effects of oophorectomy induced 
menopause (Eisen, et al., 2008; Rebbeck, et al., 2005). However, in spite of the 
aforementioned preventative measures some individuals still develop cancers of 
the breast or peritoneum (Finch, et al., 2006; Olivier, et al., 2004; Rutter, et al., 
2003).  
 
1.1.2.1  Hodgkin’s Lymphoma 
 
A less well known high risk factor for BC development is radiotherapy treatment 
for Hodgkin’s lymphoma. Hodgkin’s lymphoma is the uncontrolled proliferation 
of B-lymphocytes and their congregation in sections of the lymphatic systems 
such as lymph nodes. These proliferated B-lymphocytes are unable to fight 
infection leaving an individual vulnerable to disease. Hodgkin’s lymphoma 
usually presents at a young age and is commonly treated with radiotherapy to 
the chest area. Studies have shown that having radiotherapy for Hodgkin’s 
lymphoma puts individuals at a comparable risk of BC development to those 
with mutations of BRCA1 and BRCA2 (Swerdlow, et al., 2012). It has also been 
found that risk of BC is inversely correlated with age at treatment and reducing 
the proportion of breast tissue exposed during treatment may reduce the risk of 
BC in the future (De Bruin, et al., 2009; Swerdlow, et al., 2012). Maximum risk 
of BC development was found at ages 50-59 and while an individual would be 
eligible to participate in the national screening programme, there are 
suggestions that they would benefit from more frequent screening which should 
continue for more than 40 years after radiotherapy (De Bruin, et al., 2009; 
Swerdlow, et al., 2012). Currently. in Scotland, if a person’s risk of BC 
development is more than 30%, (as for individuals who had been treated with 
radiotherapy for Hodgkin’s lymphoma) they are eligible for increased 
surveillance as detailed in the guidelines for high and very high risk individuals 
above in Table 1.2 (The Scottish Government., 2009). 
 
1.1.2.2 Histological and Molecular Breast Cancer Types. 
 
BC can occur as either a non-invasive or invasive tumour. Non-invasive cancers 
are further subdivided into ductal carcinoma in situ (DCIS) and lobular 
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carcinoma in situ (LCIS). In situ refers to the state and location of the breast 
epithelial cells; they have gone through malignant transformation and are now 
proliferating but remain at the site of origin and do not penetrate the basement 
membrane into surrounding tissues. DCIS and LCIS are not at risk of metastatic 
spread as there are no blood vessels or lymphatics in the epithelial layer of the 
breast (Sakorafas and Farley, 2003). 
DCIS is also referred to as intraductal cancer and originates from the terminal 
duct lobular epithelium and is a significant risk factor for development of 
invasive BC (Leonard and Swain, 2004). DCIS usually presents as micro-
calcifications in a mammogram where calcium deposits have formed during 
areas of rapid epithelial proliferation. Difficulties can arise when determining 
whether DCIS will become invasive and therefore whether treatment for DCIS is 
necessary. Treatment usually involves a small excision of cancerous ducts but 
in some cases mastectomy is required. LCIS is rarer than DCIS and is a 
proliferation of identical small cells forming a mass in multiple breast lobules 
and sometimes in ducts. There is strong evidence to suggest that untreated 
LCIS can develop into BC (Coopey, et al., 2012; Simpson, et al., 2003). In 
contrast to DCIS, LCIS is almost impossible to detect via mammography as it 
does not cause micro-calcifications and is not a substantial lesion however 
areas of increased density in mammograms have been linked to LCIS (Beute, 
et al., 1991; Georgian-Smith and Lawton, 2001; Sonnenfeld, et al., 1991). 
The two most common types of invasive BC are invasive ductal carcinoma 
(IDC) and invasive lobular carcinoma (ILC). Approximately 75% of BCs are IDC 
with ILC accounting for a further 10%. The remaining 15% of diagnosed 
invasive BCs are made up of rare types such as Mucinous, Medullary, Tubular, 
and Papillary (Underwood, 2004). 
IDC commonly presents as irregularly dense area of soft tissue with pointed 
surface projections or as a palpable lump. As the name suggests IDCs originate 
in the ductal epithelium but ultimately invade the surrounding breast tissue 
allowing cancerous cells to infiltrate vascular and lymphatics systems which can 
result in carriage to secondary locations forming metastases (King and Robins, 
2006). A diagnosis of IDC often occurs when a tumour does not fit one of the 
“special types” such as ILC since IDCs do not possess distinguishing features. 
ILC is typically an asymmetrical thickening or bumpiness of the breast stroma 
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rather than a lump in the breast (IDC) that results in patients having much larger 
tumours by the time they are symptomatic compared to patients with IDC. ILCs 
do not usually present with microcalcification so are difficult to identify in 
mammograms but a characteristic feature of ILC cells is their lack of E-
cadherin, a cell adhesion molecule (de Leeuw, et al., 1997). Treatment for both 
IDC and ILC involves surgery and usually chemotherapy, radiotherapy or 
hormone therapy depending on the severity and hormone receptor status of the 
tumour.  
In recent years research studies have provided a further classification of 
tumours (mainly IDCs) in the form of molecular subtypes (Curtis, et al., 2012). 
Four molecular subtypes of BC have been identified: normal breast-like, 
luminal, basal-like and human epidermal growth factor 2 (HER2) with the 
luminal subtype later being subdivided into luminal A and luminal B (Hu, et al., 
2006; Perou, et al., 2000; Sørlie, et al., 2001; Sørlie, et al., 2003). Of the four 
molecular subtypes, luminal (both A and B) is the only subtype possessing 
oestrogen receptors (ER) and are identified by having genes activated that are 
linked to an ER pathway, low molecular weight cytokeratins. When subdivided, 
Luminal A is usually a low histological grade, has high expression of ER-
activated genes, low expression of proliferation genes, and is associated with a 
good prognosis. However, Luminal B subtypes have a worse prognosis and 
display higher proliferation rates and histological grades (Sotiriou, et al., 2003). 
The remaining three molecular subtypes (normal breast-like, HER2 and basal-
like) do not possess ERs. Normal breast-like subtypes show high expression of 
genes usually found in adipose tissue and show similar gene expression to 
normal breast samples during micro-array analysis (Peppercorn, et al., 2008). 
This subtype tends to have a good prognosis but in many cases this may be a 
false negative result due to the fact that there are not enough cancer cells 
present in the sample.  Therefore, further investigation is required to assess the 
clinical significance of this subtype (Correa Geyer and Reis-Filho, 2009; 
Pusztai, et al., 2006). HER2 and basal-like subtypes are linked with aggressive 
clinical features such as larger tumour size and higher tumour grade (Voduc, et 
al., 2010). The HER2 subtype is determined by overexpression of HER2 and its 
associated genes as well as lack of ER and progesterone receptors (PR) 
(Weigelt, et al., 2010). However some tumours with HER2 overexpressed are 
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not categorized as HER subtypes but are considered Luminal B if they have an 
ER positive status (Parker, et al., 2009; Rouzier, et al., 2005). Lastly, despite 
extensive research, the definition of basal-like tumours varies widely. They are 
typically defined as tumour cells expressing genes found in normal basal 
epithelial cells and tend to be triple negative (discussed in more depth in section 
1.1.3.1) meaning they lack ER, PR or HER2 although this is not always the 
case (Rakha, et al., 2008; Weigelt, et al., 2010).   
 
1.1.2.3 Histological Breast Cancer Staging. 
 
Patients can be grouped by the severity of their disease which allows clinicians 
to construct a suitable treatment plan, give an indication of prognosis, evaluate 
the effect of treatment, exchange information with other treatment centres and 
contribute to cancer research. The TNM system of cancer classification was 
developed by the Union for International Cancer Control (UICC; previously the 
International Union Against Cancer) and is based on three main components: 
extent of the primary Tumour; presence or absence and extent of surrounding 
lymph Node metastasis and presence or absence of distant Metastasis. This is 
one of the most commonly accepted approaches for determining the stage of 
cancer and is normally presented as groups of stages that indicate chances of 
patient survival (see Table 1.3). Other classification systems include the 
Nottingham Prognostic Indicator (NPI), an index combining tumour size, lymph 
node status and grade to divide patients into three prognostic groups (good, 
moderate and poor) using the calculation 0.2 x tumour size (cm) + grade (1-3) + 
lymph node status (1= no nodes; 2= 1-3 nodes; 3= ≥3 lymph nodes are 
involved) (Harmer, 2011). 
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Table 1.3    TNM System of Classification.   Method of grouping cancer 
patients based on tumour dimension (no primary tumour present i.e. T0 and ≥5cm or 
progression into chest wall/oedema/ulceration being T4); lymph node infiltration with N0= no 
lymph node metastasis to N3= infiltration into internal mammary lymph nodes and distant 
metastasis where M0= no metastasis and M1= distant metastasis (Sobin, et al., 2009). 
 
1.1.3 Clinical Features of High Risk Breast Cancer. 
   
Higher risk of BC development is associated with early age onset and 
aggressive clinical features.  While there is some debate surrounding what age 
confers “young”, most studies agree that this refers to women below the age of 
35-40. Approximately 7% of all BCs are diagnosed in women younger than 40 
(National Cancer Institute., 2012) and there is evidence to suggest that this 
number is rising (Leclère, et al., 2013). BC within this group tends to be 
aggressive, have a high histological grade, be triple negative (TN), and possess 
a basal-like phenotype. 
Research has revealed that BC in younger women arises through distinct 
biological pathways compared to older women (Anders, et al., 2008).  Younger 
women (<40) with BC had an altered molecular phenotype distribution in 
comparison to a general population with BC (Collins, et al., 2012). The age of 
diagnosis has been shown to inversely correlate with poor prognosis; the risk of 
mortality increasing by 5% for every year reduction in age of diagnosis (Gajdos, 
et al., 2000; Han, et al., 2010). Younger patients often have much larger, more 
T N M
Stage 0 0 0 0
Stage 1 1 0 0
0 1 0
1 1 0
2 0 0
2 1 0
3 0 0
0 2 0
1 2 0
2 2 0
3 1/2 0
Stage 3B 4 0/1/2 0
Stage 3C Any 3 0
Stage 4 Any Any 1
Stage 2A
Stage 2B
Stage 3A
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invasive tumours, have nodal involvement with more nodes affected and the 
majority were diagnosed at stage II or III. A further feature differing between 
young and older BC sufferers is that young patients are more likely to present 
with a palpable mass as opposed to a mammographic lesion but this is due to 
mammography screening not being routinely recommended for young women 
unless they are at increased risk of BC development (Gajdos, et al., 2000). 
Additionally, risk of local and distant recurrence is increased if BC develops at a 
young age (Dubsky, et al., 2002; Nixon, et al., 1994). Age is not an independent 
risk factor for BC development but biological factors alone fail to explain the 
differences between BC in younger and older women. 
 
1.1.3.1 Triple Negative BC. 
 
TN tumour status is also a key clinical feature of BC presentation in high risk 
women. TN tumours are characterised by lack of ER and PR (known collectively 
as hormone receptors) as well as HER-2 through immunohistological tests. 
Triple negative breast cancer (TNBC) accounts for approximately 15% of all 
diagnosed BC (Anders, et al., 2009), with up to 80% of BRCA1 related tumours 
being TN (Lakhani, et al., 2002a) whereas BRCA2 linked tumours do not favour 
a particular BC subtype (Armes, et al., 1999). TNBC is associated with younger 
age at diagnosis, higher tumour grade, rapid growth, early metastasis, poorer 
prognosis and increased risk of recurrence (Bauer, et al., 2007; Blows, et al., 
2010; Chacon and Costanzo, 2010; Dent, et al., 2007; Schneider, et al., 2008). 
Dent, et al. (2007) key investigation highlights many of the aggressive features 
linked to TNBC. For instance, the mean age of TNBC diagnosis was 
significantly younger, with tumours more likely to be grade III and larger in size 
when diagnosed as two thirds of TNBC’s were ≥3cm. Additionally the TNBC 
group were almost 10% more likely to have lymph node invasion with no 
correlation between node status and tumour size as even small tumours had at 
least one affected lymph node. This provides evidence that TNBC carries an 
increased risk of early metastasis. The study also showed that TNBC sufferers 
were almost twice as likely to die from the disease within 10 years compared to 
other BC types, which may be due limited treatment options. Distant and local 
recurrence was also analysed with TNBC patients having a higher rate of 
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distant recurrence primarily in the immediate three years after diagnosis while 
risk of local recurrence was similar to that of other BC types.  
There is some overlap between triple negative histological subtype and basal-
like molecular subtypes in the literature but the two are not synonymous. There 
is controversy surrounding the definition of basal-like BCs (for a recent review 
see Badve, et al. (2011) while there is definitive agreement TNBCs are ER, PR 
and HER2 negative. Furthermore, in a clinical setting immunohistological 
staining is more readily available than testing used to determine molecular 
subtypes, thus tumours are more likely to be classified as TN than basal-like 
(Nielsen, et al., 2004). This study will refer to TNBCs throughout. 
 
1.1.4 Current Breast Cancer Biomarkers. 
 
A biomarker is defined as a measurable characteristic that can be evaluated to 
indicate normal biological processes, pathogenic processes or monitor 
therapeutic interventions (Atkinson, et al., 2001). Biomarker research is thought 
to be imperative as clinical benefits could include earlier disease detection, 
improved monitoring of disease detection and treatment (Popescu, et al., 2010; 
Whelan, et al., 2008). A main priority of cancer detection is to develop 
biomarkers that can be detected via less invasive and complex methods and 
which also have the sensitivity and specificity to identify cancer earlier 
(Somasundaram, et al., 2009), thus improving mortality rates, cost-effectiveness 
and potentially reducing the need for invasive treatment. However, there are 
very few biomarkers currently capable of this and those that are, often require 
improvement through the use of a biomarker panel to be successful (Anderson, 
2005; Rifai, et al., 2006). 
With regards to BC, finding a suitable serum biomarker would be of great 
importance to those with an increased risk since the current methods, although 
greatly improving detection, such as palpation, mammography and MRI 
scanning (magnetic resonance imaging) are not capable of identifying all 
tumours. Additionally, repeated exposure to radiation from mammography 
screening increases risk of developing a cancer by 0.3-0.6 fold (Berrington de 
González, 2011). For instance, calcium deposits surround a lesion that could 
indicate BC onset cannot be visualised using MRI, smaller tumours in the early 
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stages may not be palpable and mammography has decreased sensitivity in 
women with dense breasts (Checka, et al., 2012).  A BC biomarker, particularly 
one that is a blood constituent, could enable identification of disease presence 
where imaging technologies fail and could allow more frequent screening 
starting at a younger age than can be provided using mammography. 
Presently, there are only two clinically adopted biomarkers capable of 
distinguishing BC existence from “healthy” individuals but not for early diagnosis 
only for evidence of metastasis and evaluating treatment success. The first is 
carcinoembryonic antigen (CEA), a glycoprotein generated during foetal 
development by the large intestine although it has also been found in adult 
human blood at very low levels. Serum concentrations of CEA are increased in 
patients with ovarian, lung, pancreatic, liver, colorectal, prostate and BCs. In 
particular, women with metastatic BC show a 30-50% increase in CEA levels 
and a positive correlation between therapeutic response and CEA in women 
with metastasis (Cheung, et al., 2000; Mughal, et al., 1983; Williams, et al., 
1988). The second marker for BC is mucin 1 (MUC-1), a glycoprotein bound to 
the surface of epithelial cells of the stomach, pancreas, ovaries, bladder, 
respiratory tract and breast. Production of MUC-1 is upregulated and glycan 
chains of MUC-1 become truncated during BC compared to MUC-1 from normal 
breast epithelials. Cancer antigen 15.3 (CA15.3) is a secreted and soluble form 
of MUC-1, the concentration of which can be used to determine prognosis.  
CA15.3 has a similar specificity but much higher sensitivity when compared to 
CEA testing alone and is regarded as the “gold standard” test for BC 
management (Seregni, et al., 2008). 
Over 80% sensitivity is achieved for detection of metastasis when measuring 
CEA and CA15.3 together (Robertson, et al., 1999). An investigation by 
Ebeling, et al. (2002) revealed that elevated levels of CA15.3 and serum CEA 
prior to surgical intervention were positively correlated with death from BC and 
early relapse. A decline in levels of CA15.3 and CEA were noted post-surgery. 
However, in patients where the concentrations of CEA decreased by over 33% 
were at significantly higher risk of death and relapse, which multivariate analysis 
showed to be an independent prognostic indicator. Research by Nicolini, et al. 
(2006) showed that a combination of classical BC biomarkers CEA, CA15.3 and 
tissue polypeptide (TPA) was more effective than the MCA (mucin-like 
carcinoma associated antigen)-CA15.3 biomarker panel at detecting early BC 
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relapse. Using all three markers greatly improved overall sensitivity with only a 
minor decrease in specificity. Another study revealed that combined 
measurement of CA15.3 and SLex might be better at detecting metastasis and 
monitoring BC than the CEA-CA15.3 combination (Kurebayashi, et al., 2006). In 
2001 Gion and colleagues published a paper confirming their earlier work in 
1999 that cancer antigen 27.29 (CA27.29) was of comparable quality to CA15.3 
for management of BC patients and was more sensitive when there was a 
limited antigen concentration (Gion, et al., 1999; Gion, et al., 2001). 
Earlier research has already revealed several potential BC biomarkers. 
However, most of these are not sensitive or specific enough. Yet, advances in 
proteomic technologies that detect prospective biomarkers have enabled 
analysis of new biomarker possibilities. For instance, identification of tumour 
antigens through a proteomics approach allows for post-translational 
modifications to be assessed whereas previous methods detection methods 
such as analysis of recombinant proteins did not. This enables detection of 
autoantibodies that react to naturally occurring proteins, including lysates from 
tumours and their cell lines, allowing antigenicity towards changes in post 
translational modifications such as glycosylation to be uncovered (Misek and 
Kim, 2011). Profiling of serum and nipple aspirate fluid has been enhanced by 
using mass spectrometry to interrogate bodily fluids for possible biomarkers. 
Mass spectrometry permits direct protein content analysis of human biofluids 
enabling fast detection of prospective biomarkers (Gast, et al., 2009; Pawlik, et 
al., 2006). Recently, several new biomarker candidates have been investigated 
(see Table 1.4).   
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Biomarker Type 
CA15.3 Serum Protein 
HER-2/neu Serum Protein 
RS/DJ-1 Serum Protein/Autoantibody 
p53 Autoantibody 
HSP60 Autoantibody 
HSP90 Autoantibody 
Mucin-related Autoantibody 
α-2-HS-glycoprotein Ductal Protein 
Lipophilin B Ductal Protein 
β-globin Ductal Protein 
Hemopexin Ductal Protein 
Vitamin D-binding protein Ductal Protein 
 
Table 1.4  Prospective Breast Cancer Biomarkers.  [Adapted 
from Misek and Kim (2011)] Recently investigated potential biomarkers for breast cancer. 
While these biomarkers are appropriate for monitoring BC progression and 
treatment efficacy they are all unsuitable for detecting the onset of BC, and 
there are currently no biomarkers that can.  
AGP is a potential BC biomarker due to it displaying aberrant glycosylation 
during diseases such as cancer (Turner, et al., 1985; Hashimoto, et al., 2004; 
Saldova, et al., 2007) and its suitability as a BC biomarker is discussed further 
in section 1.3.4. 
 
1.1.5 Need for a Diagnostic Breast Cancer Biomarker. 
 
The overview provided earlier in this chapter highlights a need for increased 
surveillance for those at greater risk of BC. While mammography is a highly 
specific and sensitive method of detection for BC in national screening 
programmes, there are some BCs that go unnoticed and  screening can only be 
offered every few years to avoid excess radiation exposure that could induce 
cancer (Berrington de González, 2011; NHS Breast Screening Programme, 
2003). Magnetic resonance imaging (MRI) can also be used for detection of BC 
in addition to mammography and can be offered at a younger age and more 
frequently that mammography. However, due to cost, this is not currently 
funded in Scotland for women at increased risk of BC due to family history or 
mutation status. Both these detection methods run the risk of over diagnosing 
patients resulting in an individual receiving unnecessary treatment for a lesion 
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that would not have developed into cancer. However, at present there is no way 
of telling whether an abnormality detected during screening will develop into 
cancer and so the best option is to proceed with treatment (Marmot, et al., 
2012). Therefore, there is still a need for a more cost-effective, less harmful 
method of BC screening that could be used more often for women at increased 
risk of BC or the general population. A model biomarker would be located in the 
blood with the ability to be used for both detection and prognosis. A blood 
based biomarker would require minimally invasive procedures to retrieve and 
components could be easily isolated for analysis. To date, no suitable blood-
based biomarkers have been identified for the detection of BC. While 
biomarkers such as CEA and CA15.3 glycoprotein are routinely used clinically, 
there are none suitable for early diagnosis of BC or screening programmes. 
This is because they may also be raised in benign conditions and have very low 
sensitivity and specificity  [for a recent review see Mirabelli and Incoronato 
(2013)]. Absence of an effective blood-based biomarker leads to late diagnosis 
of many BC sufferers, limiting their treatment options and increasing their 
mortality. As both CEA and CA15.3 are glycoproteins capable of evaluating BC 
prognosis, investigation of other glycoproteins as potential biomarkers may be 
beneficial.  
 
1.2 Glycosylation and Cancer 
 
Investigation into the altered metabolism of cancer cells has enabled the 
definition of six hallmarks of cancer which have been widely researched and 
were originally defined as: sustaining proliferative signalling; evading growth 
suppressors; activating invasion and metastasis; enabling replicative 
immortality; inducing angiogenesis and resisting cell death (Hanahan and 
Weinberg, 2000). More recently, these six hallmarks have been expanded by a 
further four to include avoiding immune destruction; genome instability and 
mutation; tumour-promoting inflammation and deregulating cellular energetics 
such as the Warburg effect (Hanahan and Weinberg, 2011; Warburg, et al., 
1928) giving a new total of ten cancer hallmarks. Aberrant glycosylation of a 
number of molecules is a known consequence of cancer (Dube and Bertozzi, 
2005) and contributes to several of the above hallmarks of cancer. 
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Changes in glycosylation may be due to a number of factors including differing 
levels of glycosyltransferases and glycosidases as well as their location within 
the cell, availability and activity of nucleotide sugars, availability of protein 
substrates and expression of molecules that regulate glycoprotein folding 
(Varki, et al., 2009). The altered glycosylation may disrupt normal cellular 
functions and contribute to tumour growth, metastasis and immune evasion or 
may be a consequence of altered cell metabolism that could be used as 
biomarkers (Varki, et al., 2009). 
Glycosylated molecules such as glycoproteins exist as secretory molecules or 
as glycoconjugates on cell surfaces; therefore it is important to consider both 
when discussing their involvement in cancer. The most common glycan 
alterations during cancer occur in N- and O- linked glycans and include 
sialylation, fucosylation, truncation and branching (Stowell, et al., 2015). 
Additionally, cancer cells often revert to expression of oncofetal antigens which 
are more commonly expressed in foetal tissue during development as opposed 
to normal adult tissue (Sapra, et al., 2012).  
Sialylation is the addition of sialic acid residues usually as terminal structures, 
such as Neu5ac, to glycans which are involved in cell adhesion, cell to cell 
signalling and cellular recognition (Varki, et al., 2009). Increases in sialylation 
have been identified in active cancer and this correlates with a decreased cell 
adhesion which may aid the metastasis of tumour cells (Dennis, et al., 1982; 
Nadanaka, et al., 2001; Renkonen, et al., 1997 and Ugorski, et al., 2002). 
Furthermore, the viability of cancer cells may be increased by alterations of α2-
6 sialylation expression that contribute to tumour growth via mechanisms 
independent of glycoproteins (Kroes, et al., 2010, Bobowski, et al., 2012). It has 
also been proposed that increased sialylation of cancer cells provides protection 
from the immune system and subsequent eradication (Bull, et al., 2014).  
Similarly, fucosylation is the incorporation of the monosaccharide fucose into 
glycan chains and this process has been shown to occur at differing rates 
during the early and late stages of cancer. Early stage cancer appears to favour 
increased fucosylation as research has shown an upregulation of 
fucosyltransferase 8 (FUT8) which may aid cell proliferation (Chen, et al., 2013). 
However, once established, tumours display less fucosylation which may assist 
their survival via NK cell evasion through interaction with a secondary signalling 
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pathway known as tumour necrosis factor-related apoptosis-inducing ligand 
(TRAIL; Moriwaki, et al., 2009). Furthermore, increased fucosylation is 
associated with an increase in Sialyl LewisX (SLeX) terminal structures. SLeX is 
a ligand involved in cell adhesion, therefore increased expression may play a 
role in metastasis through increased binding of tumour cells in secondary 
organs (Julien, et al., 2011). 
Another characteristic of cancer cells is truncated glycans, particularly O-linked 
glycans. These usually exist as more complex structures however during 
cancer, mucin-like O-linked glycans become truncated resulting in formation of 
Tn or Sialyl Tn (STn) stuctures. A solitary GalNAc confers Tn while and GalNAc 
joined to a sialic acid denotes STn. In both instances GalNAc remains attached 
to the protein via a linkage to the hydroxyl group of Serine or Threonine. 
Research has indicated that truncation of O-glycans may enhance malignant 
properties of cells including proliferation rate, invasive growth, loss of growth 
inhibition and tissue architecture as well as alterations in the adhesion of 
basement membranes (Radhakrishnan, et al., 2014). 
Additionally, the Warburg effect describes the increased uptake and anaerobic 
metabolism of glucose by cancer cells for energy to facilitate proliferation 
(Warburg, et al., 1928). Recently, the Warburg effect has been linked to 
increased O-GlcNAc transferase which catalyses the addition of N-
acetylglucosamine to proteins and lipids (Jozwiak, et al., 2014). It has been 
hypothesised that O-GlcNAcylation acts as a nutrient sensor and may link cell 
metabolism to transcription and signal transduction (Butkinaree, et al., 2010; 
Hanover, et al., 2010) resulting in enhanced proliferation, growth, angiogenesis 
and metastasis (Khan, et al., 2013; Porta, et al., 2014).  
Increases in β1-6 branching of N-linked glycans arises from amplified 
expression GlcNAc tranferase V and can explain the increased size of 
glycopeptides derived from tumour cells. GlcNAc transferase V is encoded by 
MGAT5 and studies have shown their involvement in tumour growth and 
metastasis when increased. For example, increased β1-6 branching induced by 
elevated GlcNAc transferase V resulted in more cell migration as well as 
decreased cell-cell and cell-matrix adhesion (Demetriou, et al, 1995) while mice 
deficient in MGAT5 had reduced tumour proliferation and metastasis 
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(Granovsky, et al., 2000). Thus highlighting the role of increased β1-6 N-linked 
glycan branching in cancer progression. 
Finally, tumour cells often display markers normally only seen during foetal 
development. These markers are known as oncofoetal antigens and the two 
most evident in the research are alpha fetoprotein (AFP) and carcinoembryonic 
antigen (CEA), both of which are glycoproteins (Zhang, et al., 2015). AFP has a 
similar amino acid sequence to albumin, a minimal carbohydrate content of 3% 
and is present at low levels in normal adults. However, serum AFP 
concentrations of above 500ng/ml are linked with malignancy (Farinati, et al., 
2006). Similarly, CEA is also expressed in malignancy as well as foetal 
development and is currently used clinically as an indicator and monitor of 
cancer. For example, persistently elevated CEA may indicate metastasis or 
ineffective therapy (Dallas, et al., 2012; Prager, et al., 2014) and pre-operative 
CEA can give an indication of patient prognosis (Amri, et al., 2013). 
 
1.2.1 Glycosylation and Breast Cancer 
 
Breast cancer remains the leading and most common cancer diagnosed in 
women (Information Services Division: ISD Scotland., 2014; Northern Ireland 
Cancer Registry., 2013; Office for National Statistics., 2011; Welsh Cancer 
Intelligence and Surveillance Unit., 2014) and as such, extensive research has 
been undertaken to identify potential biomarkers of diagnosis and prognosis as 
well as therapeutic targets. Much of this research has investigated altered 
glycosylation during BC using antibodies and lectins to recognise specific 
carbohydrate structures which unveiled variations in cell surface and serum 
protein glycosylation between BC and normal individuals. Elevated expression 
of truncated O-linked glycans, such as Tn and STn antigens, as well as 
increased N-linked β1-6 branching have been observed in breast cancer (Wu, 
et al., 2010, Saldova, et al., 2011). Increased sialic acid and fucose content was 
also noted due to the over expression of Lewis type structures such as SLex 
(Saldova, et al., 2011). Observations in serum proteins during BC have also 
indicated variations in mannose content and it is hypothesised that changes in 
processing of glycans which would normally trim Man9 structures leads to an 
increased expression of high mannose structures in place of complex and 
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hybrid N-linked glycans (de Loez, et al., 2011). All of the aforementioned glycan 
alterations correlated with changed expression of the corresponding 
glycosyltransferases that contribute to their formation – galactosyltransferases, 
fucosyltransferases, sialyltransferases and N-acetylglucosaminyltransferases 
(Potapenko, et al., 2010; Wu, et al., 2010; Burchell, et al., 1999).  
The effects of these glycan alterations on patient prognosis and metastasis 
have also been investigated. Such research has shown that increased N-linked 
β1-6 branching and over expression of Lewis type epitopes is associated with 
poor outcomes in BC patients (Madjid, et al., 2005; Cui, et al., 2011) with 
expression of both SLex and SLea linked to higher risk of metastasis (Julien, et 
al., 2011; Nakagoe, et al., 2002). Additionally, the increased presence of high 
mannose structures have been shown to correlate with breast cancer 
progression (de Loez, et al., 2011). 
Finally, aberrant glycosylation observed during BC has led to the use of 
glycoproteins such as CEA and CA 15-3 as serum BC biomarkers (discussed in 
more detail earlier in section 1.1.4). However, these glycoproteins lack the 
specificity and sensitivity required of diagnostic biomarkers so are not suitable 
for screening purposes (Anderson, 2005; Rifai, et al., 2006). Similarly, changes 
in glycosylation observed during BC are also displayed in other cancer types as 
mentioned in the previous section of this literature review (1.2). Therefore, a 
clear necessity for further investigation of altered glycosylation during BC has 
been highlighted. 
 
1.2.2 O- and N- Glycosylation as Drivers for the Breast Cancer Subtypes 
Discussed in This Thesis. 
 
The main BC subtype discussed throughout this thesis is TNBC, which may 
also be referred to as basal-like BC in the literature. As discussed in section 1.2, 
O-linked glycosylation is the post-translational addition of GalNAc to hydroxyl (-
OH) groups of Ser/Thr followed by attachment of further monosaccharides by 
various glycosyltransferases (Varki, et al., 2009). N-linked glycosylation is more 
complex (see Figure 1.4) and occurs as the transfer of a donor molecule 
(Glc3Man9GlcNAc2) to the amino groups of Asn residues at sites where the 
correct amino acid sequence exists (Asn-X-Ser/Thr) (Varki, et al., 2009). 
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Currently, little research has been performed with regards to glycosylation 
patterns within BC subtypes. Yet, O- and N-linked glycosylation of particular cell 
surface molecules have been found to aid the progression of certain BC 
subtypes (Srinivasan, et al., 2014).  
A recent study carried out by Lee, et al., 2014 revealed structural glycan 
alterations of luminal A, HER2 and basal-like cell secretions compared to 
normal breast epithelial cells using LC-MS. Their research showed an increase 
in hybrid N-linked structures, higher levels of glycan branching, increased SLex/a 
terminal structures as well as elevated fucosylation and overall degree of 
sialylation in basal-like BC cells. However, similar results were also seen in 
luminal and HER2 subtypes apart from basal-like cells having bisecting GlcNAc 
present and higher concentrations of α2-6 sialylation. Alpha 2-6 sialylation can 
occur in both O- and N-linked glycans with increases being linked to late stage 
BC (Alley and Novotny, 2010). As glycan sialylation is believed to aid tumour 
growth and contribute to metastasis through its functions in cell-cell recognition, 
cell adhesion and cellular recognition, increases in α2-6 sialylation are not 
unexpected in late stage cancer. Furthermore, TNBC is notoriously aggressive, 
fast growing and is linked with poor patient outcomes (Bauer, et al., 2007; 
Blows, et al., 2010; Chacon and Costanzo, 2010; Dent, et al., 2007; Schneider, 
et al., 2008). This also fits with the hypothesis that increased α2-6 sialylation of 
O- and N-linked glycans could be a contributing factor. 
With regards to cell surface molecule glycosylation driving BC subtypes, 
research by Srinivasan et al (2014) revealed that N-linked glycosylation of 
ADAM8, a transmembrane metalloproteinase, occurred in ER negative tumours 
but not in ER positive tumours and that ADAM8 activity was reliant on correct N-
linked glycosylation. ADAM8 has been shown to be upregulated in TNBC and is 
involved in cell adhesion as well as activation of growth pathways such as β1-
integrin which promotes invasion and metastasis (Romagnoli, et al, 2014). 
Furthermore, MUC1 - a heavily O-glycosylated protein located in cell 
membranes – has been shown to express aberrant O-linked glycans on its 
surface after malignant transformation of cells (Gendler, et al., 1988). Recent 
research has shown a high expression of MUC-1 in TNBC tumour cells which 
correlated with tumour grade (Siroy, et al., 2013). However, other studies have 
noted an inverse correlation between MUC1 expression and tumour grade 
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(Rahn, et al., 2001). Throughout cancer MUC1 has been shown to interact with 
p53 to inhibit apoptosis which enables malignant cells to proliferate unimpeded 
(Wei, et al., 2005) and promote tumour invasion through beta-catenin. This 
association with beta-catenin results in the promotion of metastasis through 
epithelial-mesenchymal transition. This is the transformation of epithelial cells to 
mesenchymal stem cells through loss of cell-cell adhesion and cell polarity with 
enhancement of invasive and migratory mechanisms (Schroeder, et al., 2003 
and Roy, et al., 2011). Therefore, increased expression of MUC1 in TNBC may 
contribute to the aggressive development and poor patient outcome linked with 
this BC subtype.  
 
1.2.3 Glycobiology 
 
Glycobiology is the study of proteins and lipids which have covalently linked, 
oligosaccharide chains added to their surface catalysed by enzymes 
(Rademacher, et al., 1988). Oligosaccharide chains (also known as glycans) 
are composed of monosaccharides that share a (CH2O)n  chemical formula. The 
chains are synthesised as a co-translational and/or a post-translational 
modification. Glycosylation takes place in the endoplasmic reticulum and Golgi 
apparatus, generating a variety of particular glycoconjugates in the form of 
either glycolipids or glycoproteins.  At a molecular level, glycosylation is 
controlled by enzyme clusters known as glycosyltransferases, within the 
endoplasmic reticulum and Golgi, which catalyse the joining of 
monosaccharides, arranging them in precise sequences to generate 
oligosaccharide chains. Therefore, glycosylation is not directly regulated 
genetically like the majority of protein or lipid alterations (Kobata, 1992; 
Sasisekharan and Myette, 2003). The variety of glycoconjugates (i.e. 
glycoproteins or glycolipids) produced can be affected by similar enzymes being 
present in other cell and tissue types causing trimming and/or additional 
monosaccharides being added to a glycan resulting in glycoforms. Glycoforms 
are proteins with the same amino acid sequences but possess different glycans 
(Lis and Sharon, 1993; Rademacher, et al., 1988). Variation between 
glycoconjugates is known as heterogeneity and the collections of glycoforms 
that arise are referred to as the glycome.   
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Glycoconjugates are essential, having a vast array of functions such as acting 
as adhesion molecules and sometimes as enzymes. Generation of 
glycoconjugates uses large amounts of energy in an ordered and complex 
manner (Kornfeld and Kornfeld, 1985; Taylor and Drickamer, 2003; Varki, 2009) 
with glycosylation often being  responsible for large amounts of a protein’s (or 
lipid’s) mass (Rademacher, et al., 1988). For instance, oligosaccharides 
account for 45% of the molecular mass α-1-acid glycoprotein (AGP). It is also 
reported that approximately 70% of proteins undergo glycosylation (Wormald 
and Dwek, 1999).   
These factors, imply that glycosylation of macromolecules is purposeful. For 
example, cancer progression has been shown to rely on glycans being present. 
For instance, increased sialyl Lewis X antigen (SLex; an inflammation derived 
terminal antigen structure containing fucose) present on glycans during cancer 
amplifies interactions with P-selectins which aids dissemination of tumours 
(Kim, et al., 1998). This has enabled links to be drawn between glycan function 
and many pathophysiological or physiological conditions (Varki, 1993).  
Overall, glycobiology is an important area of biomedical research that has yet to 
be fully explored. An accumulation of research in this area highlights that 
glycosylation is involved in many aspects of human life, from development to 
cancer progression. Therefore, it is possible that glycan composition could be 
used as a biomarker for BC onset. 
 
1.2.4 Glycan Components 
 
As discussed in section 1.2.1 glycosylation is the post-translation modification of 
a molecule through the addition of glycans (sugar chains). Glycans are 
comprised of monomeric units known as monosaccharides which can be 
discriminated between by their functional groups. There are two fundamentally 
different monosaccharides that differ in their functional groups at carbon 1 (C1; 
the anomeric carbon atom), namely, keto and aldehyde, which are composed of 
the C1 carbon atom linked covalently by a double bond to oxygen. When the 
structure of a monosaccharide is considered in its open-chain form, if a keto 
group is present, the double bond is located within a chain (>C=O) and the 
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monosaccharide is described as a ketose. Whereas aldoses have an aldehyde 
group with the double bond situated at the C1 end (-CH=O) (Bertozzi and 
Rabuka, 2009). 
Oligosaccharides occur when eight or less monosaccharides undergo 
polymerisation (Bertozzi and Rabuka, 2009). The number of carbon atoms 
within the structure can be used to sub classify monosaccharides for instance; 
galactose (Gal), glucose (Glc) and mannose (Man) possess six and are 
therefore termed hexoses. Fucose (Fuc)  also has six carbons but is referred to 
as a deoxyhexose as carbon 6 (C6) is missing a hydroxyl group (-OH), while 
sialic acids (SA; Gal with common terminating sugars α-2-3 or α-2-6 linked, also 
known as neuraminic acid NeuAc) are located on glycan termini and have nine 
carbons (Varki, 1992). Furthermore, a second group of monosaccharides 
known as hexosamines incorporate an amino group on the second of six 
carbons and tend to occur as N-acetylated structures such as N-
acetylgalactosamine (GalNAc) and N-acetylglucosamine (GlcNAc).These are 
the most common sugars found within glycoconjugates  (see Figure 1.1 below 
for summary). Monosaccharides can exist as one of two stereoisomers, either 
D- or L- (with the former being the most common within nature), depending on 
whether the -OH group on the chiral centre found farthest away from the –CHO 
functional group has the D-glyceraldehyde configuration (OH to the right in the 
Standard Fischer Projection formula) or the L-glyceraldehyde configuration (OH 
to the left in the Standard Fischer Projection formula) (Bertozzi and Rabuka, 
2009). 
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Figure 1.1 Hemiacetal Configuration of Common Monosaccharides 
within Glycans. Chemical structures of a selection of monosaccharides that normally 
compose glycoprotein oligosaccharide chains, as stable hemiacetal rings. As Fuc is a 
deoxyhexose the “missing” –OH group on C6 has been emphasised using         . 
  
The formation of glycan chains occurs when monosaccharides join together 
through the –OH group of C1 and another –OH group of a neighbouring residue 
forming a glycosidic bond through the loss of a H2O molecule (condensation 
reaction) shown in Figure 1.2.  Depending on the conformation of the –OH 
group of C1, the adjacent –OH must be in either the α or β anomeric position 
and the types of monosaccharides that are linked during the reaction determine 
whether the subsequent oligosaccharides are homo- or heterogenous. This 
creates a large assortment of glycans from few monosaccharides (termed 
heterogeneity), as the structure can vary marginally in length of chains, 
sequence, number of chains attached or type of bond. This structural diversity is 
illustrated by the fact that only six tripeptides can be generated from three 
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amino acids but 27, 648 trisaccharides can be produced from just three 
hexoses (Maeder, 2002). Furthermore, sugars are able to possess various 
linkage positions resulting in more complex structures being produced and by 
displaying α and β anomers even more glycan varieties can be formed. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.2 Formation of Glycosidic Linkages. Examples of α- (A) and β- (B) 1, 4-
linkages between two sugar molecules. Linkages can also occur between carbon 1 and carbon 
6 (1, 6-linkage). 
 
Overall, it is remarkable that oligosaccharide structures are capable of such 
wide variation in composition. It is this variation in structure and glycan 
attachment to proteins to form glycoproteins that is of great interest for 
discovery of a BC biomarker.  
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1.2.5 Glycoproteins 
 
Glycoproteins are polypeptides covalently linked to oligosaccharide moieties 
that usually have a SA residue at their terminus. The biosynthesis of glycans is 
a complex process but necessary as glycans contribute to stability and function 
of the recipient polypeptide. The addition of glycans to the polypeptide 
backbone can occur as a co- and/or post-translational modification.  
Glycans commonly become linked to polypeptides via either N- or O-linkages at 
the reducing end of the oligosaccharide chain. At specific asparagine residues 
within the protein portion, N-linkages can occur through the amide nitrogen, 
while O-linkages arise via an –OH group of serine/threonine (Ser/Thr). It is 
known that approximately 97% of all blood plasma glycoproteins possess N-
linked glycans (Finne and Krusius, 1979). Their synthesis is complex and 
attachment to the polypeptide requires the specific tripeptide sequence Asn-X-
Ser(Thr) in order to occur.  This sequence can be used to predict which Asn 
residues in the protein backbone will become glycosylated via an N-link (Gavel 
and von Heijne, 1990). Due to specific requirements such as an appropriately 
positioned consensus sequence, sufficient oligosaccharyltransferase activity 
and variety of fully assembled, glycosylated lipid-linked oligosaccharide donors, 
glycosylation only occurs on roughly one third of Asn residues (Kornfeld and 
Kornfeld, 1985). The intricate synthesis of N-linked glycans from a common 
precursor results in the possession of a characteristic core structure of 
GlcNAc2Man3. 
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Figure 1.3 Representation of Bond Between Terminal GlcNAc and Asn 
Residue. [Adapted from Garrett and Grisham (2005)] Depiction of linkage between 
terminal monosaccharide GlcNAc and the Asn residue in the consensus sequence of the 
recipient protein to form a basic glycoprotein prior to processing. 
 
In comparison, O-linked glycan synthesis is much simpler, without the 
requirement for a consensus sequence in the inner core; it is GalNAc normally 
attached to Ser/Thr.  However, thereafter glycan diversity is increased due to 
numerous core structures being generated by such a simple synthesis. O-linked 
glycans may contain Glc within the oligosaccharide chain and tend to exist on 
glycoproteins originating from epithelial cells (Dell and Morris, 2001).  
Many glycoproteins are exclusively either N- or O- linked. For example AGP, α-
1-antitrypsin (AAT), tissue plasminogen activator, interferon β and interferon γ 
only possess N-linkages while granulocyte colony stimulating factor (GCSF) 
and interleukin-2 (IL-2) are solely O-linked. It is possible for glycoproteins to 
carry an assortment of N- and O-linkages as is the case of coagulation factor 
VIII and the hormone erythropoietin (EPO) (Lis and Sharon, 1993). 
Integration of glycoproteins in different cell types strongly influences their 
expression. The polypeptide backbone is synthesised through the transcription 
and translation of particular genes and co-ordinates glycosylation sites (Freeze, 
2001). Glycoform expression from different cell types is capable of producing a 
wide variety of glycans as each type has a diverse assortment of enzymes 
which catalyse glycan formation, resulting in a large amount of heterogeneity. 
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Therefore, variance between glycan compositions can reveal the biochemical 
and physiological conditions present during production as well as tissue or cell 
origin (van Dijk, et al., 1994). Glycosylation of proteins with a diverse 
assortment of glycans is essential for normal mammalian function as glycans 
are involved in biomolecule and cellular recognition, movement of enzymes 
within cells and ceasing leukocyte rolling during inflammation. However, to gain 
a wide variety of glycans, a complex mode of synthesis is required which is fully 
explored in the following section. Glycan heterogeneity affects the conformation 
of a glycoprotein which changes its physical properties such as solubility or 
stability. This influences functions such as cell-cell, protein-protein or protein-
saccharide recognition; intracellular enzyme trafficking and inhibition of 
leukocyte rolling during inflammation (Durand and Seta, 2000; Sears and Wong, 
1998).  
The majority of serum proteins possess surface glycans. The glycosylation of 
proteins is the final stage in the maturation of the protein structure. If 
glycoproteins fail to become glycosylated, their function may be altered or lost 
entirely. EPO is an example of a protein whose activity is reduced when it is has 
incomplete glycosylation. In order to function correctly EPO must be 
glycosylated at three N-linked sites (positions 24, 38 and 83) and one O-linked 
site (126). EPO regulates red blood cell synthesis upon release from the 
kidneys, but is rapidly eliminated by the liver if reduced SA content of the 
glycans occurs. Removal of SA residues can occur during or after biosynthesis 
during recycling of cell surface molecules (Varki, 2009).  This highlights the 
importance of glycosylation as anaemia can occur in an individual if EPO is 
removed before it can participate in the synthesis of red blood cells (Macdougall 
and Eckardt, 2006). 
 
1.2.5.1 Biosynthesis of N-linked Glycans. 
 
N-linked glycosylation occurs in the membrane of the rough endoplasmic 
reticulum (RER) and Golgi. It is the en bloc transferal of a Glc3Man9GlcNAc2 (a 
tetradecasaccharide) from a polyisoprenyl donor onto the amide nitrogen 
located at the terminus of an Asn side chain acting as an acceptor protein.  
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In order for N-linked glycosylation to occur on the amide group of Asn residues, 
β-turns within the secondary structure of polypeptides must be formed. β-Turns 
are formed when hydrogen bonds arise between the hydroxyl (-OH) group of 
Ser/Thr and an Asn residue amide (CO-NH2) group (Smith, et al., 1997). 
Therefore, the consensus sequence (Asn-X-Ser/Thr) resides as a β-turn, where 
X can be any amino acid except proline (Pro) as it is missing an α-amide proton 
preventing β-turn configuration (Bause, 1983). A bond can now form between 
the –NH group of the Asn amide residue and terminal monosaccharide 
(GlcNAc) of a basic glycan chain resulting in the beginning of a glycoprotein 
(see Figure 1.3). It may also be possible for N-linked oligosaccharides to react 
with neutral, aromatic amino acid side chains in the three amino acids adjacent 
to glycosylated Asn residues (Yet and Wold, 1990). Newly added glycans are 
then processed and trimmed in the RER and Golgi by competitive enzymes 
known as glycosidases and glycosyltranserases e.g. mannosidase, glucosidase 
and galactotransferase. These enzymes can catalyse several varied reactions 
due to their competitive nature, increasing microheterogeneity of the glycans 
produced (Couldrey and Green, 2000; Guile, et al., 1996). 
N-linked glycosylation occurs in four locations (summarised in Figure 1.4). In 
the cytosol of the RER, monosaccharides become bound to nucleotides to 
create high energy molecules such as GDP-Man and UDP-GlcNAc that attach 
to the lipid dolichylphosphate (Dol-P) situated in the RER membrane, forming 
Man5GlcNAc2-Dol-P. The transfer of nucleotide-bound monosaccharides to Dol-
P is catalysed by GlcNAc-transferase, GlcNAc-1-phosphotransferase and 
mannosyltransferase. Transporter proteins termed flippases then cause the 
structure to move from the RER cytosol to the RER lumen (Sanyal and Menon, 
2009) where another seven monosaccharides are joined to the structure via 
glycosidic bonds creating the oligosaccharide precursor Glc3Man9GlcNAc2. 
Oligosaccharyltransferase (OST) is a multimeric complex that transfers the 
oligosaccharide precursor from Dol-P to Asn in the consensus sequence (Asn-
X-Ser/Thr) of nascent glycoproteins (Dennis, et al., 1999; Imperiali and 
O’Connor, 1999). The structure is then trimmed by glycosidases whilst being 
translocated through the RER and Golgi. In the medial Golgi GlcNAc-
transferases perform substitutions and lastly, in the trans Golgi network the 
structure is elongated before leaving the Golgi. 
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Regulatory stages take place during synthesis to ensure that defective glycans 
are not created. For instance, glycoproteins enter the calnexin/calreticulin cycle, 
once they have two Glc removed in the RER by α-1,2-glucosidase I and α-1,3-
glucosidase II, which prevents incorrectly folded proteins from remaining in the 
pathway. If an improperly folded protein is detected, a Glc residue is added to 
the protein in the RER lumen by a glycosyltransferase targeting it to re-enter the 
calnexin/calreticulin cycle. The faulty protein remains in the calnexin/calreticulin 
cycle until folded correctly, at which point the added Glc residue is removed by 
glucosidase II (Deprez, et al., 2005; Sousa, et al., 1992).  
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Figure 1.4 N-linked Glycosylation. [Adapted from (Larkin and Imperiali, 2011; Rich 
and Withers, 2009; Varki, 2009)] A summary of the synthesis and processing of N-linked 
glycans in the RER and Golgi which differ depending on the type of N-linked glycan attached. 
 
 
= Gal =SA = GlcNAc = Man = Fuc = Glc 
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1.2.5.2 Types of N-linked Glycans: High-Mannose, Complex and Hybrid. 
 
N-linked glycans share a common pentasaccharide core (Man3GlcNAc2) but 
can differ in overall structure due to the biosynthetic process of trimming and 
adding monosaccharides (Albani and Plancke, 1998) as shown in Figure 1.4. 
Three types of N-linked glycans termed high-mannose, complex or hybrid 
(shown in Figure 1.5) are produced via trimming and processing of the glycan 
precursor by enzymes in the RER and Golgi.   
High-mannose structures are distinguished by the possession of a 
heptasaccharide core which is formed when the pentasaccharide core gains 
between two and six Man residues (see Figure 1.5). A maximum of four Man 
residues can join to the Man located at the non-reducing terminus of the core 
and as suggested by the name high-mannose, the only monosaccharides found 
in these chains are Man (Imperiali and O’Connor, 1999; Kobata, 1992). If high-
mannose structures become phosphorylated, producing mannose-6-phosphate, 
they are targeted towards the lysosomes through binding to the Man-6-
phosphate receptor and exit from the cis golgi without being involved in the rest 
of the processing pathway (Smith, et al., 1997). 
Synthesis of complex N-linked glycans requires more processing as they tend 
be capable of a wider assortment of linkages and monosaccharides. They 
consist of a trimannosyl core (three Man) with two GlcNAc residues linked to a 
glycoprotein and during processing have sugars added to them such as 
GlcNAc, Gal, Fuc and SA as shown in Figure 1.5. Structural variation of the 
glycan may be increased by a Fuc residue bonding to the innermost GlcNAc 
(Kobata, 1992). In comparison to high-mannose structures which tend to 
express only 2 GlcNAc residues and between 5-9 Man, complex glycans 
usually have 4-6 GlcNAc residues and 5-7 neutral sugars (Fan, et al., 1994). 
Complex glycans can exist as bi-, tri-, tetra- and penta-antennary chains and 
can be subdivided as such, with a SA residue  at the terminus allowing the 
glycans to avoid being destroyed by the liver and circulate in the blood (Morell, 
et al., 1971).  
Hybrid structures arise when mannosidase (hydrolyses Man) does not act upon 
addition of a GlcNAc residue to the core structure in the Golgi. Similar to high-
mannose, Man residues can join core outer Man residues as well as GlcNAc, 
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while Fuc can bind to the innermost GlcNAc residue in a similar manner to 
complex glycans (see Figure 1.5). This results in a combination of high-
mannose and complex characteristics as hybrids possess a Man α-1,6 branch 
(high-mannose) and a Man α-1,3 branch incorporating Gal and more GlcNAc 
residues comparable to complex glycans (Durand and Seta, 2000; Kobata, 
2000).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.5 Types of N-linked Glycan Structure. [Adapted from Varki et al., 
2009] Illustration of high-mannose, complex and hybrid N-linked glycan structures emphasising 
the common pentasaccharide core. 
 
1.3 Alpha-1-acid Glycoprotein 
 
Alpha-1-acid glycoprotein (AGP) is an N-linked glycoprotein, exclusively 
expressing complex glycans that can be bi-, tri- or tetra-antennary, which occurs 
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naturally in plasma through secretion by hepatocytes (primarily), breast tissue 
(Gendler, et al., 1982), cardiac cells (Siegal, et al., 1985), testes, 
gastrointestinal tract (Twining, et al., 1977) and number of immune cells such as 
monocytes and lymphocytes (Gahmberg, et al., 1978). Therefore, AGP 
glycosylation could prove to be a suitable biomarker for BC detection due to 
secretions of AGP carrying aberrant glycosylation from malignant BC tumour 
cells. 
AGP is predominantly secreted by hepatic parenchymal cells and while its 
primary function has yet to be discovered, it is known that AGP is involved in 
plasma protein binding of drugs for transportation, regulation of homeostasis, 
and immunomodulation (Fournier, 2000). For instance, AGP has been shown to 
increase in concentration during inflammation suggesting its implication as an 
anti-inflammatory and immunomodulatory molecule. Increased AGP 
concentrations as well as changes in glycosylation have been shown to occur 
during several pathophysiological and physiological states such as cancer.  
 
1.3.1 AGP Structure 
 
AGP is named due to its migration with the α-1 protein group during plasma 
protein electrophoresis as it has a low pI of 2.8-3.8 (Nakano, et al., 2004). AGP 
is formed when a 201 residue single polypeptide precursor is cleaved after the 
first 18 residues (Ceciliani and Pocacqua, 2007). The remaining protein portion 
contains roughly 59% of AGP’s structure and 23kDa of its total mass (Albani, et 
al., 2000; Liao, et al., 1985) with the rest being composed of carbohydrate. 
Human AGP was initially thought to be composed of 181 amino acids creating a 
single polypeptide (Schmid, et al., 1973). However, research by Dente, et al. 
(1985) proved that AGP was 183 amino acids in length due to an extra Lys and 
an Arg residue at positions 173 and 174 respectively. There is also the potential 
for 22 amino acid substitutions within the molecule. These 22 sites of 
substitution are linked to the differences between the genes that code for AGP 
(AGP 1 and 2) and the gene products are present in a 3:1 ratio in human 
plasma under normal physiological conditions.  
There are three main genetic variants of AGP with expression of these variants 
controlled by three adjacent genes located on chromosome 9. AGP-A (also 
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referred to as ORM-1) encodes variants F1, F2 and S while AGP-B and AGP-B’ 
(ORM-2) code for A (Colombo, et al., 2006; Katori, et al., 2011). The three 
genes are very similar in structure with AGP-A only differing from identical 
genes AGP-B/B’ by 22 base substitutions. As F1, F2 and S are all encoded by 
two alleles of AGP-A, they are collectively known as F1*S and differ by less 
than five amino acids each. However, variant A has approximately 20 amino 
acids substituted but with all variants containing 183 amino acids in total this is 
only a minor difference (nearly 11%) (Schmid, 1989). It is not yet known 
whether these substitutions affect gene product glycosylation but, it is thought 
that they may be located within AGP’s glycosylation sites at positions 15, 75 
and 85 as shown in Figure 1.8 (van Dijk, et al., 1991). F1*S is the main 
constituent of serum with a 3:1 ratio compared to A but this may be due to AGP-
B/B’ being expressed 100 times less than AGP-A (possibly owing to 
transcription occurring only at the first gene within the cluster) (Dente, et al., 
1987). However, the level of each variant has been shown to change during 
diseases such as lymphoma, ovarian cancer and melanoma with ratios of up to 
8:1 reported (Budai, et al., 2009). Figure 1.6 shows a structural representation 
of the F1*S variant (A) and the A variant (B) acquired by x-ray crystallography 
which reveals the folding pattern of F1*S and A are the same but the binding 
pockets differ as F1*S has three lobes and is wide but A only has two lobes 
thus is narrower and may affect binding function (Taguchi, et al., 2013). Figure 
1.6 A/B shows unglycosylated AGP variants as the extensive glycosylation 
makes x-ray crystallography difficult therefore glycans are removed. 
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Figure 1.6 Unglycosylated Structure of AGP Variants. X-ray Crystallographic 
structure of AGP variants F1*S (AGP-A) and A (AGP-B/B’) from Taguchi et al., (2013). 
 
The molecular structure of AGP is comprised of α-helix (15%), β-sheet (41%), 
reversed β-turns (12%), bands (8%) and unordered structures (24%) (Kopecký 
Jr, et al., 2003). This structure shows similarities with lipocalins (of which AGP 
is a subfamily via the immunocalin group) which also contain a large number of 
β-sheets and have been shown to have significant immunomodulatory effects. 
Similar to lipocalins, AGP folds as a highly symmetrical β-sheet structure 
containing a single antiparallel β-sheet with eight strands (Flower, 1996; 
Kopecký Jr, et al., 2003).  
AGP has a carbohydrate content of over 40% of the molecular weight as it is 
extensively glycosylated with five highly sialylated complex N-linked 
oligosaccharide chains (Yoshima, et al., 1981) with four of these being linked to 
Asn residues in areas with a high number of polar residues or inside reverse β-
A – F1*S variant  
B – A variant  
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turns (Ceciliani and Pocacqua, 2007; Kremer, et al., 1988). The consensus 
sequence Asn-X-Ser(Thr) where X cannot contain a proline (Pro) residue due to 
it preventing a  β-turn, necessary for glycan attachment.  
A number of amino acids such as all three tryptophan (Trp) residues, certain 
tyrosine (Tyr) residues and the majority of phenylalanine (Phe) residues have 
preferences of location within AGP’s folded structure (see Figure 1.7) due to 
molecular interactions within the polypeptide backbone (Albani, 2003). While 
some residues lie close to or above the surface of AGP such as Trp 122 which 
is located between the surface and the hydrophobic binding site and Trp 160 
(exposed), Trp 25 is buried in the hydrophobic binding site. Trp residues are 
more capable of rotation the closer they reside to the surface (Friedman, et al., 
1985). Furthermore, 5-7 Tyr and the majority of the Phe residues lie buried – 
partially or completely – in the native state. 
 
AGP-A           MQIPLCANLVPVPITNATLDQITGKWFYIASAFRNEEYNKSVQEIQATFFYFTPNKTEDTI 60 
AGP-B/B’        MQIPLCANLVPVPITNATLDRITGKWFYIASAFRNEEYNKSVQEIQATFFYFTPNKTEDTI 60 
                 *******************:**************************************** 
 
AGP-A            FLREYQTRQDQCIYNTTYLNVQREN-TISRYVGGQEHFAHLLILRDTKTYMLAFDVNDEK 119 
AGP-B/B’         FLREYQTRQDQCFYNSSYLNVQRENGTVSRYEGGREHVAHLLFLRDTKTLMFG---DDEK 117 
                 ************:**::******** *:*** **:**.****:****** *:.   :*** 
 
AGP-A            NWGLSVYADKPETTKEQLGEFSYLEALDCLRIPKSDVVYTDWKKDKCEPLEKQHEKERKQ 179 
AGP-B/B’         NWGLSFYADKPETTKEQLGEF--YEALDCLCIPRSDVMYTDWKKDKCEPLEKQHEKERKQ 175 
                 *****.***************   ****** **:***:********************** 
 
AGP-A            EEGES 184 
AGP-B/B’         EEGES 180 
                 ***** 
 
Figure 1.7 Protein Alignment of AGP Variants.  [adapted from Taguchi, et 
al., 2013 and created using Clustal 2.1 software] The start methionine is highlight in green and 
sites of transcript variation are highlighted in red. “:” (colon) indicates conservation between 
groups of strongly similar properties. “.” (period) indicates conservation between groups of 
weakly similar properties. 
 
The remaining 41-45% of the AGP molecule is composed of glycan chains and 
galactoglycoprotein (Schmid, et al., 1980) is the only molecule to surpass AGP 
in its unusually high glycan content with 76%. At residues 15, 38, 54, 75 and 85 
there are five variable, highly sialylated heteropolysaccharide complex-type N-
linked glycans attached to Asn residues usually in the first half (from the N-
terminus) of the polypeptide (Eap and Baumann, 1993; Israili and Dayton, 
2001). The negative charge and low pI (2.8-3.8) is due to C1 of SA possessing 
a –COOH group as well as acidic amino acids being present (Elg, et al., 1997; 
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Hochepied, et al., 2003). It is estimated that 11-12% of AGP is comprised of up 
to 16 SAs, which results in the low pI of AGP, with each having an approximate 
weight of 314Da and if these are lost through desialylation, AGP becomes 
inactive. Mature unglycosylated AGP has a higher pI of 4.97 (Devereux et al., 
1984). The glycan structure of AGP is also composed of Gal, GlcNAc and Man 
(14%) as well as Fuc (1%). (Dente, et al., 1987; Kremer, et al., 1988). The 
innermost pentasaccharide core is common to all N-linked glycans. 
Fournier, et al. (2000) revealed that Fuc can be linked via the external branch to 
GlcNAc using an α-1-3 bond as well as being linked to a core GlcNAc or Gal via 
a α-1-6 and α-1-2 bond respectively. This may account for the degree of 
variation in fucosylation between individuals which tends to increase when 
greater numbers of tri- and tetra antennary chains are present in the structure. 
Approximately 30% of human serum proteins do not contain Fuc but AGP is in 
the minority of glycoproteins that can possess tetra antennary N-linked glycans 
along with bi- and tri- antennary, therefore allowing for the presence of Fuc. Fuc 
accounts for 0.8% of AGP with Gal, GlcNAc, Man and SA completing the 
molecule with 6.3%, 14.9%, 5.2% and 11.3% respectively.  
The presence of glycans allows for the vast structural variability of AGP creating 
the potential for 105 different glycoforms. This is known as microheterogeneity. 
Only 12-20 of these are expressed during normal (non-pathological) 
circumstances with varying levels of fucosylation, branching and sialylation 
demonstrated by each (Albani, 1997). AGP expresses two types of 
microheterogeneity: type I and type II which can be sub-classified and are not 
associated with the peptide backbone but rather the glycan chains. Type I is the 
major form, responsible for the reduced tri- and tetra-antennary chain 
expression in favour of bi-antennary branching. However, type II (the minor 
form) is associated with the degree of sialylation and fucosylation of AGPs five 
oligosaccharide chains (Albani, 1997). As shown in Figure 1.8, Asn residues 
express glycans selectively depending on their degree of branching which 
reduces the possible number of glycoforms. Asn 15 and 38 are the first and 
second sites of glycan expression and usually have bi-antennary glycans linked 
to them. Additionally, Asn 15 never carries tetra-antennary chains just as Asn 
38 will not bind fucosylated glycans. However, branched glycans are favoured 
by Asn 75, which only binds tri- and tetra-antennary chains, and Asn 85 which 
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displays the highest levels of α-1,3- fucosylation (Higai, et al., 2005). Fournier et 
al., (2000) proposed that these are the only two sites with the ability to bind 
tetra-antennary glycans with multiple Fuc residues due to increased branching. 
AGP glycans are 10-15% bi-antennary with the majority (85-90%) being either 
tri- or tetra-antennary (Perkins, et al., 1985). 
Smith, et al. (2002) demonstrated that AGP is more metabolically stable than 
other glycoconjugates as tri- and tetra-antennary chains are bound more tightly 
by their termini than bi-antennary chains to the polypeptide core. As well as this, 
it was shown that glycan microheterogeneity variation is established by sugar 
nucleotide availability, tissue-specific glycosyltransferase gene regulation and 
enzyme competition during the processing of the glycan. 
 
 
Figure 1.8 Illustration of AGP N-linked Glycosylation Possibilities.      
Glycan branching is shown as described previously in the text, however chain length can differ. 
The particular Asn sites that glycans link to are also labelled with certain residues only 
expressing a specific type of glycan branching (bi-, tri- and tetra-antennary). 
 
1.3.2 AGP Function 
 
The primary in vivo function of AGP is still debated despite rigorous 
investigation, however, it is reported that AGP production contributes to 
regulation of homeostasis, plasma protein binding to drugs and 
immunomodulation. With immunomodulatory functions being influenced by 
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glycosylation pattern (Ceciliani and Pocacqua, 2007) as summarised in Table 
1.5. The structure of the glycans AGP carries can affect its function (Chiu, et al., 
1977) and as a member of the lipocalin family, AGP has a highly conserved 
structure with a largely varied protein sequence allowing it to perform the 
transportation of small hydrophobic molecules (Flower, et al., 2000; Treuheit, et 
al., 1992). 
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Table 1.5  Summary of AGP Functions. 
 
AGP glycoforms have differing immunomodulatory roles due to varying glycan 
structure, particularly in cancer patients. For example, Pukhal'skiĭ, et al. (1994) 
isolated AGP from ascitic fluid in stomach cancer patients as well as from the 
blood of a healthy population and investigated the effects of lymphocyte 
Activity AGP Involvement Examples Study 
Anti-inflammatory  Injury healing carried out by neutrophils and 
complement is reliant on SLe
x
 groups.  
 AGP with little or no bi-antennary glycans enables 
inhibition of CD3-induced lymphocyte proliferation.  
 Reduces neutrophil influx and TNF-α expression in 
mice with renal ischemia and reperfusion injury. 
 Inhibits complement cascade if carrying the correct 
glycan composition. 
Pos, et al. (1990b) 
Kalmovarin, et al. (1991) 
Williams, et al. (1997) 
Daemen, et al. (2000)  
Pro-inflammatory  AGP co-induces monocyte production of IL-1β, IL-6 
and TNF-α in the presence of LPS. 
 Can stimulate fMLP preactivated neutrophils to 
produce a secondary ROS response. 
 Local AGP production by monocytes in response to 
cytokines. 
Boutten, et al. (1992) 
Drenth, et al. (1996) 
Su and Yeh (1996) 
Hochepied, et al. (2003) 
Gunnarsson, et al. (2010) 
Immunomodulation  Modulation of lymphocytes by decreasing their 
responsiveness to PHA, Con A and PWM. 
 Lymphocyte function is maximally suppressed by 
agalactosylated and asialylated AGP. 
 Inhibits activation and migration of neutrophils. 
 Inhibits apoptosis and the resulting inflammation. 
 Inhibits phagocytosis and platelet aggregation. 
Snyder and Coodley (1976) 
Chiu, et al. (1977) 
Bennett and Schmid (1980)  
Athamna, et al. (1996) 
Hochepied, et al. (2003) 
de Vries, et al. (2004) 
Mestriner, et al. (2007) 
Matsumoto, et al. (2007)  
Drug Binding  High affinity binding sites can bind neutral and 
basic drugs as well as steroids and plasma. 
 Can bind tamoxifen, imipramine, warfarin, quinine, 
imatinib, disopyramide and methadone. 
 Elevated AGP can reduce adverse effects of toxic 
drug doses by binding to the toxic component and 
subsequently inactivating it. 
 Binds toxic lectins and LPS produced by 
microorganisms. 
Otagiri, et al. (1987) 
Chatterjee and Harris (1990) 
Pos, et al. (1990a) 
Silamut, et al. (1991) 
Hervé, et al. (1998) 
Libert, et al. (1994) 
Moore, et al. (1997) 
Frantz, et al. (2000) 
Israili and Dayton (2001) 
Matsumoto, et al. (2002) 
Kopecký Jr, et al. (2003) 
Gambacorti-Passerini, et al. (2003) 
Widmer, et al. (2006) 
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responsiveness. AGP isolated from patients with stomach cancer contained 
more bi-antennary glycans and proved a better inhibitor of lymphocyte 
proliferation than AGP from healthy individuals. However, AGP possessing two 
bi-antennary glycans stimulated both IL-2 and lymphocyte proliferation. 
Therefore, AGP can have an immunomodulatory effect through the inhibition of 
IL-2 secretion; however this effect seems to be influenced by structural 
differences of AGP. Additionally, positive correlation between inhibition of 
lymphocyte proliferation by AGP and decreased IL-2 secretions has also been 
noted (Elg, et al., 1997).  
The immunosuppressive actions of AGP may have implications in cancer 
management as the immune system is not activated against cancer cells 
allowing them to proliferate unnoticed. AGP lacking Gal and SA gave the most 
potent inhibition of lymphocyte proliferation (Bennett and Schmid, 1980) which 
suggests that tumours may create a highly immunosuppressive environment if 
their cells contain galactosidase and neuraminidase. AGP has already been 
shown to act as an immunosuppressant in ovarian cancer by decreasing 
lymphocyte proliferation and IL-2 production (Elg, et al., 1997). Saldova, et al. 
(2008) revealed patients with ovarian cancer possessed AGP with increased 
SLex when plasma concentration was amplified. Increased SLex contributes to 
high AGP plasma levels as it reduces the accessibility of free Gal to Kupffer 
cells in the liver decreasing the rate of AGP clearance from plasma (Coombs, et 
al., 2006). Furthermore, increased endogenous sialylation has been revealed as 
a possible anti-apoptotic mechanism involved in transforming tumours to a more 
malignant phenotype in type B lymphoma cells (Keppler, et al., 1999). This links 
with research by Kato, et al. (2001) showing that sialidase expression is 
inversely correlated with tumour growth and metastatic potential of murine 
cancer cells, perhaps via a regulatory mechanism promoting apoptosis and 
suppressing cell growth. 
Overall, while the exact function of AGP remains unknown its minor functions 
contribute to cancer development and progression. AGP can suppress aspects 
of the immune system resulting in cancer cells remaining undetected and can 
potentially create more malignant tumours. 
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1.3.3 AGP in Cancer. 
 
A significant number of research studies have been undertaken to assess 
whether the subtle structure changes in AGP could act as a disease specific 
biomarker. Normally this equates to measuring SA and Fuc levels in 
comparison to healthy individuals; the variation in the degree of branching (bi,-
tri-, and tetra-antennary) of oligosaccharide chains; or the occurrence of antigen 
structures such as SLex.  Research to date has shown that AGP glycosylation is 
altered during acute and chronic inflammation, diabetes and liver disease (for 
example increased Fuc content) as well as pregnancy (increased tri- and tetra-
antennary branching) and burns victims (increased bi-antennary branching) 
(Higai, et al., 2003; Mooney, et al., 2006; Pawiłowicz, et al., 2006; Poland, et al., 
2001; Pos, et al., 1990b; Saroha, et al., 2011). 
The majority of research into AGP as a potential biomarker in cancer initially 
focussed on changes in AGP plasma concentration during disease. AGP 
plasma levels have been shown to increase 2-5 fold in the presence of cancer 
(Rudman, et al., 1974); be significantly augmented (compared to healthy 
individuals) in cancer of the ovary, breast or lung (Duché, et al., 2000; 
Routledge, 1989) as well as increased AGP levels in malignant lung and breast 
tissue (Twining and Brecher, 1977). Furthermore, it was noted by Turner et al., 
(1985) that BC patients have a 35.8% increase in AGP concentrations 
compared to a healthy population. These results are consistent with the notion 
that AGP operates as a positive acute phase protein during an APR.  
Moreover, rising AGP levels have been shown to correlate with increased 
clinical stages of primary BC (early to disseminated disease) which had 
metastasised to the liver (Chandrasekaran, et al., 1984; Roberts, et al., 1975). 
Comparison of these findings with AGP from healthy individuals, resulted in the 
discovery of two AGP forms with different molecular masses. A 45kDa form, 
possibly carrying 3-4 oligosaccharide chains and a 37kDa form potentially 
having 5-6 oligosaccharide chains attached. Similarly, increased expression of 
AGPs genetic variants has been shown when levels of AGP increase during 
disease. F1*S and A variants of AGP have been shown to increase 2.5 fold in 
lung and BC with a 1.6 fold increase being recorded in ovarian cancer. 
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However, the overall ratio of F1*S to A was not significantly altered to that of a 
healthy population (Duché, et al., 2000).  
In addition to increased AGP concentration, disease specific modifications of 
AGP glycosylation and expression have been observed between cancer, and 
healthy populations. AGP in cancer patients has been shown to carry higher 
levels of bi-antennary glycans, fucosylation and sialylation (Turner, et al., 1985). 
Increased SA was related to the occurrence of the APR, while increased Fuc 
seemed to be linked to the spread of malignancy, thus indicating the potential of 
AGP as a cancer biomarker. Croce, et al. (2005) revealed that AGP purified 
from colorectal cancer patients carries SLex groups which is a terminal structure 
containing Fuc. Shiyan and Bovin (1997) showed that unusual glycoforms of 
AGP, such as glycans with GlcNAc as terminal residues (mono-agalacto 
glycans), also occur; and that AGP carrying the maximum number of bi-
antennary glycans present in cancer patients showed more immunomodulatory 
activity than AGP from healthy individuals.  
Levels of AGP in fluid from patients with various diseases enabled Rudman, et 
al. (1974) to distinguish congestive heart failure and liver cirrhosis (which do not 
result in excessive cell proliferation) from pancreatic, breast, lung and ovarian 
cancer. They also found that the majority of the fluids isolated from cancer 
patients had an abnormal monosaccharide content displaying decreased 
hexosamines (GlcNAc and GalNAc), hexoses and SA while a small number of 
samples showed increased hexosamines. Rudman, et al. (1974) concluded that 
invasive mechanisms used by cancer cells when the disease spreads could be 
correlated with their results. 
In parallel, an investigation by Roberts, et al. (1975) showed that BC 
progression and prognosis could potentially be monitored by analysing serum 
AGP concentration. Patients with early tumours <5cm had greatly increased 
concentrations of serum AGP compared to a healthy control group, and patients 
with early tumours >5cm had even higher levels of serum AGP than those with 
smaller tumours. Patients with recurrent BC had higher serum AGP levels when 
compared to the previous two groups and the last group (disseminated BC) had 
the biggest increase in serum AGP concentration out of all the cohorts tested. 
Therefore, showing increased AGP levels are good indicators of BC 
progression and prognosis. 
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The studies reviewed to date conclude that AGP serum concentration can be 
used as an indicator of disease however the changes in concentration are not 
capable of being disease specific or definitively monitoring prognosis. 
Therefore, AGP surface glycosylation patterns have been analysed in a number 
of conditions in order to determine validity of AGP as a biomarker. 
Investigations by Hansen et al., (1984) showed that variations in 
oligosaccharide branching allowed researchers to differentiate between a 
healthy population and those with lung carcinoma or benign lung disease. 
Benign lung disease and healthy populations had less bi-antennary branching 
but AGP from cancer cohorts contained more bi-antennary branches. This 
investigation was repeated using the same method by Bleasby et al., (1985) 
however; their findings for AGP microheterogeneity disputed those of the 
previous study with AGP showing no significant differences to enable 
discrimination between benign diseases and cancer. 
Turner, et al., (1985) reported that patients with advanced stage cancer had 
higher serum concentrations of Fuc. Elevated SA levels were also noted in 
cancer patients and occasionally it was noted that rises is SA accompanied 
increases in Fuc. Turner, et al., (1985) concluded that measuring these two 
together (along with APP concentrations) could prove useful for monitoring 
individuals with cancer. They proposed that Fuc concentrations may predict the 
degree of tumour infiltration and that incidence of APR could be revealed by SA 
content. Furthermore, research revealed that primary and secondary liver 
cancer could be distinguished between by analysis of AGP glycoforms and 
these findings could be used to determine the stage of ovarian cancer and 
monitor the success of therapy in advanced ovarian cancer (Mackiewicz and 
Mackiewicz, 1995). 
Additional investigation into AGP fucosylation and branching in cancer by 
Hashimoto, et al. (2004) demonstrated that cancer prognosis and progression 
could be assessed by changes to AGP microheterogeneity. Good prognosis 
was associated with advanced stage cancer for patients who possessed normal 
AGP branching and fucosylation for the majority of time after surgery, while 
poor prognosis was linked to those with highly branched AGP glycans and who 
also had elevated fucosylation. Furthermore, Saldova, et al. (2007) showed that 
increased expression of SLex structures by AGP could be used in combination 
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with elevated FA2 (fucosylated, agalactosylbiantennaryglycan) levels on IgG 
antibodies to distinguish between ovarian cancer and benign gynaecological 
conditions. 
Therefore, increased AGP concentration on its own is merely a non-specific 
indication that something has changed within an individual and cannot be 
diagnostic for a certain pathophysiological condition. However, modifications of 
AGP glycosylation in various diseases, such as cancer, have the potential to be 
manipulated as biomarkers for diagnosis and progression of disease and 
changes in glycosylation structure can alter the function of glycoproteins which 
may also link to particular diseases. There is still a need for further research to 
discover more disease-specific markers to enhance survival rates by improving 
diagnosis, prognosis and monitoring of disease. While the primary function of 
AGP remains elusive there is evidence linking altered AGP glycosylation to 
various diseases including cancer. Therefore, AGP glycosylation is an ideal 
candidate for investigation as a diagnostic BC biomarker. 
 
1.3.4 AGP is an Ideal Candidate for a BC Biomarker. 
 
Throughout the previous sections several features of AGP have been discussed 
that make it an excellent candidate for investigation as a BC biomarker in this 
research study. Firstly, AGP is not only produced by hepatocytes but extra 
hepatic production has been reported in breast tissue as well (Gendler, et al., 
1982), inferring that alterations in AGP glycosylation may result during BC from 
breast tumour secretions as well as hepatocellular AGP secretions. 
Concentrations of AGP have also been shown to rise in line with BC 
progression (Roberts, et al., 1975) which may further indicate the role of BC 
tumour secretions. Additionally, AGP is one of the most heavily glycosylated 
proteins in existence (approximately 45%) expressing various bi-, tri- and tetra-
antennary complex N-linked glycans (Yoshima, et al., 1981; Schmid, et al., 
1980) making AGP a highly suitable model for glycosylation studies. Research 
has shown that AGP displays aberrant glycosylation during a variety of 
pathophysiological conditions including cancer (Turner, et al., 1985 and 
Hashimoto, et al., 2004). Therefore, it is possible that AGP may display uniquely 
altered glycosylation patterns during TNBC or BRCA1/2 related BC. Lastly, 
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acquisition of AGP from BC patients would be minimally invasive as AGP can 
be isolated from whole blood. Thus individuals could be tested through the 
provision of a small blood sample which is a key aim of biomarker development 
(Misek and Kim, 2011). Overall, the reasons listed above provide evidence of 
AGP’s suitability for the current research study investigating the potential of 
AGP glycosylation as a biomarker in TNBC and women at increased risk of BC 
development due to family history and/or genetic predisposition via BRCA1 and 
BRCA2 mutations. 
 
1.4 Research Strategy. 
 
Glycoproteins are present in all human blood and are the most heterogeneous 
group of posttranslational modifications known. Glycans reflect fluctuations in a 
person’s health via high structural diversity which has been proven to correlate 
with the development or progression of cancer as well as other disease states 
(Block, et al., 2005). Plus, there is increasing evidence that glycoprotein glycans 
are modified during BC (Abbott, et al., 2008; Burchell, et al., 2001; Dennis and 
Laferté, 1989; Fernandes, et al., 1991; Goodarzi and Turner, 1995; Hayes, et 
al., 1989; Hull, et al., 1989; Perey, et al., 1992a; Perey, et al., 1992b; Sewell, et 
al., 2006). As mentioned previously, BC affects thousands of women every 
year, particularly those carrying BRCA1/2 mutations. Individuals afflicted with 
these mutations are far more likely to develop aggressive forms of BC. By 
detecting cancer development earlier, more treatments would be available to 
BRCA1/2 mutations carriers increasing their chance of survival.  AGP is a 
circulatory glycoprotein whose N-linked glycosylation undergoes modifications 
between normal and diseased states such as cancer. By assessing whether a 
unique change in AGP glycosylation occurs prior to or after development of BC 
in BRCA1/2 mutation carriers a new biomarker could be discovered.  This is 
why investigation of AGP as a biomarker for proactive detection of BC in 
BRCA1/2 mutation carriers is vital.  
The purpose of the study was to determine any changes to AGP glycosylation 
in women with family history of BC. To facilitate this, a case control style study 
was performed after collection of initial data from validation of laboratory 
protocols to isolate and analyse AGP glycosylation. This type of approach has 
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been adopted in many other studies and was consistent with the range of 
samples that were available for this study.  
Preliminary findings were accumulated using plasma samples from women with 
family history of BC and/or TNBC, due to the previously described link between 
BRCA1/2 mutations and TNBC. Further to this, blood samples were collected 
from women with family history of BC attending the High Risk Familial Breast 
Screening Clinic at Edinburgh’s Western General Hospital and age-matched 
healthy controls from Edinburgh Napier University to form a case-control style 
approach. A summary flow diagram of the isolation and analytical process is 
shown in Figure 1.9 below,  
To summarise, this study sought to identify alterations to AGP glycosylation that 
may be indicative of BC onset, particularly in women at increased risk of BC 
development or those with an aggressive from of BC such as TNBC. It was 
hoped that the results of this study could lead to further investigations using 
larger cohort sizes with annual or bi-annual follow-up to monitor any BC 
development. 
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  Frozen plasma samples 
from TNBC, healthy and 
BC of unknown type 
AGP isolation by low pressure chromatography 
and desalting using centrifugal filters 
ISOLATED AGP 
Concentration determined via 
spectrophotometry 
Acid hydrolysis Enzyme digestion 
HPAEC-PAD: 
Monosaccharide analysis 
HPAEC-PAD: 
Oligosaccharide analysis 
Fresh blood samples from 
women at high risk of BC and 
age-match healthy controls 
SDS-PAGE to test purity 
Figure 1.9 Summary Flow Diagram of AGP Isolation and Analysis 
conducted in this research. SDS-PAGE = sodium dodecyl sulphate polyacrylamide 
gel electrophoresis and HPAEC-PAD = high pH anion-exchange chromatography with pulsed 
amperometric detection. 
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Chapter 2 – Materials and Methodology. 
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2.1 Introduction. 
 
This chapter details all methods used for this study along with justifications of 
any deviations from the original research strategy. The objective of this chapter 
is to provide a detailed and transparent description of the methods used to 
enable the collection and interpretation of all data presented in the chapters that 
follow.  
 
2.1.1 Dataset 1 Sample Acquisition and Demographics. 
 
As detailed previously, a strong link between TNBC and BRCA1 mutations has 
been unveiled by recent research (Anders, et al., 2009; Lakhani, et al., 2002b). 
Therefore, as this study could not obtain confirmed BRCA1/2 mutation carrier 
samples, samples of plasma were purchased from the Canadian Breast Cancer 
Foundation Tumour Bank (Alberta) from patients with TNBC with and without 
family history of BC (n=18). Patient’s family history was not determined 
genetically but through patient’s selecting a known family history on a data 
collection sheet. TNBC status was confirmed by pathology laboratories in 
Canada as part of a patient’s clinical care using immunohistochemistry (IHC; 
Edmonton) or Allred assay system (Calgary) (Gazinska, et al., 2013; Oakman, 
et al., 2010) prior to blood draw. Samples from across the age spectrum were 
requested as there is an even stronger link between BRCA1 mutations and 
TBNC in young women than those with TNBC at a later age. 
Positive control samples in the form of generic BC were purchased from Capital 
Biosciences (Maryland, USA). Samples were largely from the age range 
expected of BC sufferers (age 50-70). Samples were of a low-medium TNM 
stage and were all invasive. Similarly the ethnicity of all patient samples was 
Caucasian.  
Additionally, negative control samples used in Dataset 1 were obtained from the 
Scottish Blood Transfusion Service. No information was provided other than 
blood type but it was thought that any blood drawn with the intent of transfusion 
would be from individuals free from disease and thus inflammation. To aid the 
collection of reliable results, n=5 samples were selected for use, one of each 
blood type (A, B, O and AB) and a second type B, selected at random. All 
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samples were of positive Rhesus type as no negative Rhesus type samples 
were available. 
All samples were subjected to laboratory methods (described in detail later in 
this chapter) to isolate AGP and analyse glycan content. 
 
2.1.2 Dataset 2 NHS Sample Acquisition. 
2.1.2.1 Population Identification. 
 
Edinburgh’s Western General Hospital is home to the High Risk Familial Breast 
Screening Clinic run by consultant breast surgeon Miss Elaine Anderson. 
Women attending this clinic had been referred due to having family history of 
BC and required more frequent and earlier screening for BC development, thus 
this was identified as a recruitment site for potential participants.  Any 
participants recruited from this site would represent a population who were at 
increased risk of BC development but were yet to develop BC. While potential 
participants were identified at this site, they were invited to attend Edinburgh 
Napier University (ENU) to donate a blood sample for the study.  
 
2.1.2.2 Sample Size. 
 
Sufficient case sample size of n=12 was decided upon based on an 80% 
statistical power of detecting differences in AGP glycosylation using a 5% 
statistical significance level and by estimating the degree of agreement between 
the test system through determination of the Kappa co-efficient  greater than 
0.81. 
 
2.1.2.2 Ethical Approval. 
 
To access a clinical cohort ethical approval is needed from a local NHS 
Research Ethics Committee (REC) and Research and Development (R&D) 
department is necessary. Ethical approval was granted by NHS Lothian’s REC 
in April 2013 and shortly thereafter NHS Lothian R&D approval was received 
also (see Appendix 1). One requirement of favourable ethical opinion was for 
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the Chief Investigator (CI; myself) to obtain a Research Passport – previously 
known as an Honorary Contract – prior to undertaking the study. A Research 
Passport for the CI was obtained in October 2013. Further ethical approval was 
granted by NHS Lothian’s REC and R&D in December 2013 to increase the 
maximum number of study participants to n=20 (see Appendix 2). 
 
2.1.2.3 Recruitment and Informed Consent. 
 
The consultant surgeon identified potential research participants with the aid of 
clerical staff from Ardmillan House Breast Screening Centre, Edinburgh. An 
invitation letter (see Appendix 3) from the consultant was included in an 
information pack containing a patient information sheet (PIS, Appendix 4), draft 
consent form (Appendix 5), reply slip (Appendix 11) and a pre-paid reply 
envelope. Information packs were then posted out to 50 potential participants 
with the aim of recruiting a minimum of n=12. Women who were willing to take 
part were asked to fill in the reply slip and provide contact details allowing them 
to be contacted by the research team to arrange a suitable appointment time to 
donate a blood sample and fill in a data collection sheet (Appendix 6). By 
deciding to take part, women were agreeing that they met the inclusion criteria 
and did not knowingly have a condition that would exclude them from the study. 
At the participant’s clinic appointment an informed consent form (Appendix 5) 
was completed by a trained member of the research team including ensuring 
each potential participant had read the PIS, understood the implications of 
participating and that they had the right to withdraw without consequence at any 
time. Participants were also asked to consent to whether their GP should be 
informed of their involvement in the study. If participants consented, they were 
asked to provide contact details for their GP to enable the research team to post 
a letter and PIS to inform GP’s of the individual’s participation in the study. 
Consent was taken prior to blood draw and filling in of the data collection sheet. 
Blood samples were then subjected to the same laboratory methods as 
samples from Phase 1 (described later in this chapter) and participants offered 
a Lothian Bus Day ticket for attendance. 
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2.1.2.4 Inclusion Criteria. 
 
Women, over the age of 18 who attended the High Risk Familial Breast 
Screening Clinic at Edinburgh’s Western General Hospital due to increased risk 
of BC development. 
 
2.1.2.5 Exclusion Criteria. 
 
Women could not participate in the study if they were diabetic, pregnant or had 
a chronic inflammatory condition such as rheumatoid arthritis, Crohn’s disease 
or liver disease. This was due to previous research detailing changes to AGP 
glycosylation in these conditions which could have provided misleading results 
for this study. 
 
2.1.2.6 Blood Draw and Data Collection Sheet. 
 
Once informed consent had been obtained, participants were asked provide 
answers to the questions within the data collection sheet (Appendix 6), 
transcribed by a member of the research team, to provide information that was 
relevant to the study e.g. height, weight and questions relating to medical 
history and a 3-4 ml blood sample was drawn by a qualified member of the 
research team. 
 
2.1.3 Phase 2 ENU Age-Matched Negative Control Sample Acquisition. 
2.1.3.1 Population Identification. 
 
To complete this case control study an age-matched negative control population 
i.e. healthy participants were recruited from ENU. These participants would 
represent a population without family history of BC and without underlying 
health conditions that could affect AGP glycosylation. As before, participants 
would be required to provide a blood sample for analysis and fill in a data 
collection sheet with information relevant to the study.  
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2.1.3.2 Ethical Approval. 
 
Ethical approval was granted by ENU Faculty of Health, Life and Social 
Sciences Ethics Committee on 15th January 2014. 
 
2.1.3.3 Recruitment and Informed Consent. 
 
Posters (Appendix 7) were placed around ENU describing the study and what 
would be involved for potential participants. Posters detailed the ages that were 
required for age-matched participants and asked interested individuals to 
contact the research team. The research team then gave a PIS (Appendix 8) to 
potential participants to read, if they were still interested an appointment would 
be arranged for the individual to give informed consent (Appendix 9), have their 
family history taken (by a trained member of the research team), have a blood 
sample drawn and fill in a data collection sheet (Appendix 10) with information 
relevant to the study. Informed consent was taken by a trained member of the 
research team as was the blood sample. By taking family history the research 
team could be sure that participants had no family history of BC. Blood samples 
were again subjected to laboratory procedures described later in this chapter. 
 
2.1.3.4 Inclusion Criteria. 
 
An individual who is an age-match to one of the increased risk participants, thus 
acting as a negative control group for this study. 
 
2.1.3.5 Exclusion Criteria. 
 
Individuals were not eligible for the study if they had increased risk of BC, were 
diabetic or pregnant, had had recent surgery or had an inflammatory condition 
such as arthritis or Crohn’s disease. 
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2.1.3.6 Family History, Blood Draw and Data Collection Sheet. 
 
During a participants appointment and once informed written consent had been 
given, a trained member of the research team took a detailed family history to 
check that participants did not have an unknown family history of BC. If a 
participant was still eligible after family history was taken, a 3-4 ml blood sample 
was drawn and a data collection sheet filled in by the participant, providing 
relevant information for the study e.g. height, weight or any medication being 
taken. 
 
2.2 Laboratory Materials and Methods. 
2.2.1 Samples 
 
Dataset 1 comprised of eighteen TNBC plasma samples purchased from the 
Alberta Tumour Bank – six from patients below 35 years of age, six from 
patients aged 35-60 and six from patients over 60. Five BC samples were 
acquired from Capital Biosciences Inc., Rockville, Maryland, USA and used as 
positive controls while five “normal” plasma samples from donor without cancer 
were pooled and sourced from the Scottish National Blood Transfusion Service 
to act as negative controls. 
Dataset 2 included sixteen whole blood samples obtained from female 
volunteers at increased risk of BC due to family history and/or a genetic 
mutation who were recruited at a local High Risk Familial Breast Screening 
clinic. Ten age-matched healthy controls were recruited from members of staff 
at ENU. 
All samples were stored at -20⁰ C until further analysis was able to take place. 
 
2.2.2 AGP Isolation 
2.2.2.1 Polyethylene Glycol Precipitation. 
 
One millilitre whole blood, serum or plasma samples were transferred into fresh 
eppendorf tubes from their collection vials. PEG 3350 (Sigma-Aldrich, Poole, 
UK) was added to samples at 40% w/v (0.4g to 1ml of sample or 0.04g to 100µl 
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sample) then samples were vortexed to ensure even distribution and 
refrigerated at 4°C for a minimum of 24 hours. The samples were centrifuged at 
14,000 RPM for 30 minutes in an Eppendorf Centrifuge 5415C, the supernatant 
moved to fresh eppendorfs and the pellets discarded. Samples were frozen at -
20°C until protein purification could take place. 
 
2.2.2.2 Buffers. 
 
Buffer  Components 
Cibracron Blue 
Elution 
One hundred millimolar potassium 
chloride, 50mM Trizma and 3.07mM 
sodium azide (pH7) 
  
Cibacron Blue 
Desorption 
Five hundred millimolar of potassium 
thiocyanate to 250ml of Cibacron Blue 
Elution buffer 
Red Sepharose 
Elution 
Twenty three millimolar of sodium 
acetate to 250ml of distilled water and 
200mM of glacial acetic acid to a 
separate beaker containing 100ml 
distilled water.136ml of sodium 
acetate dilution was added to 13.5ml 
of glacial acetic dilution in a fresh 
beaker. 1000ml of distilled water was 
added to the solution (pH 5.7) 
Red Sepharose 
Desorption 
One molar sodium chloride to 100ml 
Red Sepharose Elution buffer 
 
Table 2.1 Composition of Low Pressure Chromatography Elution and 
Desorption Buffers. Composition of all buffers utilised for isolation of AGP by low 
pressure affinity chromatography are detailed in Table 2.1. All buffers were stored in Duran jars 
until use. 
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2.2.2.3 Low Pressure Chromatography. 
 
A 10ml disposable Poly-Prep column sourced from Bio-Rad Laboratories Ltd., 
Hemel Hempstead, UK, was filled to approximately 5ml with Reactive Blue 
Sepharose (Cibacron Blue 3GA) resin purchased from Sigma-Aldrich, Poole, 
UK, and this was carried out for Red Sepharose CL-6B resin (provided by Bio-
Rad Laboratories Ltd., Hemel Hempstead, UK) columns also.  The previously 
prepared Cibacron Blue 3GA column was equilibrated using 5ml of the 
appropriate elution buffer (compositions presented in Table 2.1), added at a 
flow rate of 0.5 ml per minute by a Pharmacia LKB Pump P-1 for 10 minutes, 
before adding approximately 1ml supernatant, resulting from PEG precipitation, 
simultaneously with 12.5ml elution buffer for 25 minutes at a flow rate of 0.5ml 
per minute. Changes in absorbance were monitored with a single path 
Pharmacia optical UV-1 monitor and were noted as a peak on a Kipp and 
Zonen BD41 chart recorder (see Figure 4.1 in Chapter 4) set at 2mm/min 
indicating when supernatant had passed through the column and the eluted 
fraction (approximately 9ml) was collected in a 15ml centrifuge tube. Human 
serum albumin (HSA) is bound by Cibacron Blue 3GA resin within the column 
resulting in AGP being eluted. The column was then regenerated using 7.5ml 
desorption buffer, in place of elution buffer, for 15 minutes at a flow rate of 0.5ml 
per minute, to remove previously bound HSA from the column. This was shown 
on the Kipp and Zonen BD41 chart recorder as a baseline. Before addition of 
further samples, the column was equilibrated using elution buffer. 
The eluted fraction (approximately 9ml) was concentrated to approximately 2ml 
using a Christ RVC 2-18 Concentrator at -60⁰ C (SciQuip Ltd., Shrewsbury, UK) 
and the time taken for this to occur varied between samples. The concentrated 
2ml fraction added to a previously prepared Red Sepharose CL-6B resin 
column which was equilibrated with 5ml of the appropriate elution buffer (see 
Table 2.1) for 10 minutes at a flow rate of 0.5ml per minute. 2ml of sample 
concentrated from the Cibacron Blue 3GA column was added simultaneously 
with 12.5ml elution buffer for 25 minutes at a flow rate of 0.5ml per minute .The 
movement of the sample through the column was monitored with a single path 
Pharmacia optical UV-1 monitor and were noted as peaks on a Kipp and Zonen 
BD41 chart recorder (see Figure 4.1 in Chapter 4). Approximately a 9ml eluted 
fraction was again collected in a 15ml centrifuge tube. Red Sepharose CL-6B 
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resin binds AAT and transferrin thus the eluted fraction contained isolated 
AGP.Transferrin and AAT were removed from the column by washing with 
7.5ml of the appropriate desorption buffer (see Table 2.1) for 15 minutes at a 
flow rate of 0.5ml per minute. All of the above purification methods were 
performed at room temperature. Both columns were stored in 10% ethanol at 
4°C until further use to prevent bacterial growth and drying out of the resin. 
Purified AGP in the eluted fraction (approximately 9ml) was concentrated in the 
Christ RVC 2-18 Concentrator at -60⁰ C to approximately 2ml and the time 
taken for this to occur varied between samples. Once concentrated to 2ml the 
purified AGP was ready for desalting. 
 
2.2.2.4 Desalting. 
 
Excess salt was removed from samples of isolated AGP using a Centricon® 
YM-10 centrifugal filter device with a 10,000Da cut-off filter purchased from 
Millipore Ltd., Hertfordshire, UK. Initially, the filter membrane was dampened 
with one or two drops of HPLC grade water (sourced from Rathburn Chemicals 
Ltd., Walkerburn, UK), the 2ml concentrated eluted fraction containing isolated 
AGP is then added and topped up with 2ml of HPLC grade water. To prevent 
cross contamination only one filter device was used per sample. Filter devices 
containing samples were spun in a Zentrifugen Universal 320 centrifuge by 
Hettich for 30 minute cycles at 4000 rpm, being topped up with 1ml of HPLC 
grade water after every cycle, until the full 1ml of HPLC grade water added prior 
to a cycle had filtered through. This took approximately six cycles and indicated 
that de-salting was complete. Excess salt water collected at the bottom of the 
tube was disposed of and the desalted sample was transferred into a fresh 
eppendorf then dried to completion in a Christ RVC-2-18 Concentrator.  
 
2.2.2.5 Sodium Dodecyl Sulfate Polyacrylamide Gel Electrophoresis 
(SDS-PAGE). 
 
SDS-PAGE was performed in line with the protocol devised by Laemmli (1970) 
and all reagents were purchased from Sigma-Aldrich, Poole, UK, unless stated 
otherwise. The resolving gel was composed of 10% (w/v) acrylamide (30% 
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protogel; purchased from ThermoFisher Scientific, Loughborough, UK), 0.1% 
(w/v) SDS, 0.08% (w/v) ammonium peroxodisulfate and 0.375 Tris-HCl, pH 
8.85. The stacking gels were formed using 5% (w/v) acrylamide (30% protogel), 
0.2% (w/v) SDS, 0.12% (w/v) ammonium peroxodisulfate and 0.17M Tris-HCl 
pH 6.8. Polymerisation of resolving and stacking gels was achieved by adding 
N,N,N’,N’ – tetramethylethylenediamine (TEMED) to give a final concentration 
of 0.05% (v/v) and 0.02% (v/v) respectively. Samples were denatured for 5 
minutes at 95°C after the addition of 2 x loading sample buffer (LSB) containing 
20% glycerol, 4% SDS, 200mM Tris-HCl pH 6.8 and 10mM 
ethylenediaminetetraacetic acid (EDTA). Samples were then loaded onto the 
gel and electrophoresed for 50 minutes at 185V in running buffer (0.1% SDS, 
25mM Tris, 192 mM glycine, pH8.3). Gels were stained with Coomassie brilliant 
blue R.  
  
2.2.2.6 Coomassie Staining. 
 
Gels were submerged in Coomassie brilliant blue staining solution sourced from 
Sigma-Aldrich, Poole, UK (45% methanol, 10% acetic acid, 0.2% Coomassie 
R250) after electrophoresis. Gels were then incubated at room temperature and 
gently agitated for 30 minutes. Following incubation, dH2O was used to wash 
gels which were then immersed in destaining solution (Sigma-Aldrich, Poole, 
UK; 20% methanol, 10% acetic acid in dH2O) to enable visualisation of protein 
and through reduction of back ground staining. 
 
2.2.3 Determination of Sample AGP Concentration. 
 
A standard calibration curve of absorbance against AGP concentration (mg/ml) 
was produced by dissolving commercial human AGP sourced from Sigma-
Aldrich, Poole, UK, at concentrations from 0-1.5 mg/ml, in 1ml HPLC water and 
reading the absorbance of each at 280nm. De-salted and concentrated AGP 
samples were reconstituted in 1ml HPLC grade water then the absorbance 
measured at 280nm on a Thermo Scientific™ Genesys™ 10S UV-Vis 
Spectrophotometer using a quartz cuvette with a path length of 1cm. The 
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equation of the standard curve was used to calculate the concentration of AGP 
in samples from their absorbance value in accordance with the linear 
relationship between absorbance and concentration outlined by the Beer-
Lambert law. 
 
2.2.4 High pH Anion-Exchange Chromatography. 
2.2.4.1 Acid Hydrolysis. 
 
Once the concentration of AGP in each sample was determined an aliquot of 
each sample was diluted to give 50μg/ml using HPLC water, dried down to 
completion and reconstituted in 100μl HPLC water. The 50µg reconstituted 
sample was transferred to a glass vial with an aluminium lid (to prevent 
evaporation; purchased from Sigma-Aldrich, Poole, UK) and to this 100μl of 2M 
TFA acid (Fisher Scientific, Loughborough, UK) and 50μl 4M HCl (Sigma-
Aldrich, Poole, UK) were added. Vials were then placed in a heat block set at 
100°C for 4 hours to allow glycans to separate from the polypeptide back bone 
of AGP and the bonds between glycan monosaccharides to be hydrolysed. 
 
2.2.4.2  Dowex Ion Exchange. 
 
Dowex-50 WX8 H+cation exchange resin (1 ml; purchased from Sigma-Aldrich, 
Poole, UK) was added to a Pasteur pipette packed with approximately 1 cm of 
glass wool to produce a Dowex column. The column was washed with 6ml of 
HPLC water and then the sample added. The polypeptide scaffold was bound 
by the resin while the separated glycans passed through the column and were 
collected in a fresh eppendorf. A further 1 ml of HPLC water was added to the 
column to flush out any remaining glycans which were collected in another fresh 
Eppendorf. If using multiple samples, a separate Dowex column was used for 
each sample to prevent cross contamination. Collected monosaccharides from 
each sample were dried down to completion using a Christ RVC-2-18 
Concentrator at -60⁰ C in preparation for monosaccharide analysis. Time taken 
to dry down samples to completion varied between samples. 
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2.2.4.3  Monosaccharide Analysis. 
 
Analysis of sample AGP monosaccharide content was achieved using HPAEC-
PAD on a Dionex 3000™ system with a GP50 gradient pump, an ED40 
electrochemical detector, a CarboPac™ PA-100 analytical column (4x250mm) 
and a guard column (4x50mm) (Dionex, Camberley, UK) and used in 
conjunction with a HP Compaq computer with Chromeleon™ software to control 
the automated system. This instrument separated monosaccharides based on 
the formation of oxyanions from contact with the alkaline eluents and detection 
occurred from the oxidation of these oxyanions on the gold electrode surface 
which generated a measurable electric current.  During PAD the pulse 
potentials used were 0 seconds (sec), 0.05 V; 0.29 sec, 0.05 V; 0.49 sec, 0.05 
V; 0.5 sec, 0.05 V; 0.51 sec, 0.6 V; 0.61 sec, -0.6 V; 0.65 sec, -0.6 V; 0.66 sec, 
0.05 V. 
 
Figure 2.1  Pulsed Potentials of the PAD System During HPAEC. 
 
A 15 minute regeneration of a CarboPac PA-100 pellicular anion exchange 
column was performed using 50% 0.5M NaOH (Sigma-Aldrich, Poole, UK) and 
50% HPLC water. Each dried AGP glycan sample had 45 μl HPLC water and 
5μl internal standard (2-deoxy-D-galactose, 1 mg/ml; Sigma-Aldrich, Poole, UK) 
added before 50 μl was transferred into fresh plastic Dionex vials with septum 
ready for monosaccharide analysis. The vials were then placed into the auto-
sampler of the Dionex analyser and 10 µl volumes applied to the column. 
-0.8 
-0.6 
-0.4 
-0.2 
0 
0.2 
0.4 
0.6 
0.8 
0 0.1 0.2 0.3 0.4 0.5 0.6 0.7 
P
o
te
n
ti
a
l 
(V
) 
Time (seconds) 
DELAY SAMPLING 
CLEANING 
REDUCTION 
64 
 
Monosaccharides were separated at pH13 with an isocratic elution with 30 mM 
NaOH at a flow rate of 0.5 ml/min for 35 minutes. The HPAEC column was 
regenerated for 15 minutes using 50% 0.5M NaOH/ 50% HPLC prior to further 
analyses. 
Monosaccharide peaks were identified by dividing elution time of peaks by the 
internal standard, then comparing the ratios to that of known monosaccharide 
standards purchased from Sigma-Aldrich, Poole, UK (Fuc, Man, Glucosamine, 
Galactosamine, Gal). Standard curves of each monosaccharide present on 
AGP were produced by plotting monosaccharide amount (μg) versus peak area 
in order to quantify levels of each monosaccharide within AGP samples. 
 
2.2.4.4  Enzymatic Digestion. 
 
One hundred microlitres of HPLC grade water was used to reconstitute 
approximately 100µg of AGP and the solution was transferred from an 
eppendorf into a glass vial with an aluminium lined cap which were purchased 
from Sigma-Aldrich, Poole, UK. The vial was then placed in a heating block at 
100°C for 3 hours to denature AGP. After denaturation the AGP solution was 
dried down to completion using a Christ RVC-2-18 Concentrator at -60⁰ C and 
the time required to accomplish this varied between samples.  
To perform enzyme digestion, the denatured AGP was reconstituted in 79% 
(v/v) HPLC grade water and the following reagents (New England Biolabs Inc., 
Hitchin, Hertfordshire, UK) -  10% (v/v) NP-40, 10% (v/v) NE Buffer G7 and 5 
units (U) of PNGase F enzyme giving a total volume of 100µl. One unit of 
PNGase F is defined by the manufacturer as the amount of enzyme required to 
remove >95% of the carbohydrate from 10µg of denatured RNase B in 1 hour at 
37⁰ C in a total reaction volume of 10µl. This mixture was incubated in water 
bath for 24 hours at 37°C, following which, a further 5U of PNGase was added 
and incubation resumed for another 24 hours at 37°C. 
Once enzyme digestion had occurred, protein fragments were separated from 
the oligosaccharides by ethanol precipitation. Three hundred microlitres of ice-
cold 80% ethanol was added to the 100 µl reaction mixture (3:1), the solution 
mixed thoroughly and then stored at -20°C overnight. The processed AGP was 
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then centrifuged for 30 minutes at 14000 rpm. The supernatant containing 
oligosaccharides was transferred to a fresh Eppendorf and dried to completion 
under a vacuum while the protein pellet was discarded. 
 
2.2.4.5  Oligosaccharide Analysis. 
 
HPAEC-PAD was performed on a Dionex ICS 3000™ system with a GP50 
gradient pump, an ED40 electrochemical detector, a CarboPac™ PA-100 
analytical column (4x250mm) and a guard column (4x50mm) which was 
purchased from Dionex, Camberley, UK. This was used in conjunction with a 
HP Compaq computer with Chromeleon™ software to control the automated 
system. This instrument separated oligosaccharides based size and charge due 
to the formation of oxyanions from contact with the alkaline eluents and 
detection occurred from the oxidation of these oxyanions on the gold electrode 
surface which generated a measurable electric current. The same pulsed 
potentials as monosaccharide analysis were used (see Figure 2.1) to analyse 
oligosaccharide content of samples. Initial regeneration of the CarboPac PA-
100 pellicular anion exchange column was achieved by running 50% 1M NaOH 
and 50% HPLC grade water through the column for 20 minutes prior to use. 
Samples were reconstituted in 25 μl of HPLC grade water before being loaded 
into the CarboPac PA-100 column.  Oligosaccharides were separated using the 
following eluent settings – equilibration for 10 minutes with 10% NaOH/ 5% 1M 
NaOAc/ 85% HPLC grade water; separation for 45 minutes with a linear 
gradient to a concluding eluent composition of 10% NaOH/20% NaOAc/ 70% 
HPLC grade water; regeneration for 10 minutes using 50% NaOH/ 50% HPLC 
grade water and lastly equilibration for 5 minutes using 10% NaOH/ 5% NaOAc/ 
85% HPLC grade water. All of these steps occurred at a flow rate of 1 ml/min. 
NaOAc and NaOH were sourced from Sigma-Aldrich, Poole, UK. 
A reference profile comprised of approximately 5μg of a human N-linked 
oligosaccharide library purchased from ProZyme Inc., California, USA was 
analysed for comparison with commercial AGP and patient-derived sample 
profiles. 
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2.3 Statistical Analysis. 
 
Microsoft® Excel 2010 was used to calculate the Pearson correlation coefficient 
(r2). Pearson correlation coefficient values of 0.7-1 represent strong linear 
relationships with 1 denoting a perfectly linear fit. Mean and standard deviation 
were also established using Microsoft® Excel 2010. Statistical significance 
(p<0.05) was determined using SPSS statistical analysis software package 
version 20. 
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Chapter 3 – Participant Demographics 
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3.1 Dataset 1 Sample Demographics. 
 
As detailed previously, a strong link between TNBC and BRCA1 mutations has 
been unveiled by recent research. Fully anonymised samples of plasma were 
purchased from the Alberta Tumour Bank from patients with TNBC with and 
without family history of BC. TNBC status had been determined during the 
patients’ clinical care process using IHC or Allred assay system prior to blood 
draw (Gazinska, et al., 2013; Oakman, et al., 2010). Family history was 
recorded by patients’ answering “Yes” or “No” during completion of a 
questionnaire upon their initial clinic visit, however no further details were 
requested.  Table 3.1 below gives further details regarding TNBC samples. 
Samples from a variety of ages were requested as there is an even stronger link 
between BRCA1 mutations and TBNC in young women than those with TNBC 
at a later age. Samples were separated by age into categories ≤ 35 years old 
(n=6); >35 to 60 years old (n=6) and >60 years old (n=6) giving a total TNBC 
sample size of n=18. Age of samples ranged from 22 to 81 years of age with a 
mean ± standard deviation of 53 ± 19.  Eight patients (44%) had received 
treatments prior to donation of a blood sample. 
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Sample Age* TNBC 
Family 
History 
Pre/Post 
Menopausal 
TNM 
Stage 
BMI 
Treatment Prior 
to Blood Draw 
MT3625 22  Yes  Pre 2A 22.3 TAC 
CT79 26  Yes  Pre 1 24.5  - 
MT2621 27  Unknown Pre 2A 25.5 TAC 
F5412 32  Yes  Pre 1 23.0  - 
MT3965 34  Yes  Pre 2A 26.4 TAC and RT 
MT2305 35  Unknown Pre 2B 29.0 NTAC 
MT1177 51  Yes  Post 2A 30.6  - 
MT1178 52  Unknown Post 1 30.9  - 
MT3601 54   - Post 1 33.9 TC and RT 
MT3795 57   - Post 2B 37.2 TC 
MT1937 59   - Post 1 36.6  - 
MT1106 60   - Post 1 Unknown  - 
MT3352 68   - Post 3B 20.5 CMF 
MT3959 69  Yes  Post 2B 26.0  - 
MT3442 71   - Post 1 29.9 TC 
MT3362 72   - Post 2B 27.6  - 
MT2569 75   - Post 1 34.4  - 
MT3497 81  Yes  Post 2A 41.5  - 
 
Table 3.1   TNBC Sample Information. Details provided from sample provider 
considered relevant for this study n=18. TAC (Taxotere®, Adriamycin®, cyclophosphamide), RT 
(radiotherapy), CMF (cyclophosphamide, methotrexate, fluorouracil), NTAC (neoadjuvant TAC). 
 
Positive control samples in the form of BC of an unknown histological type were 
obtained to aid the identification of any glycan similarities when compared to 
women without BC, because cancer may be in present in early stages. As 
detailed in Table 3.2 samples were largely from the age range expected of BC 
sufferers with a mean age ± standard deviation of 57 ± 8.5, bar I8 from a 46 
year old patient. Samples were of a low-medium TNM stage and were all 
invasive. Similarly the ethnicity of all patient samples was Caucasian.  No 
treatment was received prior to sample collection meaning positive control 
samples were truly reflective of AGP glycosylation during BC. 
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Sample Age* 
BC 
Type 
TNM Stage 
Treatment Prior to 
Blood Draw 
Ethnicity 
H8 61 IDC 2A  - Caucasian 
I2 54 IDC 2A  -  Caucasian 
I3 56 IDC 2  - Caucasian 
I5 69 IDLC 2A  - Caucasian 
I8 46 IDC 1A  - Caucasian 
 
Table 3.2     Positive Control Sample Information.  Relevant details provided by 
sample supplier (Capital Bioscience) n=5. All samples were taken from women suffering from 
BC of low to moderate stage. 
 
Negative control samples were obtained from the Blood Transfusion Service 
and used to represent a healthy population. Thus their AGP glycosylation 
patterns are likely to mirror those of a healthy individual. 
 
Sample Blood Type 
N1 A+ 
N2 B+ 
N3 AB+ 
N4 O+ 
N5 B+ 
 
Table 3.3     Negative Control Sample Information.    Blood type of each sample 
provided for information n=5. 
 
3.2 Dataset 2 Sample Demographics. 
 
In addition to samples collected for dataset 1, a population of 50 women at 
increased risk of BC development were identified at a local High Risk Familial 
Breast Screening Clinic. 16 women agreed to participate in the study giving a 
recruitment rate of 32%. Table 3.4 shows the information collected from each 
participant providing various factors for analysis. Ages of participants ranged 
from 25-68 years old with a mean age ± standard deviation of 48.5 ± 11.8 with 
the majority of participants (93.75%, n=15) being classed as high risk due to 
family history and/or a genetic mutation. Within the sample set (n=16) half of the 
participants had confirmed BRCA1 or BRCA2 mutations (n=8), others (n=7) had 
no confirmed mutation but one participant had a BRCA1 mutation in the family 
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but had chosen not to be tested yet. The remaining participant (n=1) was 
considered high risk due to previous treatment for Hodgkin’s lymphoma. A 
number of participants had opted for preventative surgical measures (n=9) 
which is reflected in the menopause column of Table 3.4. Further information 
including smoker status and BMI (calculated from height and weight data 
collected) are also shown in Table 3.4. 
 
Sample Age Risk Gene Mutation BMI Smoker 
Prophylactic 
surgery 
Pre/Post 
Menopausal 
W1 47 High BRCA1 28.2 N Full Hysterectomy Surgery 
W2 68 High BRCA 2 20.2 N Full Hysterectomy Post 
W3 68 High  -  23.7 N  -  Post 
W4 43 High BRCA2 32.4 N Oopherectomy No HRT 
W5 25 High Not tested but BRCA1 in family 27.4 N  -  Pre 
W6 42 High BRCA2 20.9 N Oopherectomy No HRT 
W7 47 High Hodgkins lymphoma 26.1 N   Pre 
W8 37 High BRCA1 24 N Mastectomy Pre 
W9 52 Mod  -  23 N  -  Peri 
W10 45 High  -  24.8 N  -  Pre 
W11 51 High BRCA2 20.4 Y Full Hysterectomy Surgery 
W12 43 High  -  25.2 N  -  Pre 
W13 63 High   -  24.1 N   -  Post 
W14 34 High BRCA1 34.2 N Full Hysterectomy Surgery 
W15 53 High BRCA1 21.9 N Oopherectomy Surgery 
W16 58 High  -  28.2 N Full Hysterectomy Surgery 
 
Table 3.4  At-Risk Sample Demographics  Details from data collection 
sheet completed by participants (n=16) at clinic appointment. Collected information includes 
age, BC risk status, genetic mutation (if any), height and weight to calculate BMI, smoker status, 
preventative surgery and menopausal status.   
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Sample Age BMI Smoker Pre/Post Menopausal 
C1 47 22.4 Y - not for 21 years Peri 
C2 68  25.6 Y – not for 33 years Post 
C4 43 27.7 Y - not for 8 years Peri 
C5 25 25.6 Y - not for 4 years Pre 
C6 42  23.5 No Pre 
C7 47 28.5 No Pre 
C8 37 20.6 Y - not for 8 years Pre 
C11  51 32.5 No  Peri 
C12 43 26.4 N Pre 
C13 63 29.3 Y - not for 20 years Post 
 
Table 3.5 Age-Matched Healthy Control Sample Demographics.  Table 
provides demographic information about recruited age-matched control samples (n=10) for 
dataset 2. 
 
3.3 Patient Demographic Discussion. 
 
Current BC detection methods struggle to detect BC in its very early stages. 
Detecting BC as early as possible is particularly important for women at high 
risk of BC development as these women often develop more aggressive 
tumours at a younger age and would greatly benefit from earlier diagnosis that 
could be provided by a blood-based biomarker such as AGP. Earlier detection 
would increase treatment options and likelihood of survival.  
Dataset 1 of this study investigated AGP glycosylation in a patient population 
with BC to examine AGP glycosylation during disease. The ideal sample 
population for phase 1 would have been high risk women with family history or 
BRCA1/BRCA2 mutations who had developed BC however, despite extensive 
searching this population was not accessible. Thus, with recent research 
indicating up to 80% of BRCA1 mutation carriers develop TNBC, samples from 
women of varying ages with TNBC with and without family history were 
obtained. Triple negative status was determined using IHC and All Red Assays 
at pathology laboratories in Canada as part of a clinical process. IHC is the 
staining of histological tissue samples using antibodies for the detection of 
various cellular components such as ER and PR. While IHC diagnostic 
thresholds differ between laboratories, there are suggestions that any result 
>1% should be considered positive for hormone receptors. The Allred system is 
a form of IHC results are given as a score from 0-8 calculated from percentage 
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of cells stained and intensity of staining. A higher score indicates greater 
presence of hormone receptors and high staining intensity. A TN result is given 
if no staining occurs (<1%) and an Allred score of 0 or 1 (depending on 
laboratory diagnostic protocols) (Gazinska, et al., 2013; Oakman, et al., 2010). 
All TNBC samples in Phase 1 were reported as testing negative for ER, PR and 
HER2 however the diagnostic thresholds used were not obtainable. 
Within the dataset 1 sample population, approximately half (55.5%) had not 
undergone any treatment prior to blood draw. Of the remaining samples, 
various treatments had been employed. TAC, CMF and NTAC are different 
combinations of chemotherapy drugs Taxotere®, Adriamycin® (known 
generically as Docetaxel and Doxorubicin respectively), Cyclophosphamide, 
Methotrexate, and Fluorouracil. NTAC means chemotherapy was given prior to 
surgery in an attempt to reduce the size of the tumour. The treatments given to 
this sample group reflect that chemotherapy and RT are the treatments of 
choice for TNBC as hormone therapies such as Tamoxifen are not feasible due 
to lack of ER, PR and HER2. It has been shown previously by this research 
team that altered AGP glycosylation during BC returns to a normal glycosylation 
pattern upon treatment with Tamoxifen (Doak, 2008). Therefore, by choosing 
untreated and treated BC samples a comparison can be drawn to investigate 
differences in AGP glycosylation. 
Dataset 1 samples were mainly of low TNM staging with n=8 stage 1, n=9 stage 
2 and n=1 stage 3 and were all invasive ductal cancers. This was highly 
beneficial for assessment of AGP glycosylation as a detection biomarker 
because by choosing early stage TNBC, the AGP glycosylation patterns and 
composition were reflective of that during the beginnings of TNBC development.  
Furthermore, Phase 1 samples were from TNBC sufferers with ages ranging 
from 22-81 giving a mean age of 53. Samples were equally separated into three 
age categories of ≤35, >35-60 and >60 years of age. As discussed in section 
1.1.3, approximately 7% of BCs are diagnosed in women below the age of 40 
and this figure may be rising. BC diagnosed in young women is more likely to 
be aggressive, of a high grade, TN and is associated with poor prognosis. 
Recent research has revealed distinct differences between BC in younger 
women compared to older women and each is thought to develop via different 
biological pathways (Anders, et al., 2008; Anders, et al., 2009). Recently, it has 
74 
 
been suggested, in the United States that women who develop BC below the 
age of 35 to be referred for genetic testing for BRCA1 of BRCA2 mutations due 
to the links discovered between early presentation of BC and mutations of these 
genes.  
The positive control for dataset 1 was samples from women who had developed 
BC; no information was available on the molecular or histological subtype of the 
tumour (n=5). This was to determine whether changes in AGP glycosylation 
occurred differently between generic BC and samples known to be TN. 
Additionally the samples chosen to represent a positive control were all of low 
stage BC, again to provide a better representation of AGP glycosylation during 
early stage BC as well as enabling a better comparison with TNBC samples. 
Blood samples donated by the Blood Transfusion Service were used to 
represent a healthy population as a negative control (n=5). No information other 
than blood type was provided for these samples however, individuals are 
screened prior to blood donation to assess their health status and suitability for 
donation. Therefore, it is highly likely that these samples were provided by 
healthy individuals and suitable for use as a negative control in this study. 
Dataset 2 samples were collected in a case-control manner, where each case 
(a woman at increased risk of BC) was age-matched to a healthy control for 
comparison. This was to examine if altered AGP glycosylation in the at-risk 
population could be an indicator of BC development and opposing that whether 
similarities in AGP glycosylation to healthy control samples could indicate no 
BC development. As discussed in Chapter 1, women can be considered at 
increased risk of BC development for several reasons. In this study women 
were recruited from a High Risk Familial Breast Screening Clinic and those that 
chose to participate were at increased risk because of a known BRCA1 or 
BRCA2 mutation, strong family history of BC but no mutation detected or tested 
for and one participant was at increased risk due to previous treatment for 
Hodgkin’s lymphoma which involves radiation to the chest area. A variety of 
ages were recruited ranging from 25 to 68 years of age with a mean age of 47 
which is approaching the age that women at normal risk of BC would be sent for 
screening in Scotland. These women were all under increased surveillance as 
stated in the screening guidelines with some having had prophylactic surgery to 
aid BC prevention. None of the at-risk population were taking any type of 
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preventative drugs such as Tamoxifen. Unfortunately, no follow up of the “at 
risk” participants was possible because if BC is detected during screening they 
are referred to another clinic for treatment and no further information is provided 
to the screening clinic regarding their treatment or progression. 
Use of an age-matched healthy control population allowed for a direct 
comparison to be drawn between AGP glycosylation in at-risk and not at-risk 
individuals increasing the likelihood that any changes in AGP glycosylation seen 
in the at-risk population was due to disease occurrence. Unfortunately due to a 
poor recruitment rate, not all age-matched controls could be recruited for this 
study. However, of the participants recruited, there was variation in ages and 
pre/peri/post-menopausal status. The age of participants ranged from 25-68 
years and the mean age was 46 which was very similar to that of the at-risk 
population recruited. Therefore, despite not all age-matched samples being 
successfully recruited, a sufficient variation of control samples were collected. 
Smoking status was recorded as inflammation of the lungs due to smoke 
inhalation could alter AGP glycosylation producing a false result. 
Dataset 2 of the study required individuals to self-select to participate which 
removed any bias from the investigator but samples could still be biased in 
terms of other factors such as age. Participants were also responsible for 
reporting whether they met any of the exclusion criteria listed. Participants may 
have had undiagnosed conditions that could result in altered AGP glycosylation 
and thus affect results of the study. 
Overall, it was considered that the samples recruited for both datasets would be 
able to effectively test the hypothesis and aims of the study. 
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Chapter 4 – AGP Isolation and Level Determination 
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4.1 AGP Isolation. 
 
This study used an adapted version of Smith, et al. (1994) for the isolation of 
AGP from blood samples. This utilised a low pressure chromatography 
procedure to isolate AGP which preserved the structural integrity of both the 
protein and glycans.  
Samples were precipitated with PEG 3350 and the supernatant collected prior 
to further purification using low pressure chromatography.  Sample 
supernatants were applied to a Cibacron Blue 3GA Sepharose low pressure 
chromatography column which binds HSA and the fraction containing AGP was 
collected when a peak was illustrated by the chart recorder approximately 5 
minutes (according to defined operating conditions) after addition of a sample to 
the column (Figure 4.1 A). Eluted fractions were collected until baseline 
absorbance was reached. The column was then regenerated for approximately 
20 minutes by the addition of desorption buffer to remove HSA bound to the 
Cibacron Blue 3GA Sepharose resin. The eluted fraction was concentrated 
before application to a Red Sepharose CL6B to further remove impurities 
including AAT. Approximately 10 minutes after sample application the AGP 
fraction was eluted and collected when a peak was illustrated by the chart 
recorder (Figure 4.1 B). Again, the column was regenerated using a desorption 
buffer. 
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Figure 4.1 Low Pressure Chromatography Chromatograms Produced 
During AGP Isolation   A) Cibacron Blue 3GA Sepharose  B) Red Sepharose 
CL6B 
 
Following isolation of AGP all samples were subjected to desalting using 
Centricon filter devices to prevent sample contamination and remove excess 
salts that could interfere with absorbance readings at 280nm, thus altering AGP 
concentration calculated from those results. 
 
AGP purity and effectiveness of the isolation technique stated above were 
proved using SDS-PAGE as shown in Figure 4.2. 
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Figure 4.2  SDS-PAGE Gel Proving AGP Purification.   Gel shows protein 
molecular mass marker ladder (lane A), commercially available AGP (lane B), PEG-precipitated 
plasma (lane C) and two samples that have undergone the isolation technique (lanes D and E). 
Purified AGP is highlighted using a      while bands likely to be HSA and AAT are indicated 
by a                .                
                  
The SDS-PAGE gel showed AGP had been isolated to the same standard as 
commercially available AGP and that unpurified plasma (lane C) contains 
several impurities that have been removed from the isolated AGP samples. The 
main impurities removed by the isolation technique are HSA (67kDa) and AAT 
(52kDa). 
 
4.2 Calculation of Sample AGP Concentration. 
 
 A calibration curve of absorbance values of commercial AGP ranging from 
0.0625-1.5 mg/ml at 280nm was used to produce a line of best fit (Figure 4.3) 
with equation of y = 0.5663 x (R2 = 0.99). Isolated concentrations of AGP from 
normal blood samples obtained from the blood transfusion service (negative 
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control; n=4), samples from individuals with varying degrees of BC (positive 
control; n=5), and samples from individuals with TNBC (n=18) with or without 
family history as well and the means of each group are shown in Table 4.1. 
 
 
Figure 4.3 Plot of Variation of Absorbance with Concentration of 
Commercially Purchased Human AGP (n=3). R2>0.9. Relative amount of AGP in a 
sample (x): x = Absorbance at 280nm/ 0.5663. 
 
4.3 Dataset 1 AGP Concentration. 
 
Using the equation shown in Figure 4.3 AGP concentrations from dataset 1 
were determined as shown below in Table 4.1.  
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Table 4.1 Summary of Isolated AGP Concentrations. AGP concentrations of 
BC (n=5), healthy (n=5) and TNBC (n=18) samples are given as µg/ml with the difference 
between each sample and the mean ± SD AGP concentration of healthy samples provided in a 
separate column. 
 
All TNBC samples showed AGP concentrations elevated above mean healthy 
controls, with over 80% having over double the mean healthy AGP 
concentration. AGP concentration of TNBC samples was comparable across all 
age categories with only a small decline in mean concentration with increasing 
N1 178  -
N2 331  - 
N3 16  - 
N4 68  - 
N5 234 -
Negative Control Mean ± SD 165.5 ± 126.5
Breast Cancer H8 4156  + 4007.7
Breast Cancer I2 4417  + 4268.7
Breast Cancer I3 536  + 387.7
Breast Cancer I5 161  + 12.7
Breast Cancer I8 137  - 11.2
Positive Control Mean ± SD 1881.4 ± 2203.1
MT 3965 474.1  + 325.8
MT 3625 280.2  + 131.9
MT 2305 544.6  + 396.3
CT 79 1073.5  + 925.2
F 5412 579.9  + 431.6
MT 2621 333.1  +183.0
TNBC Under 35 Mean ± SD 547.5 ± 316.4
MT 1177 562.3  + 414.0
MT 1178 474.1  + 325.8
MT 3601 685.7  + 537.4
MT 3795 421.2  + 272.9
MT 1937 650.4  + 502.1
MT 1106 403.6  + 255.3
TNBC 35-60 Mean ± SD 532.9 ± 128.9
MT 3352 262.6  + 114.3
MT 3497 791.4  + 643.1
MT 3442 685.7  + 537.4
MT 3362 579.9  + 431.6
MT 3959 456.5  + 308.2
MT 2569 315.5  + 167.2
TNBC 60 and Over Mean ± SD 515.3 ± 230.5
Sample
Concentration 
(μg/ml)
Level Compared to 
Mean Healthy AGP
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age. All except one of the BC positive control samples had AGP concentrations 
above that of the mean healthy controls. Samples H8, I2 and I3 were greatly 
increased above mean healthy control concentration whereas sample I5 was 
comparable to the mean heathy controls and sample I8 revealed a slightly lower 
AGP concentration. As only one repeat of TNBC samples was possible due to 
small sample volume, mean AGP concentration values were calculated for age 
category for comparison with each control (BC and healthy) and are shown 
below in Figure 4.4. 
 
Figure 4.4 Plot of Variation of Mean Isolated AGP Concentrations  from all 
sample groups (n=3), significance at p<0.05 indicated by *. 
 
Mean concentrations of isolated AGP from normal blood samples was 
significantly lower (p<0.05) than isolated AGP from both BC samples (positive 
controls) and samples from individuals with TNBC with/without family history. 
Similarly, there was a significant difference between all TNBC groups and 
positive control. There was no significant variation between mean AGP 
concentrations in TNBC groups (p<0.05) when a one-way analysis of variance 
(ANOVA) was used although a slight decrease in concentration with increasing 
age was noted.  
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4.4 Dataset 2 AGP Concentration. 
 
Sample  
At Risk 
(μg/ml) 
Age Matched Healthy 
Control (μg/ml) 
Difference Between “At Risk” 
Sample and Healthy Control 
(μg/ml) 
1 455.5 243.6 + 211.9 
2 441.5 305.5 + 136.0 
3 384.9 - + 111.2 * 
4 443.2 183.6 + 259.6 
5 471.4 356.7 + 114.7 
6 517.3 303.7 + 213.6 
7 342.6 247.2 + 95.4 
8 226.0 151.8 + 74.2 
9 459.1 - + 185.4 * 
10 799.9 -  + 526.2 * 
11 420.2 499.7  - 79.5 
12 706.3 220.7 + 485.6 
13 148.3 224.2  - 75.9 
14 148.3 - - 125.4 * 
15 287.8 -  + 14.1 * 
16 277.2 -  + 3.5 * 
Mean ± SD 408.1 ± 196.5 273.7 ± 99.8 
  
Table 4.2 Summary of Isolated AGP Concentrations of At-Risk Samples 
Compared to Age-Matched Healthy Control Samples. AGP concentrations of “at 
risk” (n=16) and healthy controls (n=10) are given as µg/ml. Where comparison to an age-
matched control was not possible, a comparison was drawn between the mean healthy AGP 
concentration (273.7µg/ml) and indicated by an *. 
 
The majority of “at risk” samples (87.5%) revealed increased AGP 
concentrations compared to age-matched healthy controls or mean AGP 
concentration of healthy controls. However, samples W11 and W13 showed 
AGP concentrations below that of healthy controls while samples W15 and W16 
were only marginally elevated above healthy control concentrations. Sample 
W10 had the highest AGP concentration at 799.9µg/ml closely followed by W12 
at 706.3µg/ml, and samples W13 and W14 both had the lowest AGP 
concentration of 148.3µg/ml. Of the age-matched healthy controls C11 
possessed highest AGP concentration of 499.7µg.ml with C8 having the lowest 
at 151.8µg/ml. 
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Figure 4.5 Mean AGP Concentration of “At Risk” and Age-Matched 
Healthy Control Samples. Mean AGP concentration of “at risk” (n=16) and 
healthy control (n=10) samples is given in µg/ml. Data was gathered in triplicate and calculated 
using the equation in Figure 4.3 as above. Statistical significance of p<0.01 indicated by **. 
 
Use of a one-way ANOVA determined a significant difference between mean 
AGP concentrations of “at risk” samples and healthy controls (p<0.01) with the 
“at risk” population having significantly elevated AGP levels. 
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Figure 4.6 Isolated AGP Levels of At-Risk Samples Compared to Age-
Matched Healthy Controls or Mean Healthy Control. Graph shows a direct 
comparison between AGP concentrations from “at risk” sample and an age-matched healthy 
control. Where an age-matched healthy control was not possible, “at risk” samples are 
compared to the mean AGP concentration of the healthy control population. Significant 
differences are indicated as * for p<0.05 and ** for p<0.01 
. 
The majority of “at risk” samples (12/16) showed significantly higher levels of 
AGP (p<0.01; W10 and W12 p<0.05) compared to controls, However, W11 and 
W14 had significantly lower AGP levels and W15 and W16 showed no 
significant difference. As mentioned previously, absorbance measurements 
were taken in triplicate and used to calculate AGP concentration with little 
variation displayed between readings as shown by small error bars in Figure 
4.6. Overall AGP concentrations of the “at risk” population show a 1.4 fold 
increase compared to the healthy control population. 
 
4.5 Discussion. 
4.5.1 Purification of AGP. 
 
The aim of the research discussed in this chapter was to confirm purification of 
AGP and determine concentrations of isolated AGP to assess the variation in 
levels from two sample populations - Dataset 1 included of samples from 
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healthy individuals, women with BC of unknown type and women with TNBC as 
well as Dataset 2 containing samples from women at increased risk of BC 
development and age-matched healthy controls. This was performed using low 
pressure chromatographic isolation of AGP, desalting, SDS-PAGE and 
spectrophotometry. 
The isolation of plasma proteins from whole blood was once a problematic and 
laborious task, due to the presence of large amounts of HSA in plasma 
(approximately 50%) (Travis et al., 1976). HSA was difficult to remove 
completely as it has a similar molecular mass and charge to other plasma 
proteins, therefore effective removal techniques are essential (Travis et al., 
1976).  
There are several protocols of AGP isolation available, most of which exploit 
AGP’s low pI or extremely high solubility (Chan and Yu., Charlwood et al., 1976; 
Hellerstein et al., 1985; 1991; Sugiyama et al., 1985; Routledge et al., 1980 and 
Weimer et al., 1950). However, the majority use harsh acidic conditions that will 
affect the structural integrity of glycans bound to AGP which would affect 
investigation of glycosylation. For instance, an initial AGP isolation method used 
by Weimer, et al. (1950) used ammonium sulphate to precipitate AGP at low 
pH. Low pH could result in glycan structure alterations such as desialylation 
(Varki, et al., 2009). Other methods of AGP isolation include hot phenol 
extraction (Chan and Yu, 1991) but this was shown to be ineffective as AGP 
purified in this way was more readily cleared upon injection into mice which 
indicated a change in glycan structure such as desialylation (McCurdy, et al., 
2011). 
Another method was proposed by Herve, et al. (1996), who created a two-step 
purification of AGP from plasma comparable with the protocol of Smith, et al. 
(1994). 
The method utilised in this study was an adapted form of Smith and colleagues 
(1994) protocol which in turn adapted Laurent, et al. (1984) method using PEG 
3350 and low pressure affinity chromatography to isolate AGP without 
denaturation or desialylation. Thus allowing AGP’s in vivo glycan structure to be 
analysed for unique characteristics that could indicate presence of BC. Previous 
studies by Doak (2008) and Gallacher (2009) have shown this AGP isolation 
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method is suitable for both fresh and frozen samples as AGP remains stable. 
Subsequently methods such as Herve, et al. (1996) were comparable with 
Smith, et al. (1994). 
Initial addition of PEG 3350 to samples at 40% w/v enables precipitation of 
proteins less soluble than AGP and blood cells, leaving AGP and other major 
plasma constituents such as HSA and AAT (Smith, et al. 1994). PEG 3350 
functions by drawing water molecules away from proteins in the suspension, 
increasing the number of protein to protein interactions in the plasma. Proteins 
can no longer dissolve when these interactions become abundant leading them 
to precipitate (Ingham, 1990). The main advantages of PEG 3350 are two-fold: 
firstly, PEG 3350 does not denature the proteins it interacts with, preserving the 
in vivo nature of AGP when used. This is imperative when performing a 
structural analysis such as this study. Secondly, PEG 3350 removes a number 
of potentially interfering plasma components in one simple step (Smith, et al., 
1994) as shown in Figure 4.2. However, after centrifugation, HSA and AAT 
remain in the removed supernatant, both of which can interfere with AGP 
analysis and thus require removal.  
This study employed low pressure affinity chromatography in the form of a 
Cibracron Blue Sepharose 3GA column which facilitated the removal of HSA 
from samples, further isolating AGP. As shown in Figure 4.1a, after addition of a 
sample to the column, the first fraction containing AGP eluted at approximately 
15 minutes, represented by a peak deviating from the baseline. The addition of 
a desorption buffer (see Table 2.1) resulted in column-bound HSA eluting from 
the column shown as a second peak on the chromatogram. Complete 
regeneration of the column occurred within 20 minutes.  
Use of Cibacron Blue for removal of HSA has been recognised for several years 
with Travis, et al. (1976) reporting removal of up to 98% HSA when using a 
Cibacron blue column. HSA possesses bilirubin binding sites and as Cibacron 
Blue dye is similar to bilirubin as it contains negatively charged planar aromatic 
ring systems, HSA binds to the dye (Leatherbarrow and Dean, 1980). Cibacron 
Blue dye works well for this study as it removes HSA allowing the remaining 
plasma constituents to pass through the column unhindered. 
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The original method used by Smith, et al. (1994) contained a Q-sepharose step 
to further isolate AGP after removal of HSA describe previously. However, the 
method was designed for larger sample volumes (50ml) which could afford the 
loss of sample at this stage but due to small sample quantity the step was 
removed to preserve sample volume. Removal of this step has been shown to 
have little effect on AGP purity by members of the research team through 
immunodiffusion and SDS-PAGE (Behan, 2010; Gallacher, 2009). Therefore, 
the next stage of AGP isolation was elimination of AAT from samples.  
For removal of AAT, concentrated samples from the previous step were applied 
to a Red Sepharose CL-6B column; a peak indicating sample elution from the 
column was seen between 13-25 minutes and collected as before. Application 
of a desorption buffer to the column resulted in a second peak illustrating the 
elution of AAT previously bound to the column. Whilst in the column, AAT and 
proteins such as kinases, dehydrogenases and transferases bind to the resin. 
However, AGP is so heavily glycosylated there is not enough of the protein 
portion available to facilitate binding, allowing AGP to pass through the column 
unimpeded. The eluted sample fraction now contained only purified AGP as 
shown in Smith, et al. (1994) study by the appearance of a single band on SDS-
PAGE at the 45kDa mark and detection of only AGP through immunodiffusion. 
The current study confirmed the successful isolation of AGP using SDS-PAGE, 
which in figure 4.2 shows a single band at approximately 45kDa in line with 
previous investigations Smith, et al. (1994). 
 
4.5.1.1 Potential Problems with Purification Method 
 
The purification method described in section 2.2.2 successfully purified AGP 
from whole blood and plasma samples to facilitate the current study. However, 
issues did arise that could be improved in the future. Firstly, due to small 
sample volumes there was limited unused sample to perform techniques such 
as SDS-PAGE or lectin ELISA’s to confirm AGP purification. Therefore, use of 
this purification method in subsequent studies would benefit from larger initial 
sample volumes of approximately 3-4ml. Another potential problem with this 
purification method was that the same Cibracron Blue Sepharose 3GA and Red 
Sepharose CL-6B columns were used for purification of all samples used in this 
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study. Despite rigorous cleaning of the columns with desorption buffers after 
application of each sample, sample remnants may have remained in the column 
which could have resulted in cross-contamination. However, use of a freshly 
prepared column for each sample to avoid cross-contamination entirely would 
have proved costly and so was not feasible for this study.  Additionally, due to 
the introduction of salts, from use of a NaOAc buffer during the isolation 
process, it was necessary to filter isolated samples using Centricon filter 
devices with a 10kDa molecular weight cut off. Presence of salt in isolated AGP 
samples would interfere with absorbance readings at 280nm, as both NaOAc 
and AGP absorb at this wavelength, which would subsequently affect 
calculation of AGP total mass in samples. Although desalting of isolated AGP 
samples was performed there was no way to ensure all salt had been removed 
which could have falsely elevated AGP concentrations measure 
spectrophotometrically. 
Despite the potential problems with the purification method it is unlikely that 
there was any negative implications for AGP glycosylation as several studies 
have successfully utilised this purification methods for analysis of AGP glycan 
content without detriment to glycosylation (Behan., 2010; Behan and Smith., 
2011; Behan, et al., 2013; Doak., 2008; Gallacher., 2009; Smith et al., 1997; 
Smith et al., 2002).  
 
4.5.2 Determination of Isolated AGP Levels. 
 
AGP levels were determined after purification through a standard curve created 
using varying concentrations of commercially available AGP. Phe, Tyr and Trp 
residues present in AGP’s protein backbone absorb at 280nm, the protein 
backbone is not distorted by isolation techniques used making the use of 
spectrophotometry more reliable (Smith et al.,1994; Behan., 2010). 
A standard curve was constructed using concentrations of commercial AGP at 
0.0625-1.5 mg/ml as these are similar to in vivo AGP levels and gave 
absorbance readings <1. The linearity of the Beer Lambert equation breaks 
down with absorbance values above 1.0 indicating that the sample is too 
saturated to give a dependable result (Williams and Fleming, 2007). There is 
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good correlation between commercial AGP concentration and absorbance at 
280nm with an r2 value of 0.99.  
4.5.3 Alternative Supportive Methodologies. 
 
Sample volume and funding permitting, additional methodologies exist that may 
have supported the purification method used in this study to aid the confirmation 
of results and enhance the outcomes. Efficiency of the low pressure 
chromatography columns used could have been verified through the use of 
plasma samples spiked with known concentrations of AGP to measure the 
percentage of AGP recovered from the column. SDS-PAGE of all fractions after 
application to each low pressure chromatography column would have 
evidenced the removal of different unwanted sample components by each 
column as opposed to the before and after purification samples shown in figure 
2.4.  Western Blotting of SDS-PAGE gels using AGP specific antibodies could 
have confirmed purification of AGP (Behan, 2010). Use of a Bradford assay 
(Bradford, 1976) to determine total protein concentration or a sandwich ELISA 
incorporating antihuman AGP and antihuman AGP conjugated with horseradish 
peroxidase could have been utilised (Hashimoto, 2004) to measure AGP 
concentration (McCurdy et al., 2011) and could have been used to corroborate 
calculated AGP concentrations from absorbance measurements and improve 
the reliability of results. However, this would have reduced the already limited 
sample volume available for this study.   
 
4.5.4 Variation of Isolated AGP Content in Healthy Individuals. 
 
Isolated AGP from healthy control samples in dataset 1 ranged from 16-
331µg/ml with a mean ± SD of 165.5 ± 126.5µg/ml indicating large variation of 
isolated AGP levels in samples from healthy individuals within this dataset. 
However, levels of isolated AGP from age-matched healthy controls in dataset 2 
were more consistent, ranging from 151.8-499.7µg/ml with a mean ± SD of 
273.7 ± 99.8 µg/ml. Differences in isolate AGP levels between healthy controls 
of both datasets could be due to the way samples were stored and the length of 
storage prior to use. Healthy control samples for dataset 1 were stored at in a 
freezer at -20⁰ C for several months prior to purification whereas samples from 
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age-matched healthy controls used in dataset 2 were collected fresh and the 
purification process started immediately without prior freezing. Therefore it is 
possible that degradation of AGP occurred while healthy samples from dataset 
1 were stored at -20⁰ C as proteins should be stored at -80⁰ C to prevent 
degradation (Saraswathy and Ramalingam, 2011). Degradation could also 
account for the large disparities between healthy control samples in dataset 1 
depending on length of storage. Additionally, as AGP concentration is known to 
increase during inflammation and several diseases (Cecilani and Pocacqua, 
2007) asymptomatic volunteers may have considered themselves healthy but 
been unaware of having pathological conditions that could have falsely elevated 
levels of AGP isolated from samples used as healthy controls and increased 
variation between samples.  
Interestingly, studies by Kishino et al., (2002) and Orzyck-Powiiowicz (2006) 
revealed that gender may influence AGP levels in healthy individuals in that 
men may have higher concentrations of AGP than women and that AGP 
content can vary throughout a woman’s menstrual cycle. As no gender 
information was supplied with healthy samples for dataset 1, variation in 
isolated AGP levels could be due to a mixture of male and female samples 
being supplied by the Blood Transfusion Service for this study. 
Previous studies have shown the mean concentration of AGP in healthy 
participants to range between 360-1460µg/ml (Blain, et al., 1985; Jørgensen, et 
al., 2002). However, earlier research using an identical purification method has 
shown mean levels of AGP in healthy populations at 53µg/ml, 78µg/ml and 
830µg/ml (Behan, 2010; Doak, 2008; Smith et al., 2002).  In this study, mean 
isolated AGP levels of healthy participants were marginally lower than the 
majority of previously published results. This may be because samples were 
obtained from the Blood Transfusion which implements a strict health criterion 
prior to blood donation, leading to very low AGP concentrations. However, it is 
more likely that some sample loss has occurred during the purification process 
or ineffective sample storage. 
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4.5.5 Isolated AGP Levels from Dataset 1. 
 
Isolated levels of AGP from all sample groups in dataset 1 are shown in table 
4.1 and were calculated using the standard curve in figure 4.3 which revealed 
that mean AGP levels in a healthy population (165.5 ± 126.5μg/ml) were 
significantly lower than those of both BC samples (positive control; 1881.4 ± 
2203.1μg/ml) and TNBC samples regardless of age (547.5 ± 316.4; 532.8 ± 
128.9 and 515.2 ± 230.5μg/ml respectively). 
  
4.5.5.1 Isolated AGP Levels of BC Positive Control Samples 
 
In comparison to healthy controls used in this study, BC samples acting as 
positive controls had a significant (p<0.05) 11 fold greater mean concentration. 
However, research by Blain, et al., (1985), Jørgensen, et al., (2002) and Smith 
et al., (2002) showed AGP levels of 360-1460µg/ml isolated from healthy 
individuals. Therefore, if applying this healthy AGP reference range to BC 
samples in this study, only two out of five samples (H8 and I2) had AGP 
concentrations above this range, both showing an approximate 3 fold increase. 
The elevation of isolated AGP in H8 and I2 correlates with results from a study 
by Rudman, et al. (1974) which investigated AGP in various disease states and 
showed a 2-5 fold increase in AGP concentration in the course of cancer. 
Furthermore, the results for H8 and I2 connect well to research that illustrates 
plasma AGP concentration  in BC being 2.5 times higher than healthy controls 
(Duché, et al., 2000), while Twining and Brecher (1977) illustrated a 35.8% 
increase in AGP concentration in BC sufferers compared to healthy individuals.  
However, the findings of this study do not show association an with research 
conducted by Roberts et al., (1975) which highlighted a correlation between 
increasing plasma AGP concentration and increasing severity of BC, as the 
remaining BC samples from the current study (I3, I5 and I8) have isolated AGP 
levels within or below the range indicated by Blain, et al., (1985), Jørgensen, et 
al., (2002) and Smith et al., (2002). All positive control BC samples were from 
women with low grade tumours of 1A to 2A using TNM staging. Therefore, 
given the results from the study by Roberts et al., (1975), it was expected that 
all positive control BC samples would contain similar levels of isolated AGP 
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after purification. As discussed in section 4.3.5, reasons for this unexpected 
variation could be due to storage of samples prior to purification. BC samples 
used as positive controls for this study were purchased in advance of the 
current research study beginning and were kept frozen at -20⁰ C which may 
have caused degradation of AGP, subsequently affecting the detected 
concentration after purification (Saraswathy and Ramalingam, 2011). 
 
4.5.5.2 Isolated AGP Levels of TNBC Samples. 
 
AGP levels isolated from TNBC samples ranged from 262.6-791µg/ml with 
mean concentrations of 547.5 ± 316.4; 532.8 ± 128.9 and 515.2 ± 230.5μg/ml 
when grouped by age as <35, 35- 60 and >60 years old respectively. All TNBC 
samples contained significantly (p<0.05) elevated levels of isolated AGP of 
approximately a 3 fold difference compared to healthy control samples. To date 
no other studies have investigated AGP concentration in TNBC. Yet, these 
increases in AGP concentration are similar to those published by Rudman et al., 
(1974) and Duche et al., (2000) who found AGP levels rose by 2-5 fold during 
cancer and 2.5 fold in BC specifically. However, if relating these results to 
isolated AGP levels from healthy individuals in other studies (Blain, et al., 1985, 
Jørgensen, et al., 2002 and Smith et al., 2002), AGP concentrations from TNBC 
samples lie below or within healthy AGP concentration ranges. Yet, unlike the 
healthy and BC control samples, lower levels of isolated AGP are unlikely to be 
due to degradation of the protein during storage. This is because samples were 
stored at -80⁰ C upon collection at the facility in Canada and transported on ice 
within seven days to Edinburgh Napier University where the purification process 
began immediately upon reciept of samples. While the possibility of sample loss 
during purification could be attributed to lower levels of AGP being isolated from 
these samples, recovery experiments were not performed prior to sample 
purification it so remains unclear whether sample loss was a factor. 
Interestingly, despite elevation of AGP concentration in the TNBC samples 
being equivalent to previous studies compared to healthy controls, isolated AGP 
levels from these samples were significantly (p<0.05) lower than BC positive 
controls. Postive controls contained 3.5 fold greater AGP concentration than 
TNBC samples. All TNBC samples were from patients with low TNM stage 
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tumours (1-2B) except MT3352 which was stage 3B. This indicated an initial 
difference between TNBC and BC of an unknown type and links to research by 
Perou et al., (2000) suggesting that perhaps BC subtypes should be considered 
separate diseases due to the different molecular mechanisms involved in their 
development. If TNBC tumours are secreting different levels of AGP than other 
BC subtypes this could be used to further differentiate between BC subtypes 
and aid early diagnosis. 
While mean levels throughout the TNBC age groups were consistent showing 
no significant differences, standard deviations highlighted variance within the 
groups. Eight patients with TNBC who donated blood samples underwent 
chemotherapy prior to blood draw. This may have accounted for variation in 
AGP concentrations in samples as AGP concentration has been shown to 
return to healthy, pre-cancer levels upon treatment (Kailajarva et al., 2000). 
However, this hypothesis could only be attributed to TNBC samples from 
women <35 years old as low AGP levels corresponded with patients who had 
received treatment prior to blood draw while those who had not received 
treatment had higher levels of AGP. This may account for the large variation 
between samples in this group (indicated by a SD of 316.4). In the other age 
groups there appeared to be no correlation between treatment and AGP levels. 
If examining AGP concentrations in TNBC samples by stage there also 
appeared to be no links between TNM stage and AGP concentration. This 
contradicts findings by Roberts et al., (1975). For example MT3352 was TNM 
stage 3B but contained 262.6µg/ml isolated AGP and CT79 was TNM stage 1 
yet had an isolated AGP concentration of 1073.5µg/ml.  
 
4.5.6 Isolated AGP Levels from Dataset 2.  
 
Dataset 2 was comprised of samples from a population at increased risk of BC 
development in comparison to samples from age-matched healthy controls. 
Where age-matched controls could not be recruited, comparisons were drawn 
using the mean AGP concentration of the age-matched healthy controls which 
in this dataset was 273.7 ± 99.8µg/ml. This is lower than the range of 360-
1460µg/ml found in previous studies by Blain, et al. (1985) and Jorgensen, et al. 
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(2002) as well as being similar to levels isolated previously by this research 
group (Behan, 2010; Doak, 2008; Smith et al., 2002).  
As this study was comparing two healthy populations, the only difference being 
that one population was it increased risk of BC, it was expected that no 
differences would be found in terms of AGP concentration. However, mean 
AGP levels isolated from “at risk” patients were significantly (p<0.01) increased 
compared to age-matched healthy controls .Similarly if examining “at risk” 
samples compared to their age-matched healthy control individually, 87.5% 
contained significantly (majority p<0.01, 2 samples p<0.05) elevated levels of 
isolated AGP. As with TNBC samples in dataset 1 isolated AGP levels from the 
”at risk” population were within the normal range reported by previous studies 
(Blain, et al. 1985; Jorgensen, et al. 2002; Behan, 2010; Doak, 2008; Smith et 
al., 2002). Yet the majority of “at risk” sample showed at least a 1.3 fold rise in 
AGP concentration compared to age-matched controls which is not as high as 
the 2-5 fold or 2.5 fold increases reported by Rudman et al., (1974) and Duche 
et al., (2000) during cancer or seen in TNBC samples from dataset 1, but an 
increase in AGP concentration could still indicate the early stages of BC 
development. Relating to this, AGP is known to possess immunomodulatory 
functions (see Table 1.5) and increases in AGP concentration are associated 
with decreased proliferation of lymphocytes (Chiu et al., 1977), decreased 
lymphocytic secretion of IL-2 (Elg et al., 1997) which aids differentiation of self 
and non-self by the immune system (Liao et al., 2011) and preliminary data 
gathered by Zsila et al., (2009) demonstrates that increased AGP concentration 
may activate cell proliferation. Therefore, the small increases in AGP 
concentration in “at-risk” samples compared to age-matched healthy controls 
may be a result of early metastatic breast cells creating an immune suppressed 
micro-environment to enhance tumour development and survival. Furthermore, 
several studies have already shown AGP’s non-specific immunosuppressive 
actions during cancer may promote immune evasion and lower the 
effectiveness of immunotherapy based treatments (Tamura et al., 1981; Samal 
et al., 1982 and Elg et al., 1997). Yet in contrast, a study conducted in 1986 by 
Watanabe et al., implicated AGP expression with inhibition of tumour growth. 
However, as AGP protein synthesis and glycosylation are independently 
regulated (van Dijk et al., 1994 and van Dijk et al., 1995) it is possible that 
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expression of altered AGP glycosylation was responsible for tumour inhibition 
rather than increased AGP concentration. 
Furthermore, previous research within this group by Doak (2008) examined 
untreated BC, tamoxifen treated BC and “at risk” individuals receiving tamoxifen 
as a preventative measure. Doak’s study revealed that an “at risk” population 
receiving tamoxifen had similar AGP levels to a “normal” healthy population 
(660µg/ml compared to 530µg/ml respectively). None of the current study’s “at 
risk” participants were receiving tamoxifen and the majority had AGP 
concentrations similar to or lower than “at risk” tamoxifen recipients in Doak's 
(2008) study. Therefore, it would appear that tamoxifen treatment has little 
effect on AGP levels in an “at risk” population. However, no information on why 
Doak’s “at risk” population were considered to be at risk of BC development 
was provided while the current study contained women who were “at risk” due 
to confirmed family history, BRCA1 or BRCA2 mutation or treatment for 
Hodgkin’s lymphoma. 
Examination of sample AGP concentration in confirmed mutation carriers within 
dataset 2 showed no correlation between BRCA1 mutation and AGP 
concentration. Nevertheless, sample W1 had an isolated AGP level 1.5 fold 
higher than other samples from BRCA1 patients which may point to initial 
development of BC (Rudman et al., 1974 and Duche et al., 2000). BRCA2 
mutation carriers had consistently higher concentrations of AGP compared to 
BRCA1 mutation carriers except for sample W1. As BRCA1 mutation carriers 
are at higher risk of BC development compared to BRCA2 carriers (Mavaddat et 
al., 2013) maybe the concentrations of AGP within these samples should be 
viewed differently. The majority of BRCA1 samples contained isolated AGP 
levels approximately 1.5 fold lower than BRCA2 samples, as BRCA1 carriers 
are more likely to develop BC, perhaps an initial decrease in AGP concentration 
is associated with BC occurrence. Similarly low levels of AGP were seen in 
samples W13 and W16 which had no known mutations. Yet, to date no other 
studies have investigated AGP in BRCA1 and BRCA2 mutation carriers so no 
comparisons can be drawn to test this hypothesis. 
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4.5.7 Variants of AGP. 
 
When assessing AGP concentration in samples it is important to note that total 
AGP concentration is the result of variants produced by three genes known as 
AGP-A (ORM1) and AGP-B/B’ (ORM2) (Katori et al., 2011). AGP-A encodes for 
F1, F2 and S variants which are more commonly referred to as F1*S and AGP-
B/B’ both encode for the A variant (Colombo et al., 2006; Taguchi et al., 2013). 
The F1*S and A variants differ by 20 amino acid substitutions (see Figure 1.7) 
but do not vary greatly in structure (see Figure 1.6). In healthy individuals the 
ratio of F1*S to A variants is approximately 3:1 (Dente et al., 1987) however 
these ratios may alter during cancer. As increases in isolated AGP levels were 
seen in BC of unknown type and TNBC samples (dataset 1) as well as “at-risk” 
samples (dataset 2) compared to healthy controls, it is possible that differences 
in AGP variant ratios was also occurring. Previous research has revealed that 
increased expression of F1*S and A variants occurs in breast, ovarian and lung 
cancer, however the overall ratio tends to remain the same (Duche et al., 1998 
and Duche et al., 2000). In contrast to this, a more recent study by Budai et al., 
(2009) using ultra high performance liquid chromatography and mass 
spectrometry instead of the isoelectric focussing and immunoblotting method 
used by Duche et al., (1998;2000), unveiled F1*S to A variant ratios of up to 8:1 
in lymphoma, melanoma and ovarian cancer. However, unfortunately it was not 
feasible to investigate the proportion of AGP variants within samples during this 
study to account for increases in overall levels of isolated AGP. 
 
4.6 Summary Statement. 
 
In summary this chapter accomplished its aim to confirm the isolation of AGP 
from blood samples using low pressure chromatography and assess variation in 
isolated AGP levels from different sample populations used in this study. 
It was noted that other analytical techniques may have been employed to 
support the findings if sample volume was not so limited; that variation of 
isolated AGP levels in healthy controls and BC of unknown type in dataset 1 
may have been due to ineffective storage and alterations in the ratios of AGP 
variants which could have accounted for increased isolated AGP levels. 
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Results from dataset 1 highlight differences in isolated AGP levels between 
healthy individuals, BC and TNBC samples. Samples from healthy individuals 
contained low mean levels of isolated AGP while BC samples had significantly 
increased AGP levels in comparison. Both sets of controls showed variation 
within the positive and negative control groups that may be a results of 
substandard storage or sample loss during purification. Interestingly, AGP 
concentration of TNBC samples were significantly raised above the healthy 
control but significantly lower than the BC control which could further 
differentiate a diagnosis using AGP in future. Age of individuals and TNM stage 
of TNBC tumour appeared to have no effect on AGP concentration while 
treatment prior to blood draw may have caused lower levels of AGP in the <35 
years of age group. 
In dataset 2 the majority of “at-risk” samples had increased isolated AGP levels 
compared to age-match healthy controls despite both sample populations being 
considered disease free. This unexpected increase in AGP concentration could 
be contributing to the development of BC by suppressing the immune system in 
the tumour vicinity to avoid destruction by the immune system. Additionally, a 
number of samples, particularly samples from BRCA1 mutation carriers, 
contained isolated AGP levels at least 1.5 fold lower than other “at-risk” 
samples which could infer that a decrease in AGP concentration occurs during 
the initial stages of BC development. 
However, isolated AGP levels alone are not indicative of BC thus this study 
focuses on alterations in AGP glycosylation. 
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Chapter 5 – Monosaccharide Analysis Results and 
Discussion 
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5.1 Introduction. 
 
Glycans attached as post-translational modifications to proteins can vary in 
structure and composition during certain physiological or pathological 
conditions. These changes can affect the conformation of the protein affecting 
function and circulation lifetime. Furthermore, a glycan pattern unique to a 
specific disease could be used as a biomarker to distinguish between healthy 
and diseased individuals. Therefore, analysis of glycan chain composition and 
structure (known as microheterogeneity) is vitally important. Analysis of 
individual sugars (monosaccharides) that are the components of glycan chains 
can indicate structural alterations of the chain as a whole (oligosaccharide). For 
example, Gal is exclusively present in the branches of AGP glycans, thus 
distinctly increased concentrations of Gal could indicate greater branching of 
AGP glycans. 
HPAEC-PAD is a well utilised, reliable and documented technique for 
monosaccharide analysis of glycans (Cataldi, et al., 2000; Corradini, et al., 
2012). While other methods of glycan composition analysis are available such 
as mass spectrometry, nuclear magnetic resonance, HPLC, gas 
chromatography and lectin ELISAs, these techniques often require 
derivatisation – the transformation of an analyte into a similar structure 
(derivative) that is more amenable to the analytical technique being used - or 
large sample quantities to obtain better separation and detection, with HPAEC-
PAD continuing to be one of the most reliable and effective methods of glycan 
analysis. HPAEC-PAD was implemented for this study as no prior derivatisation 
of samples was necessary, which would have altered the structure of 
monosaccharides and may have affected results. Secondly, HPAEC-PAD is 
highly sensitive, able to detect 10-100 picomolar concentrations (Hardy, et al., 
1988) which was very beneficial for Phase 1 of this study as only small sample 
volumes could be obtained.  
In order for monosaccharide analysis by HPAEC-PAD to occur, glycans must 
first be cleaved from the protein and the covalent bonds between 
monosaccharides disrupted. TFA and HCl are commonly used to cleave neutral 
and basic monosaccharides in preparation for analysis. This study incubated 
50µg of isolated AGP for 4 hours at 100°C with 100µl 2M TFA and 50µl 4M HCl 
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in line with the protocol devised by Smith, et al. (1997), which was proven to 
effectively cleave individual monosaccharides for analysis.  
To utilise HPAEC for monosaccharide analysis there are several requirements. 
Firstly, a highly mechanical and chemically stable stationary phase is 
necessary; commonly in the form of a column containing a polymer based 
pellicular resin. The active component of such resins is a quaternary ammonium 
ion.  Secondly, an alkaline mobile phase such as 0.03M NaOH is required to be 
used in an isocratic gradient. Lastly, a detection system must be in place to 
identify separated monosaccharides. This study used NaOH in an isocratic 
gradient to induce electrocatalytic oxidation of weakly acidic sugars this 
occurred through the ionisation of hydroxyl groups (-OH) within monosaccharide 
structures, forming oxyanions at high pH (12 or above) (see Figure 5.1). 
Monosaccharides possess several –OH groups which vary in position between 
monosaccharides resulting in different dissociation constants (pKa) ranging 
from 12-14.  HPAEC analysis exploits the pKa values of monosaccharides and 
their subsequent binding to the pellicular anion-exchange resin, to separate 
them for detection. Those with higher pKa values, such as Fuc, are less 
negatively charged and form weaker interactions with the cationic resin within 
the CarboPac™ PA-100 and are therefore eluted and detected earlier than a 
more negatively charged monosaccharide (Lee, 1990; McGuire, et al., 1999).  
Detection of eluted monosaccharides occurs on a gold electrode and prior to 
the invention of PAD the gold electrode would be fouled by a build-up of oxides 
that formed a coating on the surface, making it redundant. Since the 1980’s 
PAD has overcome the issue of electrode fouling by allowing oxides to form 
when the potential is increased thus the monosaccharides are detected but 
cleaning the electrode surface using a low potential, greatly improving the 
reproducibility of the technique (Johnson and LaCourse, 1992; Rocklin and 
Pohl, 1983). Detection occurs when an oxyanion (an ionised –OH group on a 
monosaccharide) comes into contact with the gold electrode at a high potential, 
the electrical current generated by the oxidation of the monosaccharide on the 
electrode surface is then measured and recorded. The electrode surface is then 
cleaned by lowering the potential, readying it for the next eluted 
monosaccharide (see Figure 2.1). 
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Figure 5.1 Oxyanion Formation.  [Adapted from Behan, (2010)] 
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5.2 Dataset 1 Results. 
 
The monosaccharide composition of AGP glycan chains was evaluated via 
HPAEC-PAD. Samples from dataset 1 and dataset 2 were analysed to establish 
any quantitative or qualitative differences in composition that may form the 
basis of a novel BC biomarker. 
Performing such analysis is reliant on complete separation of glycan chains 
from the polypeptide backbone of AGP and degradation of the bonds between 
individual monosaccharides. Uncleaved or degraded monosaccharides will not 
be detected by HPAEC-PAD which could alter results. Figure 5.2 shows a 
representative chromatogram of monosaccharides common to complex N-
linked glycans – Fuc, glucosamine, Gal and Man. To represent the 
deacetylation of N-acetylated hexosamines by HCl and NaOH during acid 
hydrolysis and HPAEC respectively, glucosamine was used as a standard for 
GlcNAc. The chromatogram below illustrates that HPAEC is capable of 
separating stereoisomers such as Gal and Man which are isomers of one 
another differing by the orientation of their atoms in space (see Figure 1.1 in 
Chapter 1). 2-Deoxy-galactose was used as an internal standard to aid the 
identification of sample monosaccharides through retention time ratios. The 
alkaline conditions selected, provided consistent elution order of 
monosaccharides throughout this study. 
 
Figure 5.2  HPAEC Separation Chromatogram of Common Complex N-
linked Glycan Monosaccharides Fuc – Fucose; IS – Internal standard (2-Deoxy-D-
galactose); GlcNAc – N-acetylglucosamine; Gal – Galactose; Man- Mannose. 
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However, upon monosaccharide analysis of TNBC samples a peak was 
consistently detected at approximately 15 minutes between IS and GlcNAc. 
Further investigation revealed this to be N-acetylgalactosamine (GalNAc) which, 
as shown below in Figure 5.3, has a similar retention time to that of the 
unexpected peak. As with GlcNAc, galactosamine (GalN) was used as a 
standard to represent GalNAc. GalNAc is not routinely present in N-linked 
complex glycans such as AGP but is commonly found in O-linked glycans. 
 
Figure 5.3 Identification of Unknown Chromatogram Peak. Continual 
appearance of unknown peak in TNBC samples was identified as Galactosamine as both had 
similar retention times and ratios. 
 
Reliability of the acid hydrolysis technique and HPAEC instrument was critical 
for investigation of monosaccharide content during this study. Therefore, prior to 
Phase 1 sample analysis, commercially purchased AGP test samples were acid 
hydrolysed using methods previously devised by the research group (Behan, et 
al., 2013) and the monosaccharide content analysed to ensure reliability of the 
methods. 
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Figure 5.4  Chromatogram of Commercially Purchased AGP Samples to 
Highlight Dionex Reproducibility. Commercially purchased AGP samples (n=4; 
50μg) were acid hydrolysed to release individual monosaccharides that were analysed by 
HPAEC-PAD to show consistent AGP chomatogram confirming reproducibility of technique. 
 
After reproducibility of the technique was confirmed, standard curves were 
produced using known quantities of Fuc, GlcN, Gal and Man (shown below 
Figure 5.5) and equations devised for the calculation of unknown 
monosaccharide content from Phase 1 and Phase 2 samples. Galactosamine 
standard curve was calculated and added to Figure 5.5 after detection in TNBC 
samples. Analysis of monosaccharide concentrations of 0-2ug were repeated 
five times to calculated mean values and standard deviations to plot standard 
curves with error bars. As shown below increase in monosaccharide 
concentration caused an increase in peak area detected during HPAEC 
analysis. The majority of r2 values were >0.9 indicating a strong linear 
association between monosaccharide concentration and detected peak area. 
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Figure 5.5 Plot of Peak Area Variation with Known Concentrations of 
Common N-linked Glycan Monosaccharides and Galactosamine. (n=5). 
The equation of each monosaccharide curve was rearranged to give an 
equation for generating concentration of each monosaccharide in µg. 
Concentration in micrograms was then subsequently adapted to nanomoles for 
conversion to mol of sugar per mol AGP. This allowed for direct comparison of 
monosaccharide content between sample groups in dataset 1 and dataset 2 of 
the study. 
 
Table 5.1 Equations Derived From Standard Curve to Determine mol 
monosaccharide per mol AGP Content of Each Sample. 
 
5.3 Dataset 1 Monosaccharide Content Results. 
 
Dataset 1 of the study compared the monosaccharide content of samples from 
women with TNBC (n=18), healthy individuals (n=5; negative control) and 
women with BC of an unknown hormone receptor type (n=5; positive control). 
For both positive and negative controls, analysis was carried out in triplicate and 
thus figures shown in Table 5.2 are means of three replicates and standard 
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deviation is shown. However, low TNBC sample volumes made repeat analysis 
impossible, therefore figures shown in Table 5.2 below are representative of 
only one analysis of each sample. 
 
 
Monosaccharide Content (mol monosaccharide/mol AGP) 
 
Fucose GalNAc GlcNAc Galactose Mannose 
Sample 
H8 Trace Trace 0.01 ± 0.02 0.07 ± 0.13 0.11 ± 0.13 
I2 0.02 ± 0.01 Trace 0.06 ± 0.05 0.14 ± 0.09 0.16 ± 0.24 
I3 0.04 ± 0.00 Trace 0.01 ± 0.00 1.13 ± 0.09 0.15 ± 0.02 
I5 Trace Trace 0.01 ± 0.00 0.17 ± 0.14 0.15 ± 0.20 
I8 0.01 ± 0.00 Trace  0.02 ± 0.00 0.04 ± 0.00 0.06 ± 0.06 
Mean Positive Control 0.01 ± 0.01  - 0.02 ± 0.01 0.31 ± 0.20 0.13 ± 0.02 
N1 0.02 ± 0.01 Trace Trace 0.05 ± 0.00 0.94 ± 0.07 
N2 0.01 ± 0.00 Trace  0.11 ± 0.10 0.11 ± 0.01 0.07 ± 0.10 
N3 0.01 ± 0.00 Trace 0.11 ± 0.04 0.12 ± 0.08 0.18 ± 0.17 
N4 0.01 ± 0.02 Trace 0.03 ± 0.02 0.17 ± 0.00 0.42 ± 0.18 
N5 Trace Trace 0.01 ± 0.01 0.01 ± 0.01 0.02 ± 0.01 
Mean Negative Control 0.01 ± 0.00  -  0.05 ± 0.02 0.09 ± 0.03 0.33 ± 0.17 
F5412 0.21 0.27 0.56 1.54 0.87 
MT3625 Trace Trace Trace 0.02 0.41 
MT2305 0.04 0.04 0.16 0.60 1.13 
CT79 0.04 0.08 0.27 0.62 0.29 
MT2621 0.08 0.02 0.09 0.45 0.76 
MT3965 0.02 0.45 0.06 0.83 0.25 
Mean <35 0.07 ± 0.08 0.17 ± 0.19 0.19 ± 0.20 0.67 ± 0.50 0.62 ± 0.35 
MT1106 0.04 0.02 0.35 0.71 1.76 
MT1177 0.05 0.04 0.85 1.26 3.51 
MT1178 0.05 0.38 0.24 0.57 1.45 
MT3601 0.15 0.16 0.32 0.78 1.18 
MT1937 0.05 0.12 0.20 0.38 0.80 
MT3795 0.12 0.02 0.43 0.59 1.90 
Mean Over 35-60 0.07 ± 0.05 0.12 ± 0.14 0.39 ± 0.23 0.72 ± 0.30 1.77 ± 0.94 
MT3362 0.02 0.01 0.03 0.34 0.69 
MT3497 0.12 0.08 0.46 0.66 1.80 
MT3442 0.01 0.01 0.25 0.45 0.74 
MT3959 0.04 0.02 0.26 0.13 3.03 
MT3352 Trace Trace Trace Trace 1.35 
MT2569 Trace 0.03 0.03 0.51 0.44 
Mean >60 0.03 ± 0.05 0.03 ± 0.02 0.17 ± 0.18 0.35 ± 0.19 1.34 ± 0.96 
 
Table 5.2 Monosaccharide Content of Dataset 1 Samples. Table shows 
mean of three replicates of each positive and negative control sample ± SD. While TNBC 
figures are the result of one analysis. 
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Man is only present in the pentasaccharide core of complex N-linked glycans, 
thus consistent levels are an indication that similar amounts of AGP are being 
analysed each time. While Man levels differed slightly between the three 
groups, variation was not significant and alterations in level may be due to the 
sheer accuracy of the HPAEC technique. As no significant difference was found 
this suggested that the N-linked pentasaccharide core structures were 
consistent in all samples implying that the levels of AGP being analysed were 
as intended and reliable. 
Due to only one repeat of each TNBC sample being possible, statistical analysis 
of differences between individual TNBC samples was not possible. However, 
TNBC samples were sub-divided into varying categories such as age, family 
history status, cancer grade and treatment status to statistically examine any 
alterations in monosaccharide content that could lead to a biomarker for BC in 
“at risk” individuals. Healthy and BC of unknown type samples were then 
compared to these categories using one-way ANOVA with a Tukey’s post hoc 
test to examine any statistical differences between the groups. Statistical 
significance is indicated on the graphs that follow (Figures 5.6, 5.7, 5.8, and 5.9) 
by an * symbol above the relevant column for significance at p<0.05 and ** 
symbol if significance is at p<0.001. 
 
Figure 5.6  Mean Monosaccharide Content of TNBC Samples by Age 
Compared to Controls.   TNBC samples were separated into age categories <35, >35-
60 and >60 (n=6 per category) for comparison with healthy and BC of unknown type. Statistical 
significance indicated by * for p<0.05 and ** for p<0.01. 
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Differences in monosaccharide content were observed between both negative 
and positive controls as well as across all age categories of TNBC. Healthy 
samples showed low levels of all monosaccharides whereas BC of an unknown 
type showed increased levels of Gal although these differences were not 
significant. Increased levels of Gal may indicate increased branching of glycan 
chains within a sample as Gal is only present in the branches of complex N-
linked glycans such as those on AGP. Interestingly, TNBC is shown to have 
elevated levels of all monosaccharides compared to not only the healthy 
population, but that of the BC unknown type as well. TNBC samples aged <35 
and 35-60 show similar monosaccharide content trends with levels of 
monosaccharides increasing slightly with age. However, TNBC samples from 
women >60 years of age contained lower levels of all monosaccharides than 
both the other TNBC age categories but levels were still elevated above those 
of the healthy population. Furthermore, the unusual presence of GalNAc 
appears to decrease with age, but again this was not significant. GlcNAc levels 
of the TNBC 35-60 category were found to be significantly higher (p<0.05) to 
both the healthy and BC of unknown type. Similarly levels of Gal were 
significantly higher in TNBC <35 and 35-60 age groups. This suggested that 
TNBC has a different monosaccharide content to that of BC that may be of a 
different type, significantly so at younger ages (<60) but not in the age range 
that BC commonly occurs (usually 50-70). When comparing TNBC from 
patients below and over 50 years old, only Gal was significantly higher in <50 
group compared to both controls. Analysis of samples MT3625 and MT3352 
showed unquantifiable trace amounts of the majority of monosaccharides that 
were expected to have been detected. The explanation for this is unknown but it 
is unlikely to be a true reflection of monosaccharide content. 
* 
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Figure 5.7 Mean Monosaccharide Content of Samples With and Without 
Family History. TNBC samples were separated into groups with and without family 
history (n=7 and n=8) as well as unknown family history status (n=3) for comparison with 
healthy and BC of unknown type. Statistical significance indicated by * for p<0.05 and ** for 
p<0.01. 
 
Examining the monosaccharide content of TNBC samples categorised by family 
history status, highlighted several significant differences between those with 
family history and both controls. As with TNBC separated by age, levels of all 
monosaccharides were elevated compared to healthy and BC of unknown type 
controls. Furthermore, samples from patients with family history of BC have 
higher levels of all monosaccharides compared to those with no family history 
(not significant). However, when compared to controls, samples from patients 
with family history have significantly higher Fuc compared to BC of unknown 
type. GalNAc is also significantly increased in those with family history and 
unknown family history status compared to both controls. Both controls contain 
significantly lower levels of GlcNAc compared to family history TNBC samples 
but the BC of unknown type also has signficantly lower GlcNAc levels than 
those without family history. A significantly higher level of Gal was also 
observed in family history compared to healthy samples. Samples with unknown 
family history exhibit monosaccharide trends similar to both family history and 
non-family history samples such as elevated GalNAc levels similar to family 
history samples and Gal level comparable to those of non-family history TNBC. 
Therefore there appears to be a distinct difference in the monosaccahride 
content of TNBC samples with family history compared to BC of unknown type. 
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Additionally there are few differences between non family-history TNBC 
samples and BC of unknown type other than significantly higher GlcNAc levels.  
 
Figure 5.8 Mean Monosaccharide Content of Treated and Untreated 
TNBC Compared to Controls.  Statistical significance indicated by * for p<0.05 and ** 
for p<0.01. 
 
To assess whether treatment prior to blood draw had an effect on AGP 
monosaccharide content in TNBC, samples were split into treated and 
untreated samples and compared to both controls. When sub-categorised in 
this manner, treated and untreated TNBC samples appeared to follow similar 
trends in monosaccharide content that are distinctly different to either control. 
There were no significant differences between monosaccharide content in 
treated and untreated samples implying that at this stage treatment was having 
no effect on AGP monosaccharide content in TNBC samples. However, 
significantly lower levels of all monosaccharides were found in both controls 
compared to treated TNBC samples other than Gal which was only significantly 
lower in healthy samples compared to treated TNBC. There were also no 
significant differences in monosaccharide content found in either control 
compared to untreated samples. 
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Figure 5.9  Mean Monosaccharide Content of TNBC Samples by Stage 
Compared to Controls. 
As in Figure 5.9, when TNBC samples are separated into cancer stage there 
are similar trends in monosaccharide content between Stage 1 and Stage 2 
TNBC. As there was only one Stage 3 TNBC in the cohort (MT3352) this 
sample was not used for comparison as the sample would not be a reliable 
representation of Stage 3 TNBC. Stage 1 TNBC possessed significantly higher 
levels of Fuc, GalNAc and GlcNAc (p<0.05) in comparison to both controls with 
Gal being significantly higher than the healthy population as well. Stage 2 TNBC 
also had significantly higher levels of GlcNAc (p<0.05) compared to both 
controls and Gal in comparison to the healthy population. No significant 
difference was found between Stage 1 and Stage 2 TNBC but GalNAc and Gal 
showed a 0.4 and 1.29 fold decrease in Stage 2 TNBC which may indicate a 
decrease in glycan branching. 
 
5.4 Dataset 2 Monosaccharide Results. 
 
Dataset 2 of this study examined the monosaccharide content of a population of 
“at risk” women (n=16) compared to (where possible) age-matched healthy 
controls (n=10) to determine any differences between the groups as well as any 
patterns that may indicate BC onset. Analysis using HPAEC-PAD was 
conducted five times for each sample to improve the reliability of results. 
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Therefore, figures in Table 5.3 are the means of five replicates and the standard 
deviation is given. 
 
 
Monosaccharide Content (mol monosaccharide/mol AGP) 
 
Fucose GalNAc GlcNAc Galactose Mannose 
W1 0.127 ± 0.06 0 0.351 ± 0.37 1.424 ± 0.64 0.930 ± 0.73 
C1 0.174 ± 0.08 0 1.180 ± 0.15 1.367 ± 0.42 0.631 ± 0.45 
W2 0.078 ± 0.04 0.133 ± 0.11 1.315 ± 0.85 1.518 ± 0.84 1.052 ± 0.52 
C2 0.155 ± 0.11 0 0.508 ± 0.28 0.814 ± 0.56 1.003 ± 0.52 
W3 0.146 ± 0.09 0.740 ± 0.70 1.217 ± 0.08 1.571 ± 0.26 1.264 ± 0.44 
C3  -   -   -   -   -  
W4 0.159 ± 0.13 0.213 ± 0.20 1.052 ± 0.67 1.546 ± 1.13 1.251 ± 0.74 
C4 0.174 ± 0.12 0 1.014 ± 0.15 1.448 ± 0.29 0.857 ± 0.19 
W5 0.163 ± 0.10 0.157 ± 0.09 1.120 ± 0.58 1.661 ± 0.79 1.204 ± 0.59 
C5 0.208 ± 0.19 0 1.251 ± 0.36 0.981 ± 0.90 1.497 ± 1.29 
W6 0.136 ± 0.06 0.933 ± 0.53 1.106 ± 0.58 1.086 ± 0.26 1.055 ± 0.67 
C6 0.114 ± 0.09 0 0.849 ± 0.27 0.984 ± 0.48 1.822 ± 0.63 
W7 0.116 ± 0.06 0 1.246 ± 0.66 1.670 ± 0.93 1.347 ± 0.71 
C7 0.137 ± 0.09 0 0.817 ± 0.41 1.323 ± 0.65 1.010 ± 0.49 
W8 0.086 ± 0.05 0 0.641 ± 0.37 0.430 ± 0.28 0.629 ± 0.34 
C8 0.061 ± 0.03 0 0.438 ± 0.20 0.798 ± 0.19 1.006 ± 0.59 
W9 0.050 ± 0.00 0.162 ± 0.27 0.954 ± 0.48 1.205 ± 0.63 0.936 ± 0.49 
C9  -   -   -   -   -  
W10 0.088 ± 0.02 0.298 ± 0.251 0.894 ± 0.24 1.057 ± 0.20 0.895 ± 0.19 
C10  -   -   -   -   -  
W11 0.041 ± 0.02 0.638 ± 0.37 1.257 ± 0.27 0.646 ± 0.59 0.853 ± 0.31 
C11 0.097 ± 0.11 0 0.333 ± 0.54 1.140 ± 0.49 0.742 ± 0.48 
W12 0.053 ± 0.01 0.068 ± 0.03 1.230 ± 0.17 0.098 ± 0.09 0.863 ± 0.19 
C12 0.229 ± 0.06 0 0.780 ± 0.20 1.288 ± 0.20 1.128 ± 0.59 
W13 0.081 ± 0.02 0.058 ± 0.04 1.357 ± 0.04 1.354 ± 0.14 1.224 ± 0.02 
C13 0.069 ± 0.01 0 0.924 ± 0.27 1.266 ± 0.55 0.734 ± 0.55 
W14 0.091 ± 0.01 0.777 ± 0.67 0.990 ± 0.07 1.350 ± 0.38 1.047 ± 0.13 
C14  -   -   -   -   -  
W15 0.192 ± 0.19 0.407 ± 0.434 1.309 ± 0.44 1.469 ± 1.15 1.202 ± 1.12 
C15  -   -   -   -   -  
W16 0.157 ± 0.08 0.561 ± 0.46 1.001 ± 0.13 1.614 ± 0.14 1.033 ± 0.17 
C16  -   -   -   -   -  
 
Table 5.3  Monosaccharide Content of Dataset 2 Samples.  Table shows 
the mean of five replicates of “at risk” samples and their age-matched controls ± SD. “-“ 
indicates no age-matched controls were recruited.  
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As discussed for dataset 1, Man is only present in the pentasaccharide core of 
AGP glycans and therefore the consistent levels indicate similar concentrations 
of AGP being analysed. There was no significant variation between sample Man 
levels in dataset 2 implying that consistent concentrations of AGP were 
analysed and the results of monosaccharide analysis were reliable.  
 
Figure 5.10 Mean Monosaccharide Content of At-Risk and Healthy 
Control Populations. Mean monosaccharide content in mol monosaccharide/mol 
AGP of a population at risk of BC (n=16) compared to a healthy control population (n=10) ± SD. 
 
Comparison of mean monosaccharide content of the “at risk” population and 
healthy controls as well as a one-way ANOVA revealed alterations between 
both groups. The “at risk” population had slightly decreased Fuc levels 
compared to the healthy controls (not significant), but had significantly elevated 
concentrations of GalNAc (p<0.01) and GlcNAc (p<0.05). GalNAc was present 
in 81% of “at risk” samples but not detected in any of the healthy control 
samples and mean GlcNAc levels were 1.3 times higher in the ”at risk” 
population. No significant difference was found between either group for Gal or 
Man, highlighting the same levels of AGP were analysed. 
The following graphs (Figures 5.11 A-P) give direct comparisons of AGP 
monosaccharide content between “at risk” samples and their age-matched 
healthy control or the mean monosaccharide content if an age-matched healthy 
control was unavailable. 
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Figure 5.11  Comparison of Monosaccharide Content of At-Risk Samples 
with Age-Matched Healthy Controls. Graphs A-P show direct comparisons of 
sample AGP monosaccharide content between “at risk” samples (n=16) and their age-matched 
healthy controls (n=10). Where age-matched healthy controls could not be recruited (n=6), “at 
risk” samples were compared to the mean monosaccharide content of all healthy controls. 
Figures shown represent mean of the five replicates ± SD. Statistical significance indicated by * 
if p<0.05 or ** if p<0.01. 
 
In line with previous statistical analysis in this chapter (Figure 5.10), 
comparisons between the monosaccharide content of “at risk” samples and 
age-matched controls (or mean monosaccharide content where no age-
matched control was available) were analysed using a one-way ANOVA.  
Results were considered statistically significant at p<0.05. 
Sample W1 showed no significant differences in monosaccharide levels 
compared to age-matched healthy control C1. However, GlcNAc levels were 
70% decreased in W1 compared to C1. Fuc and Gal levels were similar in both 
samples and no GalNAc was detected in either. 
Comparison of sample W2 to age-matched control sample C2 revealed no 
significant differences in monosaccharide content. While Fuc levels were 
comparable in both samples, GlcNAc and Gal were elevated in W2 compared to 
C2. Additionally, GalNAc was present in W2 but not C2 though not at significant 
levels. 
No age-matched healthy control was available for comparison to sample W3. 
Therefore, as stated, W3 was compared to the mean monosaccharide levels of 
all healthy controls. GalNAc was present at significant levels (p<0.01) in W3 
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and both GlcNAc and Gal were also elevated by 47% and 38% respectively (not 
significant).  
Sample W4 had GalNAc present (significant at p<0.05) however GalNAc was 
not present in C4. No other significant differences in monosaccharide content 
were found between W4 and C4 as levels of Fuc, GlcNAc and Gal were almost 
identical. 
Assessment of W5 and C5 revealed significant GalNAc presence (p<0.05) in 
W5 but not C5. Fuc levels were marginally lower in W5 – 0.16 compared to 0.2 
mol monosaccharide/mol AGP – and GlcNAc levels were similar in both 
samples. In contrast, Gal levels of W5 were almost double those in C5. 
Significant GalNAc levels (p<0.01) were detected in W6 whereas no GalNAc 
was found in C6. W6 also showed an increase in GlcNAc compared to C6 
however, Gal was 40% decreased in W6. Fuc levels were comparable in both 
samples. 
W7 and C7 had no significant differences in monosaccharide content, with both 
lacking GalNAc and possessing similar Fuc levels. However, GlcNAc and Gal 
levels in W7 were increased compared to C7. 
Interestingly, samples W8 and C8 had lower levels of all monosaccharides 
compared to other sample pairs.  Neither sample contained GalNAc however 
W8 contained higher levels on GlcNAc (not significant). In contrast, C8 showed 
significantly higher levels on Gal (p<0.05). Again, Fuc levels were similar in W8 
and C8 
W9 was the second “at risk” sample not to recruit an age-matched healthy 
control, so as with W3, was compared to the mean monosaccharide content of 
all healthy controls. However, no significant differences were found in 
monosaccharide content between the groups. W9 showed lower levels of Fuc 
but increased GlcNAc, similar Gal levels to the control (not significant) and 
GalNAc was present. 
W10 was also compared to the mean monosaccharide content of all healthy 
controls which revealed significant (p<0.01) GalNAc concentrations in W10. No 
other significant differences in monosaccharide content were discovered as 
levels on Fuc, GlcNAc and Gal were similar in both groups. 
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Comparison of W11 to C11 revealed that W11 contained 57.5% less Fuc than 
the age-matched healthy control. W11 also had significant levels of GalNAc 
present (p<0.01) whereas C11 contained none. When examining GlcNAc 
content, W11 had almost four times as much GlcNAc as C11 but 43% less Gal 
(not significant).  
W12 was examined against age-matched healthy control C12 and showed 
GalNAc presence (not significant) and GlcNAc levels elevated above C12. 
However, W12 Fuc levels were four times lower than C12 and unusually, Gal 
levels were significantly lower than the healthy control. GalNAc presence was 
not detected in C12. 
Similarly, GalNAc was not detected in C13 upon analysis but was present in 
W13 (not significant). No significant differences were found between the control 
and “at risk” sample for any monosaccharide despite a 32% elevation of GlcNAc 
in W13 compared to C13. 
An age-matched healthy control could not be recruited for “at risk” sample W14, 
thus comparisons were drawn between the mean monosaccharide content of all 
healthy controls and W14. Fuc, GlcNAc and Gal levels were comparable 
between W14 and healthy controls with minimal increases in W14’s GlcNAc and 
Gal content. However, a significant (p<0.01) level of GalNAc was detected in 
W14, with no GalNAc detected in the healthy control samples. 
Similarly, comparison of W15 with the mean monosaccharide content of all 
healthy controls showed significant presence of GalNAc (p<0.01) in W15 but 
none detected in the healthy control samples. W15 also showed elevation of 
Fuc, GlcNAc and Gal by 26%, 37% and 18% respectively, though no 
differences were significant.  
Lastly, as with W14 and W15, significant (p<0.01) levels of GalNAc were 
detected in W16 when compared to the mean monosaccharide content of all 
healthy controls. A similar trend followed, where Fuc, GlcNAc and Gal were 
elevated in comparison to the controls. As with previous comparison, no 
GalNAc was present in any of the control samples. 
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5.5 Discussion. 
5.5.1 Introduction. 
 
The aim of the research discussed in this chapter was to determine the 
concentrations of monosaccharides and investigate changes in 
monosaccharide concentrations from isolated AGP samples from two sample 
populations – Dataset 1 comprised samples from healthy individuals, women 
with BC of unknown type and women with TNBC as well as Dataset 2 
containing samples from women at increased risk of BC development and age-
matched healthy controls. This was performed using acid hydrolysis and 
analysis by HPAEC-PAD. 
To date several studies have explored changes to AGP glycan composition in 
BC (Croce, et al., 2005; Hashimoto, et al., 2004; Turner, et al., 1985) but none 
have investigated monosaccharide levels in TNBC. As well as increases in in 
vivo AGP concentration, unique changes in monosaccharide content of AGP’s 
five glycans occurring in a disease-dependent manner could potentially be used 
as a biomarker for disease diagnosis. 
As discussed in section 5.1, monosaccharide levels of AGP glycans from TNBC 
samples, healthy individuals and women with BC of an unknown type were 
analysed by HPAEC-PAD after subjection to acid hydrolysis. While the exact 
monosaccharide sequence cannot be determined from the cleavage of glycan 
chains into individual monosaccharides, variations in monosaccharide levels 
can be assessed for suggestions of structural changes. This can be used in 
conjunction with data collected from analysis of whole oligosaccharide chains 
(explained in Chapter 6, section 6.4) to better assess structural changes. 
While used earlier to confirm reproducibility of the HPAEC-PAD technique, 
commercial AGP was not a suitable representation of a normal, healthy 
population to act as a negative control in this study. This is because the method 
used to isolate commercial AGP was an adaptation of a large-scale 
methodology by Hao and Wickerhauser (1973) which differed from that used in 
this study. Therefore, AGP was isolated from samples sourced from the Blood 
Transfusion Service to represent a healthy population and ensure consistent 
isolation methods across all sample groups, reducing the risk of unreliable 
results. 
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5.5.2 Trends in AGP Monosaccharide Content. 
5.5.2.1 Dataset 1 
 
Analysis of sample monosaccharide content using HPAEC-PAD revealed low 
levels of monosaccharides (Fuc, GlcNAc, Galactose and Mannose) in the 
healthy controls. In comparison, BC of unknown type (acting as a positive 
control) showed increased Galactose and Mannose content. GalNAc was not 
observed in any control samples. 
Overall, TNBC samples showed increased Fuc, GlcNAc, Gal and Man content 
compared to both controls and interestingly, 88% of TNBC samples revealed 
the unusual presence of GalNAc which is associated with O-linked glycosylation 
(Varki, et al., 2009) and discussed later in section 5.5.2.4. 
 
5.5.2.1.1 Monosaccharide Content of TNBC Categorised by Age. 
 
When comparing monosaccharide content of TNBC samples by age, individuals 
<60 years of age showed increased concentrations of all monosaccharides 
monitored, including significantly (p<0.05) increased Galactose and GlcNAc 
(p<0.01 in the 35-60 age group) compared to both controls whereas TNBC 
samples from women >60 years old possessed increased GlcNAc and 
Mannose content compared to controls but had similar Galactose and Fuc 
content.  
TNBC is a notoriously aggressive form of BC particularly in young women. 
Mean Fuc levels of TNBC samples from women aged <35 and 35-60 were 
double that of those >60. Although this difference was not significant, these 
results fit with the idea that increased Fuc levels correlate with poorer prognosis 
associated with TNBC at a younger age (Anders et al., 2008 and Hashimoto et 
al., 2004). Furthermore, increased fucosylation may be due to increased 
presence of SLeX terminal structures which are linked to increased risk of 
metastasis (Julien et al., 2011 and Nakagoe et al., 2002).  
The current study also demonstrated increased GlcNAc and Gal in samples 
from women <60 which also confers to current evidence that BC at a younger 
age is more aggressive and associated with a poorer prognosis. For example, 
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data from Smith et al., 2012 showed that increased Gal sample content was 
correlated with increased AGP glycan branching in malignant BC samples 
which could define malignant samples from non-malignant samples. 
Additionally, increased N-linked β1-6 branching has been linked to poor 
outcomes in BC patients, further associating poor prognosis with younger TNBC 
patients as increases in glycan branching were observed in this patient 
population during this study (Madjid et al., 2005 and Cui et al., 2011). 
 
5.5.2.1.2 Monosaccharide Content of TNBC Categorised by Family History. 
 
Examination of TNBC sample monosaccharide concentrations categorised by 
family history of BC revealed TNBC samples from individuals with family history 
had significantly elevated monosaccharide (p<0.05; GlcNAc p<0.01) content 
compared to both controls. Increased levels of GalNAc, GlcNAc and Galactose 
in were observed in TNBC samples from individuals with family history of BC in 
comparison to samples without family history of BC. Yet no significant 
difference in Fuc content was observed between samples with or without family 
history. Monosaccharide content of TNBC samples from women with unknown 
family history of BC (n=3) did not fall distinctly into either trend seen in family 
history or no family history. Galactose and Fuc content were similar to that of 
samples without family history, yet concentrations of GalNAc were comparable 
to sample with family history of BC. Therefore, this group may have contained 
samples that could have been assigned to either the family history or no family 
history group based on monosaccharide content. Of the 3 TNBC samples with 
unknown family history MT1178 contained a monosaccharide content that 
reflected the family history category while MT2621 and MT2305 
monosaccharide content resembled that of the no family history group. 
However, the current study cannot definitively associate monosaccharide 
content with family history because no follow up of this sample population was 
available. 
Increased Fuc content of these samples could indicate worse prognosis and 
risk of metastasis associated with TNBC’s poor outcomes (Hashimoto et al., 
2004; Julien et al., 2011 and Nakagoe et al., 2002). However, comparable 
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levels of Fuc between TNBC samples from women with and without family 
history or unknown family history may indicate similar levels of metastasis risk 
between these groups and reflect overall poor prognosis of TNBC rather than 
conferring more risk to those with family history. 
However, elevated GalNAc and Gal content in TNBC samples from women with 
family history compared to those without family history could imply increased 
branching of AGP in these samples (Smith, et al., 2012). This could correlate 
with previous literature indicating poor prognosis associated with increased 
glycan branching (Smith et al., 2012; Madjid et al., 2005 and Cui et al., 2011) 
however a recent, large study by Malone et al., (2011) revealed patients with 
family history of BC had a better prognosis than women without family history. 
Therefore, it is unclear whether the increased GalNAc and Gal in TNBC 
samples from patients with family history act as prognostic indicators of survival. 
 
5.5.2.1.3 Monosaccharide Content of Treated and Untreated TNBC 
Samples. 
 
Furthermore, comparison of treated and untreated TNBC samples delivered 
similar trends in monosaccharide content and the concentrations of all 
monosaccharides were increased above both controls. Previous research by 
Doak (2008) using the same methods as this study showed that altered 
glycosylation during BC  returned to a normal glycosylation pattern similar to the 
healthy control population upon treatment.  This may indicate that treatment 
administered prior to blood draw had no effect on glycosylation composition or 
that these treatments have not had an effect on the TNBC and therefore the 
glycosylation composition remains unchanged. 
 
5.5.2.1.4 Monosaccharide Content of TNBC Samples Grouped by TNM 
Stage. 
 
In this study, the data on monosaccharide content of TNBC samples were also 
separated by cancer stage to allow comparison of TNBC at stage 1 and stage 
2. Comparison of mean Fuc content in controls and TNBC by cancer stage 
revealed that stage 1 TNBC had increased Fuc concentration compared to 
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stage 2. These results did correspond with previous research (Hashimoto, et al., 
2004; Turner, et al., 1985), which showed that levels of Fuc increased with 
increasing cancer severity. However, given that no samples of advanced stage 
TNBC were available to this study for comparison, it remains unknown if 
elevated Fuc levels would have been seen compared to early stage TNBC. 
Furthermore, with only one TNBC sample representing stage 3 a reliable 
comparison with stage 1 and 2 mean GlcNAc and Gal content could not be 
made. Stage 1 and stage 2 TNBC showed similar levels of GlcNAc while stage 
2 had slightly lower levels of Gal. Although no significant differences were found 
between TNBC stages there were significant differences (p<0.05) between 
GlcNAc and Gal in controls and TNBC stages. Healthy and BC of unknown type 
samples had significantly (p<0.05) lower levels of GlcNAc compared to stage 1 
and stage 2 TNBC. Mean Gal levels were significantly (p<0.05) higher in stage 
1 and stage 2 TNBC compared to healthy controls but not BC of unknown type. 
Thus implying that not only do both stages of TNBC exhibit greater AGP glycan 
branching but that this may be similar to that of BC of unknown type.  
Increased GlcNAc and Gal content of TNBC samples compared to the positive 
and negative controls could indicate increased branching of AGP glycans in 
these samples. The higher the TNM stage attributed to a tumour the more 
developed the cancer is, the worse the prognosis and there may be increased 
metastasis compared to lower stage tumours (Sobin, et al., 2009). Hashimoto, 
et al., (2004) highlighted that patients with various advanced malignancies 
showed more tri- and tetra-antennary branching and these results were 
confirmed via mass spectrometry in a later study (Asao, et al., 2013). A 
separate study by Hamid, et al., (2008) revealed increased tri-antennary 
branching of AGP was linked to BC progression. Therefore, the results of the 
current study contradict previous research as higher GlcNAc and Gal 
concentrations in stage 1 TNBC infer increased branching at lower stage TNBC 
compared to stage 2 TNBC. 
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5.5.2.2 Dataset 2. 
 
 Analysis of the monosaccharide content of samples from women at increased 
risk of BC development and age-matched healthy controls revealed two trends 
(see Table 5.4). Eleven of the sixteen “at risk” samples had similar Fuc 
concentrations but increased GlcNAc and Galactose content compared to their 
age-matched healthy controls (Trend 1). Meanwhile, four of the sixteen “at risk” 
samples followed another trend when compared to their age-matched healthy 
controls, again showing similar Fuc levels and elevated GlcNAc; however these 
samples had decreased Galactose concentrations (Trend 2). On the other 
hand, sample W1 did not fit either trend because although Fuc concentrations 
were comparable to those found in the age-matched healthy control (C1), the 
GlcNAc content was decreased and the Galactose level was similar to the 
control.  
 
Table 5.4 Monosaccharide Content Trends Observed in At-Risk 
Samples. Entries in the table highlight sample monosaccharide variation (↔ = 
comparable; ↑ = increased; ↓ = decreased levels compared to age-matched healthy controls) 
per trend 1 (↔ Fuc, ↑GlcNAc and ↑ Gal), trend 2 (↔ Fuc, ↑GlcNAc and ↓ Gal) or no trend (↔ 
Fuc, ↓GlcNAc and ↔ Gal). 
 
Both trends revealed little variation in Fuc concentration between “at risk” 
samples and age-matched healthy controls. This is consistent with previous 
research, given both populations are theoretically disease-free and fucosylation 
Samples 
Trend 1 Trend 2 No Trend 
 ↔ Fuc, ↑GlcNAc and ↑ Gal  ↔ Fuc, ↑GlcNAc and ↓ Gal ↔ Fuc, ↓GlcNAc and ↔ Gal   
W2 W6 W1 
W3 W8   
W4 W11   
W5 W12   
W7     
W9     
W10     
W13     
W14     
W15     
W16     
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has been shown to increase during malignancy (Hashimoto et al., 2004). Fuc is 
usually incorporated into a glycan chain as a component of a terminal structure, 
such as SLex or bound to the pentasaccharide core via the innermost GlcNAc of 
N-linked glycans. Fuc may also be integrated directly into O-linked glycans by 
O-fucosyltransferases such as POFUT1 or O-FUT2 (Wang et al., 2001; Roos et 
al., 2002). Studies have revealed that increased fucosylation in cancer patients 
increases with the stage of malignancy and is associated with a poor post-
operative outcome (Asao et al., 2013; Ferens-Sieczkowska, et al., 2013; 
Hashimoto, et al., 2004; Turner, et al., 1985). Furthermore, Hamid et al., (2008) 
and Royle et al., (2008) established that increased fucosylation of a number of 
serum proteins, including AGP, was the most significant change detected in 
serum samples from breast cancer patients. This can be attributed to the 
altered functions of aberrant fucosylation during cancer. For example, increases 
in the expression of fucosyltransferase FUT 8 may enhance malignant cell 
proliferation (Chen et al., 2013) and increases in SLeX terminal structures may 
denote enhanced metastasis (Julien et al, 2011). However, a study conducted 
by Moriwaki et al., (2009) found decreased fucosylation on established tumours 
aided evasion from NK cells. Therefore, the Fuc content from samples in 
dataset 2 may imply that immune evasion by cancer cells is occurring in these 
participants. However, as similarly low levels of Fuc were observed in both the 
“at risk” and age-matched healthy controls it is more likely that decreased Fuc 
content in these samples implies lack of malignancy. 
Variation in Mannose concentration was also observed between certain “at-risk” 
samples and age-matched healthy controls, for example W1, having 
approximately 32% more Mannose than the corresponding control. Increased 
expression of high mannose glycans during BC has been observed (de Loez et 
al., 2011) and despite AGP being known to solely complex type glycans (see 
Figure 5.12), expression of high mannose type glycans during BC onset cannot 
be ruled out. For instance a study by de Loez et al., (2011) used a mouse 
model and human serum to demonstrate the presence high mannose N-linked 
glycans during BC which may infer incomplete trimming of glycans during 
processing which would normally result in expression of complex and hybrid N-
linked glycans (see Figure 1.4). 
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Figure 5.12 Illustration of Structural Differences Between High Mannose, 
Complex and Hybrid N-linked Glycan Types.  
Moreover, inter-individual variation of GlcNAc and Galactose concentration was 
identified between age-matched healthy control samples with levels ranging 
from 0.333-1.251 mol monosaccharide/mol AGP and 0.798-1.448 mol 
monosaccharide/mol AGP respectively. Variation in GlcNAc and Galactose 
levels are associated with the degree of glycan branching. Galactose is present 
solely in the branches of N-linked glycans but GlcNAc is a component of the 
common pentasaccharide core as well as in glycan branches (Varki, et al., 
2009. Therefore, changes in concentration in each of these monosaccharides 
are a more reliable indicator of alternative branching. Alterations in AGP glycan 
branching have been evaluated in a number of conditions such as cancer and 
inflammation (Higai et al., 2005, Smith et al., 2002, and Hashimoto et al., 2004). 
Studies have shown a decrease in branching during acute inflammation through 
the presence of increased bi-antennary glycans, yet glycans switch to 
displaying more tri- and tetra-antennary glycans during chronic inflammation 
(Higai et al., 2005; Fassbender et al., 1991 and Smith et al., 2002). In the 
present study, given that healthy volunteers self-selected to participate they 
may have been unaware of or offered incomplete information regarding 
possessing inflammatory conditions that may have implications for the 
quantification of AGP monosaccharide content. Therefore this possibly could 
account for decreased or increased levels of GlcNAc and Gal in certain age-
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matched control samples. Since the age-matched healthy control samples for 
dataset 2 were collected fresh and purification began immediately, it is unlikely 
that ineffective storage may have caused alterations in AGP monosaccharide 
content of these samples (Hofbauerova, et al., 2003). 
 
5.5.2.3 Protein Glycosylation in Cancer/Breast Cancer: Summary of the 
findings of the present study. 
 
Previous research has highlighted various changes in glycosylation of proteins 
during cancer development (Dube and Bertozzi, 2005). The current study 
examined two sample populations – one with TNBC and the other at high risk of 
BC development due to family history and/or genetic mutations predisposing BC 
risk.  
Monosaccharide analysis of TNBC samples revealed increased Fuc, GlcNAc, 
and Gal compared to healthy and BC of unknown type controls (see Table 5.2). 
Increased Mannose was also detected and possible reasons for this have been 
discussed in the previous section (5.5.2.2). The majority of TNBC samples 
(88%) had the unusual presence of GalNAc detected and the significance of 
this is discussed in section 5.5.2.4. 
In contrast to this, investigation of monosaccharide content in at risk samples 
revealed two trends. Eleven samples conveyed trend 1 possessing similar 
levels of Fuc but increased GlcNAc and Gal compared to their age-matched 
healthy controls. Whereas 4 samples displayed trend 2 and showed similar Fuc 
content, increased GlcNAc but decreased Gal compared to age-matched 
healthy controls. Sample W1 monosaccharide content did not follow either of 
these trends as analysis revealed similar levels of Fuc and Gal with decreased 
GlcNAc compared to controls.  
As discussed in previous sections (literature review sections as well as 5.5.2.1 
and 5.5.2.2) changes in Fuc content have been noted in various cancers. 
Increased expression of FUT8 (a fucosyltransferase) was found by Chen, et al., 
(2013) during early stage cancer which may promote malignant cell proliferation 
through increased fucosylation. This correlates with data from previous studies 
that revealed increased fucosylation correlated with cancer severity and poor 
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prognosis (Asao, et al., 2013; Ferens-Sieczkowska, et al., 2013; Hashimoto, et 
al., 2004; Turner, et al., 1985). However, a study by Moriwaki et al., (2009) 
highlighted a decrease in fucosylation once tumours are established which may 
protect tumours from destruction by NK cells. Thus the increased Fuc content 
seen in TNBC samples from dataset 1 may reflect that these early stage (TNM 
stage 1 and 2) samples are expressing increased Fuc to enhance the growth of 
tumours which may lead to a poor prognosis for the patient. This would align 
well with the current knowledge regarding TNBC’s aggressive nature (Blows, et 
al., 2010; Dent, et al., 2007; Schnieder, et al., 2008). Meanwhile, the lack of 
change in Fuc content observed in at risk samples from the current study could 
indicate the creation of an immunosuppressive tumour environment through the 
avoidance of NK cell detection. If this is the case then use of Fuc as a marker of 
BC development in individuals at increased risk of BC may not be ideal. 
Furthermore, alterations in GlcNAc and Gal content have been demonstrated 
during cancer (Asao, et al., 2013; Cui, et al., 2011; Hamid et al., 2008; 
Hashimoto, et al., 2004; Smith, et al., 2012) and changes in their levels are 
often correspond with changes in degree of branching (Behan, et al., 2013). 
Notably, increases in both monosaccharides taken together are a more reliable 
indicator of changes in branching as GlcNAc is also present in the common 
pentasaccharide core of N-linked glycans, whereas Gal is only present in glycan 
branches (Varki, et al., 2009; see Figures 1.5 and 5.12). A study by Hashimoto, 
et al., (2004) and a separate study by Asao, et al., (2013) showed correlation 
between increases in glycan branching and cancer stage. Similarly, research 
has shown that tri-antennary glycans are predominantly displayed as BC 
progresses (Hamid, et al., 2008). Furthermore, increases in N-linked β1-6 
branching were demonstrated to correlate with increased mortality during 
cancer in studies by Majid, et al., (2005) and Cui, et al., (2011). In light of these 
previous findings, the increases in GlcNAc and Gal content observed in TNBC 
samples and eleven at risk samples (Trend 1) could be indicative of BC 
progression and poorer prognosis. However, at risk samples displaying trend 2 
(increased GlcNAc and decreased Gal compared to controls) could suggest 
less glycan branching within these samples and potentially a better prognosis if 
the participant develops BC or even less risk of BC development to those 
displaying trend 1. 
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5.5.2.4 O-glycosylation of AGP: considerations for the present study. 
 
For decades mature adult AGP has been described as solely expressing 5 
complex N-linked glycans (Yoshima, et al., 1981). Despite this, GalNAc (a 
known component of O-linked glycans) was detected in 81% of TNBC sample 
and 88% of “at-risk” samples while no GalNAc was detected in any of the 
negative or positive control samples. 
GalNAc is a known component of O-linked glycans through its addition to 
primary alcohol hydroxyl groups in the side-chains of Ser/Thr residues as the 
starting point for the addition of further monosaccharide moieties to create O-
linked glycan chains (Varki, et al., 2009). As AGP contains Ser/Thr amino acids 
within its protein backbone sequence the possibility exists for AGP to possess 
O-linked glycans (see Figure 1.7). In fact during foetal development, AGP 
expresses 3 N-linked glycans and 3 O-linked glycans with the O-linked glycans 
subsequently being lost during development (Shiyan and Bovin, 1997).  
Studies have revealed that certain proteins revert to foetal glycan expression 
during cancer due to rapid proliferation during tumour development (Sapra, et 
al., 2012; Farinati, et al., 2006). This is known as oncofoetal antigen expression 
and has been shown to occur in glycoproteins such as AFP and CEA (Farinati, 
et al., 2006 and Amri, et al., 2013). Thus, it is possible that the detection of 
GalNAc is the majority of TNBC and “at risk” samples could be due to AGP 
expressing oncofoetal antigens. 
Additionally, as GalNAc is not a constituent of the pentasaccharide core 
perhaps GalNAc was integrating into AGP glycan branches. Previous studies 
investigating AGP glycosylation have found the presence of GalNAc in a variety 
of patient populations. Anderson, et al. (2002) reported 64% of AGP samples 
from individuals with hepatitis C contained GalNAc, however GalNAc was not 
present in cirrhosis samples leading them to speculate that disappearance of 
GalNAc from samples could indicate progression of liver disease to a cirrhotic 
state. When investigating AGP glycosylation in fibrosis patients, Mooney, et al. 
(2006) detected GalNAc in 34% of samples. Both studies had limited sample 
numbers meaning no investigation into GalNAc presence could be undertaken. 
However, both groups hypothesised that GalNAc presence could be due to the 
attachment of a terminal structure on AGP glycans. This theory was 
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investigated by Gallacher (2009) after GalNAc was detected when examining 
AGP glycosylation in benign, invasive and non-invasive BC samples. Benign 
and invasive BC samples had GalNAc present therefore immunodiffusion was 
used to investigate whether this was due to addition of terminal glycan 
structures. Blood group antigen A and sialyl Tn were tested for as they are the 
most common GalNAc containing terminal structures. However, neither were 
detected indicating neither of these terminal structures were responsible for 
GalNAc presence in Gallacher’s samples. Unfortunately, it was not feasible as 
part of this study to investigate the source of GalNAc within TNBC samples. 
Nevertheless, in contrast to this study, Gallacher (2009) found an association 
between GalNAc presence and ER/PR positivity in tumours whereas this study 
only found GalNAc in TNBC samples and not BC of unknown type samples. 
A number of TNBC samples showed elevated levels of GalNAc in conjunction 
with decreased levels of Fuc and vice versa (see Table 5.2). Therefore, it may 
be possible that GalNAc is binding in place of Fuc in AGP glycans. However, no 
significant differences were found among GalNAc content when comparing 
TNBC to controls by age. Contrary to this, significant differences (p<0.05) were 
seen in GalNAc levels between TNBC with family history of BC and TNBC with 
unknown family history status compared to healthy and BC of unknown type 
controls samples.  GalNAc values were also significantly (p<0.05) higher in 
treated TNBC samples compared to both controls.  
Additionally, when investigating monosaccharide content in TNBC cancer 
stages, stage 1 TNBC showed significantly (p<0.05) higher levels of GalNAc 
than healthy and BC of unknown type controls. Thus GalNAc was not only 
present in TNBC samples but was significantly different when examining the 
data in different categories. 
AGP expression of O-glycans and hence detection of GalNAc links to recent 
literature regarding O-glycosylation of other proteins being involved in TNBC. 
For example, Milde-Langosch, et al., (2014) revealed that upregulation of O-
glycosylation related enzymes were associated with TNBC subtype and 
metastasis. The group hypothesised that since a number of ligands are 
composed of O-linked glycans, increases in their expression could increase the 
movement and binding of malignant cells away from the primary tumour site. 
Similarly, elevated expression of MUC1 (an O-glycosylated protein) has been 
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shown in TNBC and increases were associated with tumour grade (Siroy, et al., 
2013). Studies have revealed that MUC1 may promote tumour growth by 
inhibiting malignant cell apoptosis (Wei, et al., 2005) and enhance metastasis 
via epithelial-mesenchymal transition (Schroeder, et al., 2003 and Roy, et al., 
2011). Consequently, detection of GalNAc and its association with O-
glycosylation from TNBC samples in this study - such as F5412, MT3965, 
MT1178 and MT3601 which contained high levels of GalNAc - could indicate 
that these patients have a higher risk of metastasis and aggressive tumour 
growth which is already linked to TNBC (Blows, et al., 2010; Dent, et al., 2007; 
Schnieder, et al., 2008). 
 
5.5.3 Benefits and Shortcomings in the Methodology Used. 
 
The current study used the well-documented and highly sensitive technique, 
HPAEC-PAD, (Behan and Smith, 2011; Hardy and Townsend, 1988; Harazono, 
et al., 2011; Smith, et al., 2012; Townsend, et al., 1995) for the quantification of 
monosaccharides within purified AGP samples after acid hydrolysis. A benefit of 
both techniques is that they are non-discriminant - acid hydrolysis will release 
all monosaccharides from the protein backbone (Behan, 2010) just as HPAEC-
PAD will detect all monosaccharides in a sample (Smith, et al., 2012; Harazono, 
et al., 2011; Behan and Smith, 2011; Townsend, et al., 1995).  A further benefit 
of these techniques is that samples do not require derivitization to enhance 
detection as this would alter the structures of the monosaccharides (Lee, 1990). 
Use of commercial monosaccharide standards of Fuc, GalNAc, GlcNAc, Gal 
and Man with HPAEC-PAD enabled the identity and consistent elution time 
(retention times) of each monosaccharide to be established prior to each batch 
of samples being analysed (see Figure 5.2). Additionally, 5 commercial AGP 
samples were subjected to acid hydrolysis and HPAEC-PAD to confirm the 
reliability and reproducibility of the method (see Figure 5.4). 
However, as with AGP concentration analysis, inadequate sample storage may 
have affected the monosaccharide content of AGP in dataset 1. The samples 
were purchased prior to the study commencing and it was acknowledged that 
post-translational modifications such as glycosylation may degrade if stored at -
20°C instead of -80°C (Davies, 1968). Dataset 2 samples were processed 
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immediately and not stored for long periods of time, therefore, storage is 
unlikely to have affected the monosaccharide content in these samples. 
Additionally, while monosaccharide standards were analysed prior to each 
batch of sample investigation, other controls such as commercial AGP could 
have been subjected to acid hydrolysis and HPAEC-PAD to ensure 
contamination was not occurring. However, commercial AGP is expensive and 
with a limited budget for this study it was not feasible to use commercial AGP as 
a control. 
 
5.5.4 Additional Methodologies to Study Glycan Content. 
 
Additional methodologies could, in principle, have been used throughout this 
study to support and confirm the results obtained. However, due to the small 
budget and small sample volumes this was not feasible. 
Initially, given greater sample quantities, basic techniques could have been 
utilised to confirm removal of glycans from AGP by acid hydrolysis or to 
demonstrate increased branching within AGP samples. SDS-PAGE separates 
proteins by size on a gel through application of an electrical current and the 
protein bands can be visualised using stains (Laemmmli, 1970). Samples could 
have been analysed on an SDS-PAGE gel pre and post acid hydrolysis to 
detect the reduction of molecular mass that would have indicated successful 
removal of glycans from the protein. Futhermore, a periodic acid-Schiff stain, 
such as that proposed by (Hart, et al., 2003), could have been used in 
conjunction with SDS-PAGE and a nitrocellulose blot to measure glycosylation 
of AGP pre and post acid hydrolysis. Yet recovery of the AGP protein bound to 
Dowex-50 WX8 H+cation exchange resin to enable separation of proteins and 
monosaccharides after acid hydrolysis proved difficult. Therefore, this along 
with the cost implication was a factor in choosing not to use such techniques. 
Likewise, analysis of each sample using SDS-PAGE could have indicated 
increased monosaccharide content and glycan branching as these samples 
would have possessed a higher molecular mass than their counterparts with 
lower monosaccharide content. Thus, samples with a higher molecular mass 
due to increased monosaccharide content would not have migrated as far 
through a SDS-PAGE gel, giving rise to different banding for each sample. 
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However, due to limited sample volume this was not practical. That said, the 
acid mediated hydrolysis of carbohydrates and glycoproteins is a well-accepted 
technique for oligosaccharide degradation and monosaccharide analysis 
(Manzi, 2001). 
More specialised techniques could also have been used. For example, use of 
an ELISA specific for Fuc would have enabled confirmation of Fuc content of 
AGP isolated from samples (Olewicz-Gawlik, et al, 2007; Ryden, et al., 2002) 
while mass analysis of sample monosaccharides could have been carried out 
using various mass spectrometry methods after separation by HPAEC to 
quantify monosaccharide content (Hammad, et al., 2010; Yuan, et al., 2005; 
Zhu and Sato, 2007). 
 
5.6 Summary Statement. 
  
To conclude, this chapter accomplished its aim to determine the 
monosaccharide concentrations of AGP from blood samples using acid 
hydrolysis and assess variation in monosaccharide concentrations from 
different sample populations used in this study by HPAEC-PAD. 
Dataset 1 showed low levels of all monosaccharides in the healthy negative 
control population as expected while BC of unknown type showed increased 
levels of Gal. Interestingly over 88% of TNBC samples showed the unusual 
presence of GalNAc which inversely correlated with age whereas other 
monosaccharide contents showed no relationship with age. GalNAc was also 
decreased in TNBC samples with no family history or unknown family history 
compared to TNBC samples with family history of BC.  Furthermore, dataset 2 
revealed that AGP glycans in women “at risk” of BC are composed of more 
monosaccharides than their healthy control counterparts thus indicating an 
increase in branching. The reason for this alteration remains unclear as 
theoretically both groups are healthy; the only difference being that one group is 
at increased risk of BC development. One explanation for this is that women at 
risk of BC persistently have altered AGP glycosylation compared to women not 
“at risk”. Another is that, samples such as W2, W3, W5, and W7 that possess 
GlcNAc and Gal contents greatly higher than those of their healthy controls may 
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be a sign of BC development. Furthermore, GalNAc presence in N-linked 
glycans, such as those is AGP, is unusual as it is more commonly present in O-
linked glycans. Therefore, its presence in 81.2% of “at risk” samples may 
indicate BC development. 
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Chapter 6 – Oligosaccharide Analysis Results and 
Discussion. 
  
140 
 
6.1 Introduction. 
 
Alterations to AGP oligosaccharide chain structure may occur during a disease 
state (Hashimoto, et al., 2004; Turner, et al., 1985). These structural changes 
can be used in conjunction with monosaccharide data to evaluate glycosylation 
changes in AGP that could be unique to BC.  
HPAEC-PAD was implemented to separate and detect oligosaccharide chains, 
after cleavage from the polypeptide backbone of AGP using PNGaseF, due its 
highly reliable and sensitive capabilities (Hardy, et al., 1988). Similar to 
monosaccharide analysis, HPAEC detection sensitivity was greatly improved by 
the addition of PAD to purge the gold electrode of contaminants between 
sample analyses.  Oligosaccharide separation is reliant on interactions between 
the negatively charged carbohydrate molecules (due to pH13 mobile phase) 
and the positively charged stationary phase. The strength of interaction 
oligosaccharide interaction with the stationary phase is determined by 
negatively charged terminal 9-carbon carboxylated SA residues combined with 
the negative charge of component monosaccharides under alkaline conditions. 
Therefore (as shown in section 6.2 and 6.4) oligosaccharide chains with varying 
terminal SA residues and negative charge contribution from monosaccharide 
content, results in different elution times for each oligosaccharide chain. For 
instance a bi-antennary oligosaccharide chain with only one terminal SA residue 
will have a lower overall negative charge and will elute earlier than a tri-
antennary oligosaccharide chain with three terminal SA residues. Therefore, 
separation is enhanced due to the formation of oxyanions under strong alkaline 
conditions, resulting in varying pKa values of monosaccharides within the chain 
to allow differentiation between glycan structures. Thus a “fingerprint” of the 
extent of branching can be seen using HPAEC-PAD without prior derivatisation 
of samples (Lee, 1990). As such, HPAEC-PAD has remained a valuable and 
sensitive technique for structural analysis of glycans after their removal from the 
protein portion using enzymes or chemicals.  
Separation of oligosaccharide chains during HPAEC-PAD necessitates the 
removal of glycans bound to the anion exchange resin within the column. This 
removal is facilitated by an increasing linear gradient of NaOAc which acts as a 
pushing agent while 100mM NaOH provides an alkaline pH. The NaOAc 
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gradient is increased from 50-250 mM over a period of 30 minutes causing 
displacement of glycans from the column surface as the NaOAc competes for 
the anion-exchange resin. Increasing the NaOAc gradient to 250mM ensures 
the elution of all oligosaccharide chains including the highly branched and 
sialylated glycans which form the strongest bond with the column resin and 
hence are most difficult to remove. SA exists in 2 main forms that differ by a 
single OH group being present or absent, known as N-acetylneuraminic acid 
(NeuAc) and N-glycolneuraminic acid. Behan (2010) revealed that HPAEC-PAD 
is capable of separating these two SA forms by over 10 minutes in spite of the 
minute structural difference, further highlighting the sensitivity of the technique. 
During analysis of glycan structure using HPAEC-PAD, similar oligosaccharide 
chains which vary only by the extent of sialylation will separate out into distinct 
charged bands due to considerably different overall negative charges of each 
structure. Additionally the size of glycans will affect elution time within a charged 
band. Therefore, glycan chains with increased monosaccharide content will 
have a later elution time than glycan chains with a lower monosaccharide 
content but same degree of sialylation. For instance, if mono-sialylated bi-, tri- 
and tetra-antennary chains were analysed simultaneous, this would be the 
order in which they elute. This is because glycans with greater monosaccharide 
content will contain higher numbers of carbon atoms and thus have more –OH 
groups and negative charge causing an increase in retention time through a 
stronger interaction with the stationary phase resin (Paskach, et al., 1991). 
Similarly the reverse is also true whereby a highly branched chain with 
incomplete sialylation may elute prior to a less branched structure with full 
sialylation, as the overall charge of the former will be less negative due to 
missing SA residues. However, this would be a rare occurrence as lack of SA 
terminal structures usually results in degradation of the molecule, due to Gal 
being exposed at the terminus. If another terminal structure was present, thus 
hiding Gal, degradation would not occur. 
Furthermore, separation of glycan chains can be affected by different linkages 
within chain structures. Townsend, et al. (1988) discovered that variation 
between linkages connecting an SA terminal residue to a glycan chain can 
increased retention time. An SA residue can bind to the outer most Gal of a 
glycan branch via an α-(2,3) or α-(2,6) linkage, with greater expression of α-
142 
 
(2,3) giving a greater elution time due to increased interaction with the column. 
Column interaction is increased because if an α-(2,6) linkage binds SA as a 
terminal structure, the oxyanion effect at the C6 –O- group of Gal is removed as 
that carbon is facilitating the attachment of SA. Absence of this additional 
negative charge allows the glycan chain to elute faster than if an α(2,3) linkage 
occurred because an α(2,3) linkage will not utilise the oxyanion group of C6 
(Townsend, et al., 1989). Additionally the group also found when Gal is bound 
to the pentasaccharide core via a β-(1,4) bond to GlcNAc, the elution time is 
reduced compared to a β-(1,3) linkage, due to less association of the -OH 
groups with the column resin at pH13 during analysis. This allows separation of 
glycans when these linkages differ (Townsend, et al., 1989; Townsend, et al., 
1988).  
 
6.2 Dataset 1 Oligosaccharide Results. 
 
Oligosaccharide analysis was carried out using HPAEC-PAD, as described in 
chapter 2, to provide a fingerprint of the extent of AGP glycan branching within 
samples and assess any alterations between sample groups. HPAEC-PAD 
initially separates glycans into specific charged bands. Eluting first are glycans 
expressing one SA residue (10-20 minutes), secondly are bi-sialylated glycans 
(20-30 minutes), followed by tri-sialylated (30-40 minutes) and tetra-sialylated 
glycans (40-50 minutes). Figure 6.1 illustrates an N-linked oligosaccharide (5µg) 
library with groups of bi-, tri- and tetra-sialylated chains labelled at the expected 
time ranges as described by the manufacturer. This N-linked library 
chromatogram was used as a comparison for all samples to enable 
identification of sialylation of AGP branches. Unlike monosaccharides, which 
can be quantified using calibration curves, oligosaccharides cannot be 
quantified as no pure forms for use as a reference were available. Commercially 
sourced AGP was not used for comparison due to the different isolation method 
used. 
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Figure 6.1  N-linked Oligosaccharide (5µg) Library.  Illustrates the 
separation of varying degrees of branching as distinct charged bands, each labelled with their 
SA content: bi-sialylated, tri-sialylated and tetra-sialylated. 
 
In the case of dataset 1, oligosaccharide chromatograms were collect from 
TNBC samples (n=18), BC of unknown type (n=5; positive control) and “normal” 
healthy individuals (n=5; negative control). As this method was not quantitative 
there was no requirement for sample repeats unless an erroneous 
chromatogram was produced, additionally there was only enough isolated AGP 
from TNBC samples for a single oligosaccharide analysis to be performed.  
  
Figure 6.2 Oligosaccharide Chromatogram of “Normal” Healthy 
Controls Compared to an N-linked Oligosaccharide (5µg) Library.  
0 
10 
20 
30 
40 
50 
60 
0 10 20 30 40 50 60 
P
e
a
k
 H
e
ig
h
t 
(n
C
) 
Time (min) 
Bi-sialylated 
Tri-sialylated Tetra-sialylated 
-10 
0 
10 
20 
30 
40 
50 
60 
10 20 30 40 50 
P
e
a
k
 H
e
ig
h
t 
(n
C
) 
Time (min) 
N1 N2 N3 N4 N5 N-linked Library 
Bi-sialylated 
Tri-sialylated Tetra-sialylated 
144 
 
Oligosaccharide analysis of “normal” healthy controls and comparison to the N-
linked library revealed a tendency towards bi-sialylated and tri-sialylated glycan 
branches. The majority of peaks lay in the tri-sialylated time range, followed by 
bi-sialylated and lastly tetra-sialylated. Most of the healthy controls showed only 
one or two peaks in the tetra-sialylated time-frame compared to several in the 
tri-sialylated time-range. 
 
 
Figure 6.3 Oligosaccharide Chromatogram of BC of Unknown Type 
Controls Compared to an N-linked Oligosaccharide (5µg) Library. 
Use of BC of an unknown type as a positive control highlighted variations in 
glycan branching compared to “normal” healthy samples (negative control). 
Comparison to the N-linked library standard revealed BC of an unknown type 
had an increase in tri-sialylated and tetra-sialylated branches with very few 
peaks detected in the bi-sialylated time range.  
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Figure 6.4 Oligosaccharide Chromatogram of TNBC Sample CT79 
Compared to an N-linked Oligosaccharide (5µg) Library. 
Very few peaks were detected in TNBC sample CT79 but magnification of the 
chromatogram revealed peaks within the tri- and tetra-sialylated time ranges. 
No peaks were detected in the bi-sialylated time range. This right shift indicates 
increased branching within sample CT79. 
 
 
Figure 6.5 Oligosaccharide Chromatogram of TNBC Sample F5412 
Compared to an N-linked Oligosaccharide (5µg) Library. 
TNBC sample F5412 showed a significant number of tri-sialylated glycans with 
a smaller number of peaks in the bi- and tetra-sialylated area. Again this 
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showed an increase in branching similar to that of BC of unknown type as 
opposed to low levels of branching seen in healthy samples. 
 
Figure 6.6 Oligosaccharide Chromatogram of TNBC Sample MT3965 
Compared to an N-linked Oligosaccharide (5µg) Library. 
 A lower level of branching was seen in TNBC sample MT3965 resembling the 
extent of branching found in normal samples. No peaks were detected in the 
tetra-sialylated time range. However, bi-sialylated and tri-sialylated peaks were 
detected in the corresponding time frames, thus suggesting a lower degree of 
branching. 
 
Figure 6.7 Oligosaccharide Chromatogram of TNBC Sample MT2305 
Compared to an N-linked Oligosaccharide (5µg) Library. 
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Oligosaccharide analysis of TNBC sample MT2305 highlighted similar 
oligosaccharide branching to that of TNBC sample MT3965 in that tri-sialylated 
branching was most prominent with few bi-sialylated branches and no tetra-
sialylated branches detected. This degree of branching most closely reflects 
that of the normal population in this dataset. 
  
Figure 6.8 Oligosaccharide Chromatogram of TNBC sample MT2621 
Compared to an N-linked Oligosaccharide (5µg) Library. 
In TNBC sample MT2621 mostly tri-sialylated glycans were detected with three 
peaks detected late in the bi-sialylated time range. Again this corresponded with 
healthy samples’ AGP glycan branching and is similar to that of samples 
MT3965 and MT2305 which both have less branching of glycans. 
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Figure 6.9  Oligosaccharide Chromatogram of TNBC Sample MT3625 
Compared to an N-linked Oligosaccharide (5µg) Library. 
TNBC sample MT3625 showed a similar oligosaccharide profile to MT3695, 
MT2305 and MT2621 whereby late bi-sialylated branching is detected as well 
as tri-sialylated branching. However, a peak was detected in the tetra-sialylated 
time range indicating the presence of a glycan with a higher degree of 
branching that the previous samples and healthy control samples. 
 
 
Figure 6.10  Oligosaccharide Chromatogram of TNBC Sample MT1106 
Compared to an N-linked Oligosaccharide (5µg) Library. 
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TNBC sample MT1106 had a mostly tri-sialylated glycans with a small number 
of bi-sialylated peaks detected which became apparent upon magnification of 
the chromatogram. There was also a minor peak detected in the tetra-sialylated 
time area. 
 
Figure 6.11  Oligosaccharide Chromatogram of TNBC sample MT1937 
Compared to an N-linked Oligosaccharide (5µg) Library. 
Tetra-sialylated branching was identified in TNBC sample MT1937 but the 
majority of glycans still appeared in the tri-sialylated and bi-sialylated region of 
the chromatogram. However the chromatogram still indicated that that an 
increase in glycan branching was present in this sample, similar to that of the 
positive control. 
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Figure 6.12 Oligosaccharide Chromatogram of TNBC Sample MT3759 
Compared to an N-linked Oligosaccharide (5µg) Library. 
TNBC sample MT3759 displayed an oligosaccharide profile with mainly bi- and 
tetra-sialylated glycans present.  No peaks were detected in the tri-sialylated 
time period. Therefore, MT3759 appeared to have an increase in the degree of 
AGP glycan branching. 
 
Figure 6.13 Oligosaccharide Chromatogram of TNBC Sample MT1177 
Compared to an N-linked Oligosaccharide (5µg) Library. 
Interestingly, TNBC sample MT1177 showed a very clear oligosaccharide 
profile featuring a variety of types of glycan branching. Bi-sialylated and tri-
sialylated branching featured more prominently than tetra-sialylated. However, 
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the presence of tetra-sialylated glycans indicated an increase in the degree of 
branching not commonly seen within the other TNBC samples. 
 
Figure 6.14 Oligosaccharide Chromatogram of TNBC Sample MT1178 
Compared to an N-linked Oligosaccharide (5µg) Library. 
TNBC sample MT1178 clearly exhibits all identified types of glycan branching 
with peaks visible in the bi-, tri and tetra-sialylated regions of the chromatogram. 
Peaks prior to the bi-sialylated area also indicated presence of mono-sialylated 
bi-antennary glycans. Therefore, MT1178 possessed a wide variety of glycan 
branching with larger peaks in the tri-sialylated time frame suggesting a 
preference for this level of glycan branching. 
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Figure 6.15 Oligosaccharide Chromatogram of TNBC Sample MT3601 
Compared to an N-linked Oligosaccharide (5µg) Library. 
Oligosaccharide analysis of TNBC sample MT3601 highlighted larger peaks 
arising in the mono-sialylated, bi-sialylated and tetra-sialylated regions of the 
chromatogram. No peaks were detected in the tri-antennary region suggested 
that AGP isolated from this participant favoured a lesser degree of branching. 
 
Figure 6.16 Oligosaccharide Chromatogram of TNBC Sample MT2569 
Compared to an N-linked Oligosaccharide (5µg) Library.  
A preference for bi-and tri-sialylated glycans was shown by TNBC sample 
MT2569 with only one peak being detected in the tetra-sialylated region of the 
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chromatogram. Again, indicating a lesser degree of branching displayed by 
TNBC samples. 
 
Figure 6.17 Oligosaccharide Chromatogram of TNBC Sample MT3352 
Compared to an N-linked Oligosaccharide (5µg) Library. 
Analysis of TNBC sample MT3352’s branching highlighted a shift towards more 
highly branched AGP glycan chains with an increase in peaks detected in the 
tri- and tetra-sialylated time frames of the chromatogram.  
 
Figure 6.18  Oligosaccharide Chromatogram of TNBC Sample MT3362 
Compared to an N-linked Oligosaccharide (5µg) Library. 
TNBC sample MT3362 displayed a preference for bi-sialylated and tri-sialylated 
glycans with no peaks present in the tetra-sialylated region of the 
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chromatogram. Therefore, there was a predominance of less highly branched 
AGP glycan chains in this sample. 
  
Figure 6.19 Oligosaccharide Chromatogram of TNBC samples MT3442 
Compared to an N-linked Oligosaccharide (5µg) Library. 
Very few peaks were detected in TNBC sample MT3442 however peaks were 
visible during the bi-sialylated time frame and a minor peak was present in the 
tetra-sialylated area. No peaks were found in the tri-sialylated region of the 
chromatogram. Thus, a lesser degree of branching was present in this sample. 
  
Figure 6.20  Oligosaccharide Chromatogram of TNBC Sample MT3497 
Compared to an N-linked Oligosaccharide (5µg) Library. 
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Several peaks were present in the bi-sialylated and tri-sialylated areas of the 
chromatogram with one peak also detected within the tetra-sialylated time point. 
The predominance of bi- and tri-antennary glycans detected indicated a lesser 
degree of branching present in MT3497. 
 
6.3 Dataset 2 Oligosaccharide Results. 
 
Oligosaccharide analysis of dataset 2 was performed using identical methods to 
dataset 1. HPAEC-PAD was utilised to separate AGP glycans (initially by 
charge) to deliver an indication of the extent of branching and any structural 
alterations to oligosaccharide chains between samples from women at-risk of 
BC development and age-matched healthy controls. The same N-linked (5µg) 
library chromatogram given in section 6.2 (Figure 6.1) was used for comparison 
as in dataset 1 to provide elution times of the charge bands of interest – bi-
sialylated (20-30 min), tri-sialylated (30-40 min) and tetra-sialylated (40-50 min).  
 
 
Figure 6.21 Oligosaccharide Chromatogram of W1 Compared to C1 and 
an N-linked Oligosaccharide (5µg) Library. 
 
A clear difference in glycan structure could be seen between W1 and age-
matched healthy control C1. W1 had a greater number of tri-sialylated and tetra-
sialylated peaks, with the tetra-sialylated peaks also being far larger than any 
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peaks in C1. Whereas C1 showed a preference for less highly branched 
glycans with most peaks eluting in the bi- and tri-sialylated charge bands.  
 
 
Figure 6.22 Oligosaccharide Chromatogram of W2 Compared to C2 and 
an N-linked Oligosaccharide (5µg) Library. 
 
W2 also had a preference for highly branched glycans with more peaks 
detected in the tri- and tetra-sialylated charge bands. Bi-sialylated peaks were 
present in W2 however they were smaller and lower in numbers than peaks 
found in the tri- and tetra-sialylated charge bands indicating less of these types 
of glycans being present in the sample. C2 had no peaks in the tetra-sialylated 
charge band but had high numbers of peaks in the bi- and tri-sialylated elution 
region.  
 
 
-10 
0 
10 
20 
30 
40 
50 
60 
10 20 30 40 50 
P
e
a
k
 H
e
ig
h
t 
(n
C
) 
Time (min) 
W2 C2 N-linked Library 
Tetra-sialylated Tri-sialylated 
Bi-sialylated 
157 
 
 
Figure 6.23  Oligosaccharide Chromatogram of W3 Compared to an N-
linked Oligosaccharide (5µg) Library. 
An age-matched healthy control was not available for comparison of 
oligosaccharide analysis of W3 and a mean of the healthy controls could not be 
calculated as the results are not quantitative. However, structural observation 
can still be gathered from analysis. W3 had peaks in all charged bands. More 
peaks were present in the bi-sialylated charge band however, these peaks were 
small in size. A lower number of larger peaks were detected in the tri- and tetra-
sialylated elution regions. Therefore, it would appear that W3 has a preference 
for more highly branched glycans. 
 
 
Figure 6.24 Oligosaccharide Chromatogram of W4 Compared to C4 and 
an N-linked Oligosaccharide (5µg) Library. 
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Alterations in glycan structure were apparent between W4 and C4 upon 
analysis. W4 had small peaks in every charge band with the majority appearing 
in the tri- and tetra-sialylated elution regions. Small peaks were present in the 
bi-sialylated charge band however these were smaller peaks than those in the 
other charge band and there were less of them. Thus indicating AGP glycans 
from W4 displayed a higher degree of branching. C4 revealed a different pattern 
whereby no peaks were detected in the tetra-sialylated region of the 
chromatogram however several peaks were present in the tri-sialylated charge 
band with a smaller number eluting late in the bi-sialylated band. Therefore, W4 
has more highly branched AGP glycans than C4. 
 
 
Figure 6.25  Oligosaccharide Chromatogram of W5 Compared to C5 and 
an N-linked Oligosaccharide (5µg) Library. 
W5 had a larger number of peaks present in the tri- and tetra-sialylated charge 
bands upon oligosaccharide analysis showing a greater degree of AGP glycan 
branching in this sample. In comparison, C5 had a large peak in the bi-
sialylated region and several smaller peaks in the tri-sialylated charge band 
suggesting less highly branched AGP glycans compared to W5. Interestingly a 
very large peak was detected prior to the bi-sialylated charge band which may 
have indicated a large presence of mono-sialylated bi-antennary glycans. 
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Figure 6.26  Oligosaccharide Chromatogram of W6 Compared to C6 and 
an N-linked Oligosaccharide (5µg) Library. 
Oligosaccharide analysis of W6 revealed the majority of peaks lay within the bi- 
and tri-sialylated charge bands suggesting a lower level of branching compared 
to other “at risk” samples. Only two peaks were present in the tetra-sialylated 
region of W6’s chromatogram suggesting very little of this type of glycan 
branching existed in this sample. This profile was similar to that of C6 which 
also had very few peaks in the tetra-sialylated charge band but more peaks 
detected in the bi- and tri-sialylated region. Results showed that both W6 and 
C6 possessed a lower extent of AGP glycan branching. 
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Figure 6.27  Oligosaccharide Chromatogram of W7 compared to C7 and 
an N-linked Oligosaccharide (5µg) Library. 
Sample W7 possessed a large peak in the bi-sialylated charge band and 
several smaller peaks in the tri-sialylated charge band suggesting a lower level 
of glycan branching despite detection of peaks in the tetra-sialylated charge 
band as these were small and present in low numbers. C7 showed a wide 
variety of peaks present across all three charged bands with the majority 
occurring in the tri-sialylated charge band. However, two large peaks were 
detected in the bi-sialylated charge band which may highlight a preference for 
this type of AGP glycan branching. Several small peaks were detected in the 
tetra-sialylated charge band revealing low levels of higher branched structures. 
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Figure 6.28  Oligosaccharide Chromatogram of W8 Compared to C8 and 
an N-linked Oligosaccharide (5µg) Library. 
W8 had low numbers of peaks present within the sample, most of which lay in 
the tri-sialylated charge band and a less in the bi-sialylated charge band. One 
very small peak was detected in the tetra-sialylated charge band indicating an 
overall preference for a lower degree of AGP glycan branching in W8. C8 also 
showed this partiality to less highly branched structures as the greatest number 
of glycans were present in the bi- and tri-sialylated charge bands including one 
particularly large peak eluting early in the bi-sialylated region. 
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Figure 6.29 Oligosaccharide Chromatogram of W9 Compared to an N-
linked Oligosaccharide (5µg) Library. 
As with sample W3 no age-matched health control could be recruited for 
comparison to the at-risk sample W9 and no mean could be calculated so a 
general features were observed. Few peaks were detected in the bi-sialylated 
charge band however and those that were present eluted at longer retention 
times. However a great number of larger peaks were present in the tri- and 
tetra-sialylated charge bands showing W9 to have a preference for a greater 
degree of branching in AGP glycans. 
 
Figure 6.30  Oligosaccharide Chromatogram of W10 compared to an N-
linked Oligosaccharide (5µg) Library. 
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It was not possible to recruit an age-matched healthy control for comparison to 
“at risk” sample W10. Few peaks were detected in the sample however those 
that were mostly occurred in the bi- and tri-sialylated charge bands suggesting 
low levels of branching in this sample. Two minute peaks were present in the 
tetra-sialylated charge band showing presence of more highly branched 
structures however the overall preference of W10 was for less branched AGP 
glycans. 
 
 
Figure 6.31 Oligosaccharide Chromatogram of W11 Compared to C11 and 
an N-linked Oligosaccharide (5µg) Library. 
“At risk” sample W11 showed a greater tendency toward tri- and tetra-sialylated 
glycans due to the presence of higher numbers of larger peaks in these charge 
bands compared to fewer small peaks in the bi-sialylated charge band. 
Whereas no peaks were present in C11’s tetra-sialylated charge band but 
peaks were detected in the bi- and tri-sialylated regions. Therefore, W11 
appeared to have more highly branched AGP glycans than C11. 
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Figure 6.32 Oligosaccharide Chromatogram of W12 Compared to C12 and 
an N-linked Oligosaccharide (5µg) Library. 
Minute peaks were detected in at-risk sample W12 and upon magnification, the 
most significant peaks were present in the bi- and tri-sialylated charge bands 
indicating low levels of branching. However, C12 had large peaks present 
throughout the charge bands with numerous large peaks in the lower glycan 
branching bi- and tri-sialylated charge bands. While peaks were detected in the 
tetra-sialylated charge band of C12, they were present in lesser numbers than 
those in other regions. Therefore, while both samples had peaks in the same 
charge bands, W12 appeared to have a lower level of branching than C12 due 
to smaller peak sizes in these elution regions. 
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Figure 6.33 Oligosaccharide Chromatogram of W13 Compared to C13 and 
an N-linked Oligosaccharide (5µg) Library. 
W13 possessed peaks in the tri-sialylated charge band with none detected in 
the tetra-sialylated band. Several small peaks were present in the bi-sialylated 
charge band however the tendency towards tri-sialylated glycans was still 
prevalent. However, several large peaks occurred in C13’s bi- and tri-sialylated 
charge bands with lower numbers of smaller peaks detected in the tetra-
sialylated region. Thus sample W13 indicated a preference for slightly higher 
branching of AGP glycans compared to C13 which had a greater presence of 
bi- and tri-sialylated glycans. 
 
Figure 6.34 Oligosaccharide Chromatogram of W14 Compared to and N-
linked Oligosaccharide (5µg) Library. 
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Age-matched healthy controls could not be recruited for W14, W15 or W16, 
therefore observations were made without comparison to a healthy control. 
Oligosaccharide analysis of W14 showed a penchant for tri-sialylated glycans 
with only one or two peaks detected in the bi- or tetra-sialylated charge bands. 
 
Figure 6.35 Oligosaccharide Chromatogram of W15 Compared to an N-
linked Oligosaccharide (5µg) Library. 
W15 possessed AGP glycans mainly with low levels of branching as indicated 
by prevalence of peaks in the bi-sialylated charge band. Few peaks occurred in 
the tri- of tetra-sialylated regions of the chromatogram. 
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Figure 6.36 Oligosaccharide Chromatogram of W16 Compared to an N-
linked Oligosaccharide (5µg) Library. 
Tri-sialylated glycans were most predominant in “at risk” sample W16 with the 
majority of peaks occurring in this charged band. Few peak were detected in the 
bi-sialylated and tetra-sialylated region however the overall preference 
remained tri-sialylated glycans. 
 
6.4 Discussion. 
6.4.1 Introduction. 
 
The aim of the research discussed in this chapter was to investigate variation in 
the extent of branching of oligosaccharide glycan chains of isolated AGP from 
two sample populations - Dataset 1 comprised samples from healthy 
individuals, women with BC of unknown type and women with TNBC as well as 
Dataset 2 containing samples from women at increased risk of BC development 
and age-matched healthy controls. This was performed through enzymatic 
release of N-linked glycans and analysis by HPAEC-PAD. 
Release of intact AGP glycans from the polypeptide backbone is an essential 
prerequisite for investigation of their structure. This was achieved through 
denaturing isolated AGP then endoglycosidase PNGase F was used to cleave 
intact glycans from the polypeptide backbone. This study used heat to denature 
AGP as it promotes cleavage of glycans by PNGase F, whereas other methods 
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of denaturing, such as SDS, would cause destruction of glycan structures 
(Hermentin, et al., 1992). Therefore, other  denaturing methods would be 
unsuitable for the purposes of this study as they may produce unreliable results 
(Hermentin, et al., 1992). PNGase F was used because the enzyme cleaves 
only the bond between the first GlcNAc of the pentasaccharide core and the 
Asn residue within the denatured polypeptide backbone (Plummer, et al., 1984). 
A further condition of enzymatic release of glycans using PNGase F, is that the 
N-linked glycan consensus sequence Asn-X-Ser/Thr is present (Plummer, et al., 
1984). Therefore this ensured release of glycans in their entirety for analysis as 
well as guaranteeing every glycan was released. Separation of glycans by 
HPAEC-PAD was reliant on the negative charge of the ionised carboxylic acid 
group of terminal SA residues. Use of acidic conditions, such as those used to 
cleave AGP glycan monosaccharides, would have resulted in the loss of SA 
and unreliable results (Szabo, et al., 2012). However, PNGase F preserves SA 
residues allowing true ex vivo results to be collected. 
 
HPAEC-PAD chromatograms of oligosaccharides in samples versus the N-
linked library (Figures 6.1 to 6.20) show successful separation of glycans after 
PNGase F treatment into bands primarily based on the influence of the negative 
charges of SA residues. As discussed in the introduction to this chapter (section 
6.1), glycan chains are not only separated by HPAEC due negative charge of 
SA residues and size, but by component monosaccharides and the linkages 
between them as well (Hardy and Townsend, 1988). To improve peak 
resolution during separation, strong alkaline conditions of pH13 were employed 
causing formation of oxyanions which enabled isomeric structures to be 
recognised. Another possible method of improving peak resolution would have 
been to reduce glycan chains prior to HPAEC analysis. However, this may have 
caused degradation and epimerisation of any glycans structures with sensitivity 
to alkaline conditions used during analysis as well as being more time 
consuming (Lee, 1996).  
 
An N-linked library was analysed by HPAEC-PAD as a standard to indicate the 
elution time of bi-, tri- and tetra-sialylated glycans (see Figures 6.1 and 6.37). 
Sample chromatograms were subsequently compared to the chromatogram 
produced by this N-linked library to identify the presence of these glycan types 
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at the corresponding elution time points. As mentioned previously, commercially 
sourced AGP was not analysed due to the difference in isolation method and an 
inaccurate representation of glycan branching for instance, a lack of tetra-
sialylated glycans (Behan, 2010).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6.37 Illustration of Possible Glycan Branching in AGP. Diagram 
depicts bi-sialylated (2 branches), tri-sialylated (3 branches) and tetra-sialylated (4 branches) 
branching of complex oligosaccharides. 
 
6.4.2 Trends in Oligosaccharide Branching Observed in Dataset 1. 
 
Comparisons were drawn from oligosaccharide chromatograms of samples in 
all three groups from dataset 1 – BC of unknown type (positive control, n=5), 
“normal” healthy individuals (negative control n=5) and individuals suffering 
from TNBC (n=18). 
 
Oligosaccharide analysis of samples from “normal” healthy individuals (see 
Figure 6.2) revealed a preference for bi- and tri-sialylated glycans (see Figure 
6.37) as most peaks were present within the corresponding charge bands, with 
A
sn
 
 
Tri-sialylated 
branching 
 
A
sn
 
Bi-sialylated 
branching 
  
A
sn
 
Tetra-sialylated 
branching 
= Mannose = GlcNAc = Galactose = Sialic Acid 
= region of branching = pentasaccharide core 
170 
 
few peaks detected in the tetra-sialylated time frame. This conformed to 
previous published research (Asao, et al., 2013; Behan, 2010; Kimura, et al., 
2006; Maresca, et al., 2012; Smith, et al., 2012) in which it was shown that AGP 
generally had less branched glycan structures in healthy volunteers. 
Interestingly, a small number of peaks were detected in the region preceding 
the bi-sialylated charge band which could indicate the presence of mono-
sialylated bi-antennary glycans. However, previous research suggests that this 
is unlikely in AGP from healthy individuals as Gal would become exposed if an 
SA residue is missing causing the glycan to be targeted for destruction by 
lysosomes or repair by the calnexin/calreticulin cycles (Ware, et al., 1995). The 
oligosaccharide profiles generated from “normal” healthy samples correspond 
with the data collected through monosaccharide analysis in chapter 5 (see table 
5.2) in that GlcNAc and Gal levels were generally low compared to BC of 
unknown type and TNBC samples, indicating less branched glycan structures. 
 
BC of unknown type samples (see Figure 6.3) indicated a tendency for more 
highly branched structures upon oligosaccharide analysis (see Figure 6.37). 
Peaks were mainly present in the tri-sialylated and tetra-sialylated charge band 
with only samples H8 and I5 showing any presence of bi-sialylated glycans. H8 
and I5 oligosaccharide chromatograms were in agreement with previous 
research (Fujii, et al., 1988; Hansen, et al., 1984) which showed an increase in 
bi-sialylated glycans during liver and lung cancer, whereas I2, I3 and I8 
possessed an oligosaccharide profile resembling branching patterns seen by 
Hashimoto, et al., (2004) in breast cancer associated with a poor prognosis as 
there was greater expression of tri- and tetra-sialylated structures.  Samples I3 
and I5 had peaks detected in the region prior to the bi-sialylated charge band 
again suggesting the unlikely presence of mono-sialylated glycans. However, I3 
showed the presence of Fuc during monosaccharide analysis which can 
occasionally mask the negative charge of SA resulting earlier elution of glycans 
(Poland, et al., 2001). Therefore, the apparent mono-sialylated glycans could in 
fact have been early eluting bi-sialylated glycans. Yet, this would not explain the 
peak from sample I5 in the region before the bi-sialylated charge band as no 
Fuc was detected during monosaccharide analysis (see Table 5.2). 
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The majority of TNBC samples showed a preference for bi- and tri-sialylated 
branching as indicated by peaks in the corresponding region of chromatograms 
(see Figure 6.37). Ten TNBC samples showed the presence of tetra-sialylated 
branching but often only one peak was detected in this region compared to 
several peaks in bi- and tri-sialylated charged bands. Therefore, despite the 
presence of tetra-sialylated branching, there was an overall preference for less 
AGP glycan branching within TNBC samples contradicting oligosaccharide 
profiles seen during previous research into AGP branching in liver, lung and 
breast cancer (Fujii, et al., 1988; Hansen, et al., 1984; Smith, et al., 2012). Fujii, 
et al., (1988) and Hansen, et al., (1984) observed increased binding of AGP 
from patients with liver and lung cancer respectively compared to inflammatory 
conditions of these organs since AGP from cancer patients showed less binding 
affinity in a Con A column which binds bi-sialylated glycans. Similarly, Smith, et 
al., (2012) showed increased branching of AGP through HPAEC-PAD analysis 
in patient with breast cancer. However, Hashimoto, et al., (2004) and Asao, et 
al., (2013) found that increased AGP glycan branching correlated with breast 
cancer progression. Similarly, a link between expression of tri-sialylated glycans 
and BC progression was discovered by Hamid, et al., (2008). Therefore, it is 
possible that the lack of predominant tetra-sialylated glycan branching in favour 
of tri-sialylated branching in TNBC samples could be due to early TNM stage of 
tumours, with most tumours in this sample cohort being classed as stage 1 or 2. 
Indeed, a shift towards increased branching in the only stage 3 TNBC sample 
(MT3352; see Figure 6.17) was observed as this sample had an increased 
number of peaks detected in the tri- and tetra-sialylated time frames. 
 
Assessment of oligosaccharide profiles of TNBC samples by age, showed 
women <35 had much higher proportions of tri-sialylated branching. The 
majority of samples in this group had a low number bi-sialylated glycans present 
with these peaks eluting almost at the bi-sialylated time range cut off (see 
Figures 6.4 to 6.9). Looking at these results in conjunction with monosaccharide 
analysis of these samples showed that high levels of Fuc were detected in 
F5412 and MT2621. This may have meant that the late eluting bi-sialylated 
glycans were in fact early eluting tri-sialylated glycans as Fuc presence has 
been shown to reduce the elution time of oligosaccharide chains (Poland, et al., 
2001). However, this does not explain the late eluting bi-sialylated peak in 
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MT3625 as no Fuc was detected during monosaccharide analysis. This 
preference for tri-sialylated branching corresponds with previous research from 
Hamid, et al., (2008) who observed an increased presence of tri-sialylated 
branching in BC denoted progression. As TNBC in younger women is 
notoriously aggressive, shows rapid growth and is associated with high tumour 
grades as well as poor prognosis (Blows, et al., 2010; Dent, et al., 2007; 
Schnieder, et al., 2008) the detection of increased branching could correlate 
with these features and indicate that these women’s tumours are progressing to 
a higher TNM stage. 
 
Additionally, the majority of samples had peaks present in the tetra-sialylated 
charge band. The detection of tetra-sialylated glycans in the TNBC samples 
from young women further indicates that increased glycan branching observed 
in these samples could be related to cancer progression as increased branching 
corresponds with previous observations by other research groups during cancer 
development (Asao, et al., 2013; Cui, et al., 2011; Hashimoto, et al., 2004; 
Majid, et al., 2005; Smith, et al., 2012). These studies also highlighted an 
association between increased branching and poor prognosis (Hashimoto, et 
al., 2004; Majid, et al., 2005; Smith, et al., 2012). Therefore, the increased 
branching in TNBC samples from women <35 is consistent with the known poor 
prognosis associated with TNBC at a young age (Blows, et al., 2010; Dent, et 
al., 2007; Schnieder, et al., 2008).  
 
While the majority of glycans were detected in the tri-sialylated charge band, 
CT79 had no bi-sialylated glycans present; instead it showed a tendency for tri- 
and tetra-sialylated glycans unlike other samples in this age group. Increased 
AGP glycan branching is associated with poorer prognosis in cancer patients 
after surgery (Hashimoto, et al., 2004). Data provided by the Alberta Tumour 
Bank revealed that participant CT79 had undergone surgery for a stage 1 TNBC 
one day prior to blood draw. Therefore, if AGP glycan branching remained 
increased post-surgery this may indicate that participant CT79 had a poor 
prognosis for TNBC if Hashimoto and colleagues (2004) results and compared 
to this sample. In comparison, MT2305 had surgery 15 days before blood draw 
yet showed no presence of tetra-sialylated glycans thus may have had a better 
prognosis. 
173 
 
 
TNBC samples from participants aged >35-60 (see Figures 6.10 to 6.15) 
produced an oligosaccharide profile that contradicted previous studies 
investigating AGP glycan branching during cancer (Fujii, et al., 1988; Hansen, 
et al., 1984; Smith, et al., 2012) which have shown increased branching during 
various cancer types. Five of the six samples in this age bracket favoured bi-
sialylated branching while MT1177 illustrated similar numbers of peaks in the bi- 
and tri-sialylated charge bands with one particularly large peak towards the end 
of the tri-sialylated elution time. MT1177 had no treatment prior to blood draw 
but did have surgery 3 days prior to blood draw, and was TNM stage 2. Again 
this increase in branching could indicate a poorer post-surgery prognosis 
(Hashimoto, et al., 2004). MT1177’s oligosaccharide profile corresponded with 
monosaccharide data collected from the same sample, in that MT1177 had 
increased levels of GlcNAc and Gal. Increases in the levels of GlcNAc and Gal 
are indicative of increased N-linked glycan branching (Behan, et al., 2013). The 
remaining five samples in this age category showed one or more peaks in the 
tetra-sialylated charge band, however the majority of peaks were still visible in 
the bi-sialylated charge band which does not conform with previous research 
findings (Fujii, et al., 1988; Hansen, et al., 1984; Smith, et al., 2012) illustrating 
AGP oligosaccharide structures during cancer possess highly branched 
glycans. As several studies have linked increased branching with cancer 
progression and poor survival (Asao, et al., 2013; Cui, et al., 2011; Hashimoto, 
et al., 2004; Majid, et al., 2005; Smith, et al., 2012) the similarity of this TNBC 
age group’s oligosaccharide profile to the healthy control group could suggest 
better outcomes for these patients with less risk of cancer progression and 
metastasis. The oligosaccharide profiles from these samples fit the equivalent 
monosaccharide data which shows lower levels of GlcNAc and Gal than 
MT1177. 
 
Finally, AGP oligosaccharide profiles analysed from TNBC samples of women 
<60 years old, indicated an increase in bi-sialylated glycan expression in line 
with the previous age category and contradiction of preceding research. As 
previously stated, sample MT3959’s oligosaccharide chromatogram was 
discarded as an erroneous result due to erratic and closely eluted peaks being 
detected. Unfortunately due to small sample volume repeat oligosaccharide 
174 
 
analysis could not be performed. Four of the five remaining samples in this age 
category had a peak detected in the tetra-sialylated charge band but overall the 
majority of peaks were present in the bi-sialylated charge band. As discussed 
for the previous age category (aged >35-60), the preference for bi-sialylated 
glycans and resemblance to the healthy control population’s oligosaccharide 
profiles could suggest that these patients will have a better outcome given 
studies have shown that increased glycan branching is associated with poor 
prognosis during various cancers (Asao, et al., 2013; Cui, et al., 2011; 
Hashimoto, et al., 2004; Majid, et al., 2005; Smith, et al., 2012). These results 
match the monosaccharide data obtained from these samples which had the 
lowest GlcNAc and Gal content of the three age categories. 
 
6.4.3 Trends in Oligosaccharide Branching Observed in Dataset 2. 
 
All “normal” healthy control samples showed lower levels of AGP glycans 
branching as most peaks were detected in the bi- and tri-sialylated 
chromatogram regions (see Figure 6.37). While certain healthy control samples 
may have had peaks in the tetra-sialylated chromatogram region, these were 
few in number and small in size thus, still giving an overall preference for a 
lesser degree of AGP branching in healthy control samples. This matches the 
monosaccharide data obtained for these samples which displayed lower levels 
of branching associated monosaccharides, GlcNAc and Gal. Additionally no 
GalNAc was found in any healthy control samples. This corresponds with 
oligosaccharide analysis of “normal” healthy control samples from previous 
studies that demonstrated lower levels of glycan branching in healthy samples 
(Asao, et al., 2013; Behan, 2010; Kimura, et al., 2006; Maresca, et al., 2012; 
Smith, et al., 2012) as well as the glycan branching observed in healthy 
samples from dataset 1. 
Similar to monosaccharide results obtained from dataset 2, two trends were 
apparent upon analysis of oligosaccharides (see Table 6.1).  
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Samples 
Trend 1 Trend 2 
↑ Oligosaccharide Branching ↓ or ↔ Oligosaccharide Branching 
W1 W6 
W2 W7 
W3 W8 
W4 W10 
W5 W12 
W9 W13 
W11 W15 
W14   
W16   
 
Table 6.1 Oligosaccharide Branching Trends Observed in At-Risk 
Samples. Entries in the table highlight sample oligosaccharide variation (↔ = 
comparable; ↑ = increased; ↓ = decreased levels compared to age-matched healthy controls) 
pertaining to trend 1 (↑ increased branching compared to age-matched healthy controls) and 
trend 2 (↓ lower or ↔ similar branching to age-matched healthy controls). 
 
At risk samples W1, W2, W3, W4, W5, W9, W11, W14 and W16 had an 
oligosaccharide profile featuring increased branching compared to healthy 
control samples (Trend 1 and Figures 6.21, 6.22, 6.23, 6.24. 6.25, 6.29, 6.31, 
6.34, 6.36 and 6.37). Comparison with monosaccharide data collected for these 
samples previously (see Table 5.3), highlights a link between increased GlcNAc 
and Gal content and increased branching of glycan structures. All of these 
samples, bar W1 and W11 followed the initial monosaccharide trend identified 
in Chapter 5. W1 did not fit either of the monosaccharide trends found as W1 
presented with lower GlcNAc, similar Gal to its counterpart control (C1) and no 
GalNAc presence which may have accounted for any apparent increase in AGP 
glycan branching. Therefore, it is unclear why W1 displays large peaks in the 
tetra-sialylated and tri-sialylated charge bands as this data contradicts this 
monosaccharide data gathered for this sample. W11 also did not fit the first 
monosaccharide profile as it was expected that W11 would reveal a preference 
for less highly branched AGP glycans. However, several large peaks in the tri-
sialylated charge band and a number of smaller peaks in the tetra-sialylated 
band indicated a predominance of highly branched structures compared to low 
numbers of small peaks present in the bi-sialylated charge band. Yet, W11 
possessed comparable GalNAc and Gal levels. The unusual presence of 
GalNAc in such quantities could explain the appearance of more highly 
branched structures as it may be present as part of a terminal glycan structure. 
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Earlier research has linked increases in glycan branching with a number of 
unfavourable features in cancer (Asao, et al., 2013; Cui, et al., 2011; 
Hashimoto, et al., 2004; Majid, et al., 2005; Smith, et al., 2012). A link between 
increased glycan branching of AGP in cancer samples and higher cancer stage 
was found by Hashimoto, et al., (2004) and Asao, et al., (2013) using crossed 
affinity immunoelectrophoresis and mass spectrometry respectively. Similarly, 
increased presence of N-linked β1-6 branching was associated with increased 
mortality by Majid, et al., (2005) and Cui, et al., (2011); Smith, et al’s (2012) 
research also demonstrated increased glycan branching during BC. Moreover, 
studies have shown a relationship between lymph node metastasis and tumour 
growth with increased N-linked β1-6 branching (Guo, et al., 2003; Handerson, et 
al., 2005; Pinho, et al., 2009; Takahashi, et al., 2009) 
Therefore, the results observed in Trend 1 samples are unexpected because at 
the time of sample collection these women were considered to be cancer free. It 
was expected that no differences in AGP glycan branching between age-
matched healthy controls and at risk women would be identified. However, if 
previous literature is considered alongside these results, the increased 
branching detected in these samples could indicated that women displaying this 
trend are in the early stages of BC development. The results correlate well with 
glycan branching results from BC of unknown type and TNBC <35 which also 
showed a preference for increased branching which further supports the notion 
that samples from women displaying trend 1 (increased branching) may be 
developing BC.  Additionally, this shift towards increased branching denoting 
BC development may be further supported by studies relating increases in N-
linked β1-6 branching with tumour growth and metastasis. 
Seven at-risk samples – W6, W7, W8, W10, W12, W13 and W15 – had similar 
oligosaccharide profiles to those found in “normal” healthy control samples 
(Trend 2 and see Table 6.1 as well as Figures 6.26, 6.27, 6.28, 6.30, 6.32, 6.33 
and 6.35). All showed a predominance of bi- and tri-sialylated AGP glycans with 
little or no peaks detected in tetra-sialylated charge bands (see Figure 6.37). 
Samples W6, W8 and W12 oligosaccharide profiles correlated with the 
monosaccharide results collected for these sample whereby lower levels of Gal 
were detected compared to their counterpart healthy controls thus suggesting 
lower levels of glycan branching. This was particularly true for W8 as very low 
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levels of GlcNAc and Gal levels were present as well as no GalNAc being 
detected meaning it was highly likely that low levels of oligosaccharide 
branching would be present in the sample. However, W7, W10, W13 and W15 
displayed oligosaccharide profiles that contradicted their monosaccharide data 
as they all displayed increased levels of GlcNAc and Gal. Thus a lesser degree 
of branching was not expected in these samples and it is unclear why this has 
occurred. One possible reason may be that lower levels of GalNAc were 
present in these samples compared to others fitting this monosaccharide trend 
thus less branching occurred in W7, W10, W13 and W15. 
The results described for Trend 2 are more in-keeping with results expected 
from dataset 2 as a whole. As all participants of this cohort as considered at 
increased risk of BC development but as yet to develop the disease it was 
predicted that glycan branching of AGP within these samples would resemble 
that seen in age-matched healthy controls. Therefore, the AGP glycan 
branching following Trend 2 (similar or decreased branching) observed in seven 
at risk samples links well with the original hypothesis. Several studies have 
shown predominance of bi-sialylated glycans as opposed to more highly 
branched tri- and tetra-sialylated glycans (structures in Figure 6.37) in healthy 
volunteers (Asao, et al., 2013; Behan, 2010; Kimura, et al., 2006; Maresca, et 
al., 2012; Smith, et al., 2012), including healthy controls in dataset 1 of this 
study. Therefore, a link between low levels of glycan branching and a disease-
free state has been established by previous literature. In contrast to this, 
numerous research groups have shown a correlation between increased glycan 
branching and cancer (Asao, et al., 2013; Cui, et al., 2011; Hashimoto, et al., 
2004; Majid, et al., 2005; Smith, et al., 2012), which further suggests that 
samples displaying Trend 2 glycan branching in this study are indeed from 
participants who have not developed BC despite being at increased risk.  
However, Fuc was detected at low levels in all at-risk and healthy control 
samples. As explained in section 6.4.2 this could lead to early elution of peaks 
during oligosaccharide analysis due to Fuc masking the negative charge of SA 
residues (Poland, et al., 2001). Therefore, it may be that Fuc presence was 
responsible for peaks appearing prior to the bi-sialylated charge band in certain 
samples which were in fact early eluting bi-sialylated glycans as opposed to the 
more unlikely presence of mono-sialylated bi-antennary glycans. However, as 
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Fuc was present in all dataset 2 samples analysed this left-ward shift to shorter 
retention times may have occurred in all oligosaccharide chromatogram still 
enabling variations in branching to be identified. 
 
6.4.4 Profiles of Glycosylation Enzymes. 
 
The results of the current study and of prior research discussed previously in 
sections 6.4.2 and 6.4.3 demonstrate aberrant glycan branching as a hallmark 
of breast cancer. Given that building and alteration of glycans is controlled 
enzymatically, research has been undertaken to demonstrate alterations of 
glycosyltransferases and glycosidases that may be deregulated during cancer. 
Therefore, the results of this study will now also be discussed briefly in the 
context of known alterations in glycan related enzymes. 
The results of this study indicate a potential link between BC development and 
increased branching which corresponds well with similar results obtain by other 
research groups (Asao, et al., 2013; Cui, et al., 2011; Hashimoto, et al., 2004; 
Majid, et al., 2005; Smith, et al., 2012).These observed increases in glycan 
branching could be due to increased expression of N-
acetylglucosaminetransferase V and α2-3 or α2-6 sialyltransferases. 
N-acetylglucosaminetransferase V (GlcNAcT-V) is responsible for N-linked β1-6 
branching and increased levels of this enzyme have been reported to be 
involved in cancer metastasis and progression (Guo, et al., 2003; Handerson, et 
al., 2005; Pinho, et al., 2009; Takahashi, et al., 2009). Lymph node metastasis 
of BC has been shown to occur with overexpression of GlcNAcT-V (Handerson, 
et al., 2005) and target proteins of GlcNAcT-V (such as integrin and cadherin) 
with increased N-linked β1-6 branching appear to play a role in metastasis and 
promoting malignant cell growth (Guo, et al., 2003; Pinho, et al., 2009; 
Takahashi, et al., 2009). Additionally, research by Granovsky, et al., (2000) 
revealed mice without GlcNAcT-V were able to suppress tumour growth and 
metastasis. Thus, increased branching of AGP found in the majority of at-risk 
samples and TNBC samples <35 could suggest enhancement of tumour growth 
and metastatic risk. 
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Moreover, the sialyltransferase family catalyse the addition of terminal sialic 
acid to glycan branches and are overexpressed during malignancy and involved 
in glycan branching, progression, metastasis and carcinogenesis (Burchell, et 
al., 1999; Julien, et al., 2006; Ogawa, et al., 1997; Perez-Garay,et al., 2010; 
Petretti, et al., 2000; Picco, et al., 2010; Recchi, et al., 1998). Breast tumour 
formation was shown to occur in mice who over expressed α2-3 
sialyltransferase I (Picco, et al., 2010) which could indicate increased glycan 
branching due to increased addition of terminal sialic acid residues. A study 
investigating glycosylation in pancreatic cancer cell lines also established the 
involvement of α2-3 sialyltransferase III in tumour progression (Perez-Garay, et 
al., 2010). Similarly, Julien, et al., (2006) revealed enhanced breast tumour 
formation in the presence of increased α2-6 sialyltransferase III.  
Additionally, elevation of sialyltransferase levels have been associated with 
poor prognosis in various cancers (Gretschel, et al., 2003; Patani, et al., 2008; 
Sato, et al., 2002; Schneider, et al., 2001). For example, increased metastasis 
and poor prognosis were linked to increased α2-3 sialyltransferase III and α2-6 
sialyltransferase I in gastric cancer (Gretschel., et al., 2003) while elevated 
levels of α2-6 sialyltransferase I also correlated with poor prognosis in colorectal 
cancer (Schneider, et al., 2001). However, Patani, et al., (2008) revealed 
increases in α2-6 sialyltransferase I may infer a better prognosis in BC patients. 
Therefore, it may be the mode of terminal sialylation rather than increased 
levels of branching that may define prognosis in certain cancers as breast 
tumour growth was associated with increased α2-6 sialyltransferase III by 
Julien, et al., (2006).  
The results of the previous literature further support that increased branching 
observed in the majority of at risk samples and TNBC <35 could suggest 
development, progression and risk of metastasis. However, details regarding 
the mode of terminal sialic acid linkages could provide further prognostic 
indications. 
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6.4.5 Benefits and Shortcomings in the Methodology. 
 
Analysis of the extent of branching of AGP oligosaccharides first required the 
removal of N-linked glycans which was performed using PNGase F which 
cleaves high mannose, complex and hybrid N-linked glycan at the innermost 
GlcNAc to remove the oligosaccharide in its entirety (Plummer, et al., 1984). 
The successful use of PNGase F for the cleavage of N-linked glycans has been 
widely documented to remove all N-linked glycans from the protein backbone 
(Plummer, et al., 1984). This is often confirmed by SDS-PAGE to demonstrate 
the lower molecular weight of AGP post-glycan removal (Laemmmli, 1970). 
However, due to the limited funding for this study, it was not possible to confirm 
complete removal of all N-linked glycans from samples in this study. 
Additionally, using enzymatic cleavage to remove N-linked glycans avoids the 
desialylation observed when harsh chemical methodologies are used (Chan 
and Yu, 1991). Unfortunately, this study did not use controls to ensure the 
activity of PNGase F which was an oversight of the investigator. PNGase F 
minus isolated AGP and HPLC water could have been used alongside dataset 1 
and dataset 2 samples as positive and negative controls respectively and 
analysed using HPAEC-PAD (Semaan, et al., 2012). 
Furthermore, the use of HPAEC-PAD is a highly reliable and sensitive method 
for the analysis of oligosaccharide branching (Behan and Smith, 2011; Hardy 
and Townsend, 1988; Harazono, et al., 2011; Smith, et al., 2012).  Another 
benefit of HPAEC-PAD is that samples to not require derivitisation prior to 
analysis which would alter their structure in an effort to aid detection (Lee, 
1990). However, analysis of oligosaccharide chain branching by HPAEC-PAD is 
not quantitative (Smith et al., 2012) unlike analysis by mass spectrometry 
(Morelle and Michalski, 2007). 
Inadequate sample storage may have affected the oligosaccharide branching of 
AGP detected in samples as the samples were purchased prior to the study 
commencing and post-translational modifications such as glycosylation may 
degrade if stored at -20°C instead of -80°C (Davies, 1968). Similarly, other 
studies have shown that post-translational modifications are sensitive to pH and 
heat (McCurdy, et al., 2011). As dataset 2 samples were processed 
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immediately and not stored for long periods of time, storage is unlikely to have 
affected monosaccharide content in these samples. 
 
6.4.6 Additional Methodologies to Study Branching. 
 
Removal of oligosaccharide chains could have been analysed on an SDS-
PAGE gel pre and post incubation with PNGase F to detect the reduction of 
molecular mass that would have indicated successful removal of glycans from 
the protein (Laemmmli, 1970). Furthermore, a periodic acid-Schiff stain, could 
have been used in conjunction with SDS-PAGE and a nitrocellulose blot to 
confirm deglycosylation of AGP pre and post enzymatic digestion (Hart, et al., 
2003). 
Techniques to release and O-glycans present within samples could have been 
utilised with HPAEC-PAD for identification of O-glycosylation. However, there is 
no universal enzyme available to cleave O-linked oligosaccharide as there is for 
N-linked glycans using PNGase F (Jensen, et al., 2009). Therefore chemical 
removal must be used such as β-elimination or hydrazine treatment prior to 
analysis using HPAEC-PAD (Patel, et al., 1993; Xia, et al., 2005).  
Additionally, commercially available ELISA’s utilising antibodies against terminal 
α2-3 or α2-6 sialylation could have been used support the levels of branching 
detect by HPAEC-PAD through measurement of these terminal residues (Shah, 
et al., 2008). Increases or decreases of α2-3 or α2-6 sialylation are thought to 
relate directly to the degree of branching (Behan, 2010; Picco, et al., 2010; 
Smith, et al., 2012). 
Finally, use of mass spectrometry has been widely used to measure 
oligosaccharide branching in conjunction with separation techniques such as 
gas chromatography, HPLC and HPAEC-PAD (Morelle and Michalski, 2007). 
However small sample sizes available to this study would preclude using these 
techniques which mostly rely on further chemical derivatisation and purification 
steps prior to analysis (Morelle and Michalski, 2007). 
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6.5 Summary Statement. 
 
Overall, this chapter achieved its aim to investigate variation in the extent of 
branching of oligosaccharide glycan chains of isolated AGP. 
In dataset 1, TNBC samples from women aged <35 had increased AGP glycan 
branching compared to women with TNBC above this age. Oligosaccharide 
profiles of women with TNBC aged >35 resemble those found in other cancer 
studies involving AGP and BC of unknown type (positive control) samples 
where bi-sialylated branching was shown as dominant. This therefore, highlights 
a difference between TNBC in young women compared to older women as well 
as BC of unknown type. Furthermore, a difference in branching was revealed 
between TNBC and BC of unknown type in comparison to healthy controls 
which showed increased glycan branching.  
Additionally, results from dataset 2 could imply that lower levels of branching 
occurring in “at-risk” samples correlating with “normal” healthy control 
oligosaccharide profiles, may indicate that these individuals have no signs of 
BC development at present. However, deviation from this oligosaccharide 
profile with an increase in AGP glycan branching was shown in 9 of the at-risk 
samples and could suggest the beginnings of BC development in light of results 
obtained in other studies. Again the healthy control population for dataset 2 
showed a preference for lower levels of branching. 
Finally, use of PNGase F and HPAEC-PAD to facilitate analysis of AGP 
oligosaccharide branching had numerous benefits including, high sensitivity, 
ability to release and detect all N-linked glycans. However, the methodology 
used for this study could have been improved through the use of improved 
sample storage, and potentially, ELISA to support HPAEC-PAD results, SDS-
PAGE and periodic acid-Schiff staining to confirm deglycosylation of proteins by 
enzymatic digestion; removal of any O-glycans using β-elimination with analysis 
by HPAEC-PAD and quantification of all glycan structures by mass 
spectrometry. However, due to issues with funding and low sample volumes, 
these additional techniques could not be employed for this study. 
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Chapter 7 – Conclusion and Future Work 
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7.1 Conclusions. 
 
The main aim of this study was to determine whether disease-specific 
alterations in the glycosylation pattern of AGP occurred in TNBC and if this 
differed from BC of an unknown subtype or healthy individuals (termed Dataset 
1) as well as examining any variations in AGP glycosylation patterns in women 
at increased risk of BC development for onset of BC compared to age-matched 
healthy controls (termed Dataset 2). 
Currently, there is no reliable serum biomarker for BC onset and in Scotland 
detection of BC is reliant on self-examination and mammography. While 
screening of women over 50 using mammography has greatly increased the 
detection rate of BC, mammography is not a full proof detection method and 
exposes recipients to radiation (Berrington de Gonzalez., 2011). Also with 
screening only recommended for women over 50, unless determined at an 
increased risk of BC development due to family history, a BRCA1 or 2 mutation 
or previous treatment for Hodgkin’s lymphoma, women unaware of their 
increased risk may miss out on early detection of BC occurrence. Furthermore, 
with recent research unveiling that BC may need to be classified as several 
separate diseases in the future dependent on molecular subtype of a tumour 
and links between TNBC occurrence at a young age and BRCA1/2 mutation 
carriers, investigating a potential serum biomarker for BC is essential. 
Particularly because a blood-based BC biomarker may negate the need for 
costly mammography screening and its associated radiation exposure as well 
as enabling screening to occur more frequently in those at higher risk of BC 
development. 
The study acquired two sample populations termed dataset 1 and dataset 2. 
Dataset 1 sought to fulfil the aim of assessing whether AGP glycosylation 
patterns differed between TNBC, BC of an unknown subtype and “normal” 
healthy controls. Dataset 2 collected samples from women at increased risk of 
BC in comparison to age-matched healthy controls to assess any changes to 
AGP glycosylation which may have indicated BC development. Both datasets 
were subjected to the same laboratory methods for isolation and analysis of 
AGP which have been shown to preserve the in vivo state of AGP thus 
providing a true depiction of AGP glycosylation within the body. AGP isolation 
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was conducted using low pressure affinity chromatography and the isolated 
levels calculated using spectrophotometry. AGP glycans were then separated 
from the polypeptide backbone using acid hydrolysis (monosaccharide analysis) 
or enzyme digestion (oligosaccharide analysis) and analysis was performed 
using HPAEC-PAD. 
Differences in AGP levels were found between various sample groups during 
this study. As expected, in dataset 1, levels of AGP in BC of an unknown 
subtype were greatly increased above the healthy population. However, TNBC 
samples had increased AGP levels above the healthy population yet levels 
were far lower than the BC of an unknown subtype. Thus highlighting an 
alteration in AGP between the TNBC and BC of an unknown type populations, 
providing further evidence of the differences between BC subtypes. Dataset 2 
also produced unexpected results when examining AGP levels because despite 
both populations technically being considered healthy, isolated AGP levels were 
significantly raised in the at-risk population compared healthy controls. Two 
particular at-risk samples (W10 and W12) had levels more than double that of 
their controls which may have indicated BC development. 
Variation of AGP concentration observed in this study could have been due to 
increases in F1*S and A variant forms of AGP. These variants are known to 
exist in a 3:1 ratio in healthy individuals (Dente et al., 1987) and alterations 
have been shown to have increased expression of F1*S and A variants in 
breast, ovarian and lung cancer, however the overall ratio tends to remain the 
same (Duche et al., 1998 and Duche et al., 2000). However, the study by Budai, 
et al., (2009) showed a change in F1*S to A variant ratios of up to 8:1 in 
lymphoma, melanoma and ovarian cancer but these differences were not 
dependent on cancer type. Additionally, an early study by Treuheit, et al., 
(1992) revealed that AGP variants had differing preferences for bi-, tri- and 
tetra-sialylated glycans at each glycosylation site. Yet, there is little evidence of 
these preferences differing during disease. Thus analysis of AGP variants 
would be of little use as a potential biomarker specific for breast cancer. 
Analysis of AGP glycan monosaccharide content highlighted quantitative 
differences between samples groups in both datasets. In dataset 1, healthy 
samples had relatively low levels of all monosaccharides whereas BC of an 
unknown type possessed far higher levels of Gal. Most unusually, as AGP 
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solely expresses complex N-linked glycans, GalNAc was present in over 88% of 
TNBC samples. GalNAc is a component of O-glycans and previous literature 
investigating other proteins has shown a reversion to foetal glycosylation during 
cancer. Foetal AGP expresses O-linked glycans (Shiyan and Bovin, 1997) and 
there is a known link between TNBC and O-glycosylation of other proteins 
(Milde-Langosch, et al., 2014; Siroy, et al., 2013). Thus GalNAc presence could 
indicated O-glycosylation of AGP and could be a marker of TNBC as GalNAc 
was not present in the healthy control or BC of unknown type populations. 
TNBC samples were divided into several categories for comparison with one 
another as well as controls. When categorised by age (<35, 35-60 and >60) a 
similar trend was displayed throughout each group with Gal showing highest 
levels, followed by GlcNAc, then GalNAc and then Fuc. Interestingly with 
GalNAc presence was inversely correlated with age and TNBC in women >60 
had lower levels of Gal compared to the other two age categories. Similar 
monosaccharide levels were detected in TNBC samples when comparing family 
history to no family history or unknown family history. However, the no family 
history group had lower levels of GalNAc compared to those with family history 
and those with unknown family history. Little difference was seen in 
monosaccharides between treated and untreated TNBC indicating that 
treatment may not be working as previous research within this group has shown 
AGP glycosylation patterns returning to normal upon treatment. This would fit 
with TNBC’s notoriously aggressive nature. Separation by stage of TNBC also 
revealed few differences between stage 1 and stage 2 TNBC other than 
marginally lower levels of GalNAc and Gal in stage 2. Therefore, as with AGP 
levels, alterations in AGP monosaccharide content are present not only 
between healthy and BC populations but between TNBC and both controls as 
well.  
Mean levels of monosaccharides in at-risk samples and healthy control samples 
in dataset 2 showed similar levels of Fuc and Gal. However GlcNAc was 
significantly elevated in the at-risk population and GalNAc was detected in 81% 
of at-risk samples but none was present in the healthy population. Two trends 
emerge upon analysis of each at-risk samples with their age-matched healthy 
control with most samples fitting one or the other. The first trend identified was 
at-risk samples possessing comparable Fuc levels to their control but having 
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GlcNAc and Gal levels above that of the control. The second trend found was 
at-risk samples containing similar Fuc levels to their control and increased 
GlcNAc levels but having lower Gal levels than their control. Only one sample 
did not fit either of these trends (W1). Therefore, it would appear that a 
difference in AGP monosaccharide content lies between women at risk of 
increased BC development and healthy controls despite both technically being 
healthy. Furthermore, GalNAc presence in the at-risk population indicates that it 
is not disease specific as it is unlikely that all at-risk samples analysed were in 
the early stages of BC development.  
Oligosaccharide analysis demonstrated structural differences in AGP from the 
various sample populations studied. In dataset 1 there was a shift from bi- and 
tri-sialylated glycans in healthy samples to tri- and tetra-sialylated glycans in BC 
of unknown type samples which contradicted previous research from this group 
who had found truncation of AGP glycan branches in BC samples. However, 
when examining oligosaccharide profiles from TNBC samples from women 
aged 35-60 and >60 showed a preference for bi-sialylated branching in line with 
previous studies. Yet, AGP from women with TNBC <35 possessed more highly 
branched glycans, similar to BC of unknown type. Therefore indicating a 
difference between TNBC at a young age and TNBC in older women. 
Oligosaccharide analysis of dataset 2 highlighted a division of oligosaccharide 
profiles in the at-risk group. Healthy control samples in dataset 2 showed a 
similar oligosaccharide profile to those from dataset 1 where bi-sialylated and 
tri-sialylated glycans were predominant. Seven of the at-risk samples showed 
glycan profiles with similar low levels of branching to the healthy controls. 
However, nine samples featured oligosaccharide profiles with increased 
branching through preference for tri- and tetra-sialylated glycans compared to 
the healthy controls. With samples featuring in either trend, the majority fitted 
well with the corresponding monosaccharide collected for each sample for 
instance an increase in GlcNAc or Gal was matched with an increase in 
branching and vice versa. Thus, these differences in glycan branching may 
further indicate the early development of BC in the at-risk samples that have 
glycan profiles similar to those of the TNBC <35 and BC of unknown type 
samples from dataset 1. 
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Additionally, concentration determination, monosaccharide and oligosaccharide 
analysis of healthy populations in both datasets unveiled base-line variability 
within the group. This could be attributed to inter-individual variation as AGP 
glycan content and concentration are known to change during inflammation 
(Higai, et al., 2005) as well as healthy volunteers being unaware of or untruthful 
about possessing inflammatory conditions that may have affected AGP glycan 
content and concentration.  
Thus far no other research groups have examined AGP glycosylation in TNBC 
or performed a case-control style study to investigate AGP glycosylation using 
individuals confirmed to be at increased risk of BC development. Earlier studies 
have shown AGP concentration to increase dramatically during cancer and 
inflammation while remaining low in healthy populations (Rudman, et al., 1974; 
Duche, et al., 2000; Routledge, 1989; Twining and Brecher, 1977). The current 
study also revealed this pattern in BC of unknown type and healthy samples, 
yet TNBC samples showed a minimal increase compared to healthy samples 
and also showed lower concentrations of AGP compared to BC of unknown 
type. Hence AGP concentrations during TNBC appear to contradict previous 
research. Previous studies have also established that adult AGP expresses 5 
complex N-linked glycans (Yoshima, et al., 1981) while foetal AGP displays 3 N-
linked glycans and 3 O-linked glycans with the O-glycans being lost during 
development (Shiyan and Bovin., 1997) However results obtained in this study 
are suggestive of AGP expressing O-glycans in adults during TNBC and 
possible BC development in women at risk of BC development. This reversion 
to O-glycosylation could be due to expression of foetal antigens which has been 
shown to occur on other proteins during cancer (Farinati, et al., 2006 and Amri, 
et al., 2013) and may be caused by rapid cell proliferation (Sapra, et al., 2012; 
Farinati, et al., 2006). The results of this study support previous research linking 
increased glycan branching with cancer development and progression (Asao, et 
al., 2013; Cui, et al., 2011; Hashimoto, et al., 2004; Majid, et al., 2005) as TNBC 
samples <35 and at risk samples showed a higher degree of branching 
compared to other samples in this study. However, TNBC from women >35 had 
lower levels of branching detected which aligns with research by Fujii, et al., 
(1988), Hansen, et al., (1984) and Smith, et al., (2012) investigating AGP 
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glycosylation during cancer. Therefore, the current study clearly contributes new 
knowledge and builds upon existing information regarding AGP. 
The alterations of AGP glycosylation observed in this study may be linked to 
several key hallmarks of cancer such as sustaining proliferative signalling; 
evading growth suppressors; activating invasion and metastasis; enabling 
replicative immortality; inducing angiogenesis; resisting cell death (Hanahan 
and Weinberg, 2000); avoiding immune destruction; genome instability and 
mutation; tumour-promoting inflammation and deregulating cellular energetics 
such as the Warburg effect (Hanahan and Weinberg, 2011; Warburg, et al., 
1928). Aberrant glycosylation of proteins such as sialylation, fucosylation, 
truncated O-glycans, increased branching (Stowell, et al., 2015) and expression 
of oncofoetal antigens (Sapra, et al., 2012) may aid cancer progression and 
metastasis (Chen, et al., 2013; Julien, et al., 2011; Guo,et al., 2003; Handerson, 
et al., 2005; Pinho, et al., 2009; Takahashi, et al., 2009). Presence of Fuc in 
samples may enhance cell proliferation as shown by Chen, et al., (2013) who 
observed increased levels of FUT 8. Similarly, Fuc could be present as a 
component of SLex which has a role in cell adhesion thus its expression could 
be aiding the binding of cancer cells to secondary organs and facilitating 
metastasis (Julien, et al., 2011).Thus, Fuc content of AGP could play a role in 
metastasis and malignant cell proliferation in BC.  Furthermore, increased 
GlcNAc and Gal could be linked to increases in glycan branching (Behan, et al., 
2013), specifically N-linked β1-6 branching which has be shown to rise in 
cancer (Stowell, et al., 2015). Increases in glycan branching have been shown 
to contribute to lymph node metastasis and tumour growth (Guo, et al., 2003; 
Handerson, et al., 2005; Pinho, et al., 2009; Takahashi, et al., 2009). Therefore 
the increased branching of AGP and corresponding increase in GlcNAc and Gal 
observed in TNBC samples <35 and several at risk samples could indicate that 
AGP is potentially contributing to BC development and metastasis. Additionally, 
the unexpected detection of GalNAc in samples of isolated AGP in this study 
could indicate two further hallmarks of cancer – truncated O-glycans and 
regression to expressing foetal antigens (Stowell, et al., 2015). But, clearly more 
work is necessary beyond the scope of the present study. GalNAc is a 
constituent of O-glycans and not present in N-linked glycans (Varki, et al., 
2009). Thus as AGP has been shown to only express complex type N-linked 
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glycans, GalNAc presence suggests O-glycosylation of AGP. As mentioned 
previously, AGP does express O-linked glycans during foetal development but 
not in adult AGP (Shiyan and Bovin, 1997), suggesting that AGP in some 
samples from this study may have reverted back to glycan expression observed 
in foetuses. Expression of O-linked glycans during cancer is associated with 
enhancement of the malignant properties of cells such as increased 
proliferation, invasion of surrounding tissues and metastasis (Radhakrishnan, et 
al., 2014). Thus, if AGP is displaying O-linked glycosylation during BC, AGP 
could be functioning to promote BC development, progression and metastasis. 
Expression of GalNAc, potentially from O-linked glycans, may be due to 
Warburg effect which causes increased uptake and anaerobic metabolism of 
glucose by cancer cells for energy to enhance proliferation (Warburg, et al., 
1928). Increased O-GlcNAc transferase which catalyses the addition of N-
acetylglucosamine to proteins and lipids has been linked to the Warburg effect 
(Jozwiak, et al., 2014) and it has been hypothesised that O-GlcNAcylation acts 
as a nutrient sensor (Butkinaree, et al., 2010; Hanover, et al., 2010) resulting in 
enhanced proliferation, growth, angiogenesis and metastasis (Khan, et al., 
2013; Porta, et al., 2014).  
In summary, this study has fulfilled its aims of investigating variations in AGP 
glycosylation in TNBC and women at increased risk of BC development in the 
hope of identifying disease specific changes that could be utilised as a 
diagnostic biomarker. The data collected indicates that AGP glycosylation in 
TNBC varies compared to healthy controls and BC of unknown type mainly due 
to the unusual presence of GalNAc. Furthermore, differences in AGP 
glycosylation within an at-risk population that are similar to that of TNBC<35 
and BC of unknown type samples could indicate early BC development. The 
results of this study suggest that increased levels of GlcNAc and Gal correlating 
to increased glycan branching could indicate BC development. However, 
decreased GlcNAc and Gal in combination with decreased glycan branching 
implies individuals are disease free. Based on the results, it would appear that 
AGP glycosylation is a good biomarker of BC as examination of glycan content 
and branching allowed the investigator to differentiate between healthy, BC of 
unknown type and TNBC in dataset 1 as well as suggesting BC development of 
a number of at-risk samples in dataset 2. 
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7.2 Future Work. 
 
The study presented within has provided evidence of AGP’s potential as a 
biomarker of BC in at risk individuals. However, the study was limited by the 
type of samples that could be acquired for analysis as well as the sample size 
that was feasible for the author to process and analyse. Yet the current study 
has provided useful preliminary data that could lead on to subsequent research 
to confirm the results and expand on this study’s findings. The following are 
suggestions that could improve investigation into AGP’s potential as a BC 
biomarker in at risk individuals. 
Firstly, repetition of the method used in this study with larger sample cohorts to 
assess whether the current study’s findings are supported. While the sample 
sizes used in the current study were suitable for this preliminary investigation, a 
secondary study using more participants could enhance the reliability of the 
data.  
Repetition of this study using only untreated samples would allow glycosylation 
patterns that were uninfluenced by treatment to be obtained. Thus the accuracy 
of the monosaccharide and oligosaccharide data would be improved as 
changes detected in glycosylation would be a true reflection of those at the 
beginning of BC development. 
Recruitment of women at increased risk of BC development who have 
developed BC to draw direct comparisons between women at risk without BC 
and a healthy population. Therefore, it would be possible to assess whether 
glycosylation patterns observed in at risk samples that differed from age-
matched healthy controls did indicate BC. 
Conducting a study running over several years, following women at risk of BC 
and analysing their AGP glycosylation at various points to detect onset of BC if 
it occurs. Performing a study in this manner would allow monitoring of 
glycosylation patterns in at risk individuals, with the potential to have BC 
confirmed by a conventional method, such as mammography, assess aberrant 
AGP glycosylation as a biomarker of BC. 
Moreover, analysis of AGP glycosylation in other cancer types could be utilised 
in a future study. This would enable comparison of AGP glycosylation patterns 
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in different cancer types to determine whether BC can be distinguished from 
other cancer types. 
Furthermore, additional methods could have been employed to complement 
and enhance the validity of results in this study, outlined in part in sections 
4.5.3, 5.5.4, 6.4.6.  
Investigation of AGP concentration in the various sample populations employed 
in this study could have been improved by assessing the efficiency of the low 
pressure chromatography columns used known concentrations of AGP to spike 
plasma samples to measure AGP recovery. Removal of unwanted plasma 
proteins using low pressure chromatography to purify AGP could have been 
evidence by SDS-PAGE of all fractions after application to each low pressure 
chromatography column.  Western Blotting of SDS-PAGE gels using AGP 
specific antibodies could have confirmed purification of AGP (Behan, 2010) and 
a Bradford assay (Bradford, 1976) or an antihuman AGP ELISA would have 
enabled measurement of protein concentration (Hashimoto, 2004; McCurdy et 
al., 2011). Use of these techniques could have complemented the determination 
of AGP concentrations solely on absorbance methods. 
Again, SDS-PAGE could have been utilised to prove deglycosylation of AGP by 
acid hydrolysis and PNGase F through a reduction in molecular weight while 
incorporation of a periodic acid-Schiff stain for glycosylation with a nitrocellulose 
blot could have also been used to assess deglycosylation of AGP; although 
acid-mediated chemical hydrolysis is generally accepted as a quantitative 
process. Moreover, analysis of monosaccharide and oligosaccharide content 
using ELISA’s (to measure Fuc and SA) and mass spectrometry could have 
supported the HPAEC-PAD results. Lastly, possible O-linked glycosylation of 
AGP would have been possible if β-elimination or hydrazine treatment had been 
employed to release O-glycans to allow their analysis by HPAEC-PAD. 
Additionally due to limited funding and sample volume it was not possible to use 
the techniques listed above to confirm the findings of the current study. 
Unfortunately, it was not possible to recruit women at increased risk of BC who 
had developed BC for this study. This is because once women have BC 
detected at the screening clinic, they are moved to a different department for 
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treatment and contact between the patient and the screening clinic is lost. No 
follow-up is carried out.  
This study found alterations to AGP glycosylation in TNBC samples and 
samples from women at increased risk of BC development that could identify 
early BC development. While this data is preliminary, follow up studies carried 
out using the recommendations listed above could aid the development of a 
blood-based biomarker for diagnosis of BC which could revolutionise the 
screening of women for BC.    
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